

CORRECTED
VERSION*

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



BE

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 38/17, C07K 14/47, A61K 31/7076, 31/472, 31/553, C12N 5/00, A61P 35/00, 11/00		A3	(11) International Publication Number: WO 00/15246
			(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/20500		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 10 September 1999 (10.09.99)			
(30) Priority Data: 60/099,952 11 September 1998 (11.09.98) US		Published With international search report.	
(71) Applicant (for all designated States except US): PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).		(88) Date of publication of the international search report: 20 July 2000 (20.07.00)	
(72) Inventors; and (75) Inventors/Applicants (for US only): PEPICELLI, Carmen [US/US]; - (US). LEWIS, Paula [NZ/US]; 64 Park Street, Apt. 2, Somerville, MA 02143 (US). MCMAHON, Andrew, P. [GB/US]; 128 Kendall Road, Lexington, MA 02173 (US).			
(74) Agents: VINCENT, Matthew, P. et al.; Foley, Hoag & Eliot, LLP, One Post Office Square, Boston, MA 02109 (US).			
(54) Title: REGULATION OF LUNG TISSUE BY HEDGEHOG-LIKE POLYPEPTIDES, AND FORMULATIONS AND USES RELATED THERETO			
(57) Abstract			
<p>The present application relates to a method for modulating the growth state of a lung tissue, or a cell thereof, e.g., by ectopically contacting the tissue, <i>in vitro</i> or <i>in vivo</i>, with a <i>hedgehog</i> therapeutic, a <i>ptc</i> therapeutic, or an <i>FGF-10</i> therapeutic in an amount effective to alter the rate (promote or inhibit) of proliferation of cells in the lung tissue, e.g., relative to the absence of administration of the <i>hedgehog</i> therapeutic or <i>ptc</i> therapeutic. The subject method can be used, for example, to modulate the growth state of epithelial and/or mesenchymal cells of a lung tissue, such as may be useful as part of a regimen for prevention of a disease state, or in the treatment of an existing disease state or other damage to the lung tissue.</p>			

*(Referred to in PCT Gazette No. 34/2000, Section II)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

***Regulation of Lung Tissue by Hedgehog-like Polypeptides, and Formulations
and Uses Related Thereto***

5

10

Background of the Invention

15 Pattern formation is the activity by which embryonic cells form ordered spatial
arrangements of differentiated tissues. The physical complexity of higher organisms arises
during embryogenesis through the interplay of cell-intrinsic lineage and cell-extrinsic
signaling. Inductive interactions are essential to embryonic patterning in vertebrate
development from the earliest establishment of the body plan, to the patterning of the organ
20 systems, to the generation of diverse cell types during tissue differentiation (Davidson, E.,
(1990) *Development* 108: 365-389; Gurdon, J. B., (1992) *Cell* 68: 185-199; Jessell, T. M. et
al., (1992) *Cell* 68: 257-270). The effects of developmental cell interactions are varied.
Typically, responding cells are diverted from one route of cell differentiation to another by
inducing cells that differ from both the uninduced and induced states of the responding cells
25 (inductions). Sometimes cells induce their neighbors to differentiate like themselves
(homoiogenetic induction); in other cases a cell inhibits its neighbors from differentiating
like itself. Cell interactions in early development may be sequential, such that an initial
induction between two cell types leads to a progressive amplification of diversity. Moreover,

inductive interactions occur not only in embryos, but in adult cells as well, and can act to establish and maintain morphogenetic patterns as well as induce differentiation (J.B. Gurdon (1992) *Cell* 68:185-199).

Members of the *Hedgehog* family of signaling molecules mediate many important short- and long-range patterning processes during invertebrate and vertebrate development. In the fly a single *hedgehog* gene regulates segmental and imaginal disc patterning. In contrast, in vertebrates a *hedgehog* gene family is involved in the control of left-right asymmetry, polarity in the CNS, somites and limb, organogenesis, chondrogenesis and spermatogenesis.

The first *hedgehog* gene was identified by a genetic screen in the fruitfly *Drosophila melanogaster* (Nüsslein-Volhard, C. and Wieschaus, E. (1980) *Nature* 287, 795-801). This screen identified a number of mutations affecting embryonic and larval development. In 1992 and 1993, the molecular nature of the *Drosophila hedgehog* (*hh*) gene was reported (C.F., Lee et al. (1992) *Cell* 71, 33-50), and since then, several *hedgehog* homologues have been isolated from various vertebrate species. While only one *hedgehog* gene has been found in *Drosophila* and other invertebrates, multiple *Hedgehog* genes are present in vertebrates.

The various *Hedgehog* proteins consist of a signal peptide, a highly conserved N-terminal region, and a more divergent C-terminal domain. In addition to signal sequence cleavage in the secretory pathway (Lee, J.J. et al. (1992) *Cell* 71:33-50; Tabata, T. et al. (1992) *Genes Dev.* 2635-2645; Chang, D.E. et al. (1994) *Development* 120:3339-3353), *Hedgehog* precursor proteins undergo an internal autoproteolytic cleavage which depends on conserved sequences in the C-terminal portion (Lee et al. (1994) *Science* 266:1528-1537; Porter et al. (1995) *Nature* 374:363-366). This autocleavage leads to a 19 kD N-terminal peptide and a C-terminal peptide of 26-28 kD (Lee et al. (1992) *supra*; Tabata et al. (1992) *supra*; Chang et al. (1994) *supra*; Lee et al. (1994) *supra*; Bumcrot, D.A., et al. (1995) *Mol. Cell. Biol.* 15:2294-2303; Porter et al. (1995) *supra*; Ekker, S.C. et al. (1995) *Curr. Biol.* 5:944-955; Lai, C.J. et al. (1995) *Development* 121:2349-2360). The N-terminal peptide stays tightly associated with the surface of cells in which it was synthesized, while the C-terminal peptide is freely diffusible both *in vitro* and *in vivo* (Lee et al. (1994) *supra*; Bumcrot et al. (1995) *supra*; Mart', E. et al. (1995) *Development* 121:2537-2547; Roelink, H. et al. (1995) *Cell* 81:445-455). Interestingly, cell surface retention of the N-terminal

peptide is dependent on autocleavage, as a truncated form of HH encoded by an RNA which terminates precisely at the normal position of internal cleavage is diffusible *in vitro* (Porter *et al.* (1995) *supra*) and *in vivo* (Porter, J.A. *et al.* (1996) *Cell* 86, 21-34). Biochemical studies have shown that the autoproteolytic cleavage of the HH precursor protein proceeds through
 5 an internal thioester intermediate which subsequently is cleaved in a nucleophilic substitution. It is likely that the nucleophile is a small lipophilic molecule which becomes covalently bound to the C-terminal end of the N-peptide (Porter *et al.* (1996) *supra*), tethering it to the cell surface. The biological implications are profound. As a result of the tethering, a high local concentration of N-terminal *Hedgehog* peptide is generated on the surface of the
 10 *Hedgehog* producing cells. It is this N-terminal peptide which is both necessary and sufficient for short and long range *Hedgehog* signaling activities in *Drosophila* and vertebrates (Porter *et al.* (1995) *supra*; Ekker *et al.* (1995) *supra*; Lai *et al.* (1995) *supra*; Roelink, H. *et al.* (1995) *Cell* 81:445-455; Porter *et al.* (1996) *supra*; Fietz, M.J. *et al.* (1995) *Curr. Biol.* 5:643-651; Fan, C.-M. *et al.* (1995) *Cell* 81:457-465; Mart', E., *et al.* (1995) *Nature* 375:322-
 15 325; Lopez-Martinez *et al.* (1995) *Curr. Biol.* 5:791-795; Ekker, S.C. *et al.* (1995) *Development* 121:2337-2347; Forbes, A.J. *et al.* (1996) *Development* 122:1125-1135).

HH has been implicated in short- and long range patterning processes at various sites during *Drosophila* development. In the establishment of segment polarity in early embryos, it has short range effects which appear to be directly mediated, while in the patterning of the
 20 imaginal discs, it induces long range effects via the induction of secondary signals.

In vertebrates, several *hedgehog* genes have been cloned in the past few years (see Table 1). Of these genes, *Shh* has received most of the experimental attention, as it is expressed in different organizing centers which are the sources of signals that pattern neighbouring tissues. Recent evidence indicates that *Shh* is involved in these interactions.

25 The interaction of a *hedgehog* protein with one of its cognate receptor, *patched*, sets in motion a cascade involving the activation and inhibition of downstream effectors, the ultimate consequence of which is, in some instances, a detectable change in the transcription or translation of a gene. Transcriptional targets of *hedgehog* signaling are the *patched* gene itself (Hidalgo and Ingham, 1990 *Development* 110, 291-301; Marigo *et al.*, 1996) and the
 30 vertebrate homologs of the *drosophila cubitus interruptus* (Ci) gene, the *GLI* genes (Hui *et al.*

(1994) *Dev Biol* 162:402-413). *Patched* gene expression has been shown to be induced in cells of the limb bud and the neural plate that are responsive to *Shh*. (Marigo et al. (1996) *Development* 122:1225-1233). The *GLI* genes encode putative transcription factors having zinc finger DNA binding domains (Orenic et al. (1990) *Genes & Dev* 4:1053-1067; Kinzler et al. (1990) *Mol Cell Biol* 10:634-642). Transcription of the *GLI* gene has been reported to be upregulated in response to *hedgehog* in limb buds, while transcription of the *GLI3* gene is downregulated in response to *hedgehog* induction (Marigo et al. (1996) *Development* 122:1225-1233). Moreover, it has been demonstrated that elevated levels of Ci are sufficient to activate *patched* (*ptc*) and other *hedgehog* target genes, even in the absence of *hedgehog* activity.

Summary of the Invention

One aspect of the present application relates to a method for modulating the growth state of an lung tissue, or a cell thereof, e.g., by ectopically contacting the tissue, *in vitro* or *in vivo*, with a *hedgehog* therapeutic, a *ptc* therapeutic, or an *FGF-10* therapeutic (described *infra*) in an amount effective to alter the rate (promote or inhibit) of proliferation of cells in the lung tissue, e.g., relative to the absence of administration of the *hedgehog* therapeutic or *ptc* therapeutic. The subject method can be used, for example, to modulate the growth state of epithelial and/or mesenchymal cells of a lung tissue, such as may be useful as part of a regimen for prevention of a disease state, or in the treatment of an existing disease state or other damage to the lung tissue.

Wherein the subject method is carried out using a *hedgehog* therapeutic, the *hedgehog* therapeutic preferably a polypeptide including a *hedgehog* portion comprising at least a bioactive extracellular portion of a *hedgehog* protein, e.g., the *hedgehog* portion includes at least 50, 100 or 150 (contiguous) amino acid residues of an N-terminal half of a *hedgehog* protein. In preferred embodiments, the *hedgehog* portion includes at least a portion of the *hedgehog* protein corresponding to a 19kd fragment of the extracellular domain of a *hedgehog* protein.

In certain preferred embodiments, the *hedgehog* portion has an amino acid sequence at least 60, 75, 85, or 95 percent identical with a *hedgehog* protein of any of SEQ ID Nos. 10-18 or 20, though sequences identical to those sequence listing entries are also contemplated as useful in the present method. The *hedgehog* portion can be encoded by a nucleic acid
5 which hybridizes under stringent conditions to a nucleic acid sequence of any of SEQ ID Nos. 1-9 or 19, e.g., the *hedgehog* portion can be encoded by a vertebrate *hedgehog* gene, especially a human *hedgehog* gene.

In certain embodiments, the *hedgehog* polypeptide is modified with one or more sterol moieties, e.g., cholesterol or a derivative thereof.

10 In certain embodiments, the *hedgehog* polypeptide is modified with one or more fatty acid moieties, such as a fatty acid moiety selected from the group consisting of myristoyl, palmitoyl, stearoyl, and arachidoyl.

In other embodiments, the subject method can be carried out by administering a gene activation construct, wherein the gene activation construct is designed to recombine with a
15 genomic *hedgehog* gene of the patient to provide a heterologous transcriptional regulatory sequence operatively linked to a coding sequence of the *hedgehog* gene.

In still other embodiments, the subject method can be practiced with the administration of a gene therapy construct encoding a *hedgehog* polypeptide. For instance, the gene therapy construct can be provided in a composition selected from a group consisting
20 of a recombinant viral particle, a liposome, and a poly-cationic nucleic acid binding agent,


In yet other embodiments, the subject method can be carried out using a *ptc* therapeutic. An exemplary *ptc* therapeutic is a small organic molecule which binds to a *patched* protein and derepresses *patched*-mediated inhibition of mitosis, e.g., a molecule which binds to *patched* and mimics *hedgehog*-mediated *patched* signal transduction, which
25 binds to *patched* and regulates *patched*-dependent gene expression. For instance, the binding of the *ptc* therapeutic to *patched* may result in upregulation of *patched* and/or *gli* expression.

In a more generic sense, the *ptc* therapeutic can be a small organic molecule which induces *hedgehog*-mediated *patched* signal transduction, such as by altering the localization, protein-protein binding and/or enzymatic activity of an intracellular protein involved in a

patched signal pathway. For instance, the *ptc* therapeutic may alter the level of expression of a *hedgehog* protein, a *patched* protein or a protein involved in the intracellular signal transduction pathway of *patched*.

In certain embodiments, the *ptc* therapeutic is an antisense construct which inhibits the expression of a protein which is involved in the signal transduction pathway of *patched* and the expression of which antagonizes *hedgehog*-mediated signals. The antisense construct is preferably an oligonucleotide of about 20-30 nucleotides in length and having a GC content of at least 50 percent.

In other embodiments, the *ptc* therapeutic is an inhibitor of protein kinase A (PKA), such as a 5-isoquinolinesulfonamide. The PKA inhibitor can be a cyclic AMP analog. Exemplary PKA inhibitors include N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide, 1-(5-isoquinoline-sulfonyl)-2-methylpiperazine, KT5720, 8-bromo-cAMP, dibutyryl-cAMP and PKA Heat Stable Inhibitor isoform α . Another exemplary PKA inhibitor is represented in the general formula:



wherein,

R_1 and R_2 each can independently represent hydrogen, and as valence and stability permit a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, $-(CH_2)_m-R_8$, $-(CH_2)_m-OH$, $-(CH_2)_m-O$ -lower alkyl, $-(CH_2)_m-O$ -lower alkenyl, $-(CH_2)_n-O-(CH_2)_m-R_8$, $-(CH_2)_m-SH$, $-(CH_2)_m-S$ -lower alkyl, $-(CH_2)_m-S$ -lower alkenyl, $-(CH_2)_n-S-(CH_2)_m-R_8$, or

R_1 and R_2 taken together with N form a heterocycle (substituted or unsubstituted);

R_3 is absent or represents one or more substitutions to the isoquinoline ring such as a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, $-(CH_2)_m-R_8$, $-(CH_2)_m-OH$, $-(CH_2)_m-O$ -lower alkyl, $-(CH_2)_m-O$ -lower alkenyl, $-(CH_2)_n-O-(CH_2)_m-R_8$, $-(CH_2)_m-SH$, $-(CH_2)_m-S$ -lower alkyl, $-(CH_2)_m-S$ -lower alkenyl, $-(CH_2)_n-S-(CH_2)_m-R_8$;

R_8 represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle; and

n and m are independently for each occurrence zero or an integer in the range of 1 to 6.

The subject method can be used to prevent or treat various lung diseases, to control wound healing or other reformation processes in lung, and to augment lung transplantation.

Wherein the subject method is carried out using an *fgf-10* therapeutic, the *fgf-10* therapeutic preferably a polypeptide including a *fgf-10* portion comprising at least a bioactive extracellular portion of a *fgf-10* protein, e.g., the *fgf-10* portion includes at least 50, 100 or 150 (contiguous) amino acid residues of a *fgf-10* protein, preferably a human *fgf-10* protein such as shown in SEQ ID No. 24.

In certain preferred embodiments, the *fgf-10* portion has an amino acid sequence at least 60, 75, 85, or 95 percent identical with the *fgf-10* protein of SEQ ID No. 24, though a sequence identical with SEQ ID No. 24 is also contemplated as useful in the present method. The *fgf-10* portion can be encoded by a nucleic acid which hybridizes under stringent conditions to a nucleic acid sequence of SEQ ID No. 23, e.g., the *fgf-10* portion can be encoded by a vertebrate *fgf-10* gene, especially a human *fgf-10* gene.

In other embodiments, the subject method can be carried out by administering a gene activation construct, wherein the gene activation construct is designed to recombine with a genomic *fgf-10* gene of the patient to provide a heterologous transcriptional regulatory sequence operatively linked to a coding sequence of the *fgf-10* gene.

In still other embodiments, the subject method can be practiced with the administration of a gene therapy construct encoding a *fgf-10* polypeptide. For instance, the gene therapy construct can be provided in a composition selected from a group consisting of a recombinant viral particle, a liposome, and a poly-cationic nucleic acid binding agent,

Yet another aspect of the present invention concerns preparations of a *hedgehog*, *ptc* or *fgf-10* therapeutic formulated for application to lung tissue, e.g., by aerosol. For example, such formulations may include a polypeptide comprising a *hedgehog* polypeptide sequence including a bioactive fragment of a *hedgehog* protein, which polypeptide is formulated for application to lung tissue by inhalation.

Detailed Description of the Invention

Figure 1. Morphology and epithelial phenotype of *Shh*^{-/-} mouse lungs. (a) At 12.5 dpc, the wt mouse lung has branched several times to give rise to distinct lobes (arrows). (b) Trachea and esophagus are separate tubes. (c) Cross-section at the level of the lung shows branching and lobation. (d) At 12.5 dpc, *Shh*-deficient lungs have failed to undergo lobation or subsequent extensive branching. (e) Trachea and esophagus remain fused at the tracheoesophageal septum. (f) Mutant lungs have branched only once. (g) At 18.5 dpc, airsac formation is in progress in the wt and the respiratory surface is in tight association with blood vessels. (h) There is little branching or growth of the poorly vascularized mutant lungs, but airsac formation at the distal epithelial tips is apparent (arrows). (i) By 18.5 dpc, wild-type lungs have established the conducting airways and respiratory bronchioles, alveolar formation is in progress. (j) In contrast, in a mutant lung of the same stage, branching is dramatically decreased. Only a few primary branches (arrows) and air sacs (arrowheads) are present. (k) In the wild-type, trachea and esophagus are separated. The trachea is lined by columnar cells, the esophagus by stratified epithelium. (l) Air sacs are made of cuboidal cells. (m) In the mutant, trachea and esophagus are fused to form a fistula. Differentiation into columnar and stratified epithelium is apparent, (n) as is the characteristic cuboidal epithelium of the air sacs. Demarcation lines between terminal bronchioles and respiratory surface are indicated. (o) Proximal lung epithelium of the 18.5 dpc wt lung expresses *CCSP* in Clara cells, and (p) *SP-C* in type II pneumocytes of the distal epithelium. (q) *CCSP* and (p) *SP-C*

are expressed in the correct proximo-distal domain in the mutant. Bars denote 1 mm (g,h only) or 10 μ m. (a,d,g,h) are ventral views, all others transverse sections. Abbreviations: t - trachea, e - esophagus, l - lung, h - heart, s - stomach, mb - mainstem bronchus, b - bronchus, tb - terminal bronchiole, a - air sac.

5 Figure 2. In situ analysis of gene expression in the lungs of *Shh* mutants. Expression of the genes indicated was investigated in whole mount vibratome sections through lungs removed from wt 11.5 and 12.5 dpc, and *Shh*-mutant 12.5 dpc embryos.

10 Figure 3. Mesenchyme differentiation at 18.5 dpc. (a) Both wt and mutant lungs display cartilaginous rings around the trachea as indicated by alcian-blue staining. (b) While in the wild-type lung a layer of smooth muscle surrounds the conducting epithelium, the mutant lung mesenchyme does not differentiate into muscle (right panel). Bars denote 10 mm

Detailed Description of the Invention

15 Development of the lung, through a process known as branching morphogenesis, is strictly dependent on interactions between endodermally derived epithelial cells and the splanchnic mesenchyme. Cell-cell interactions form the functional basis for branching morphogenesis and occur through the activity of a number of mediators, including the extracellular matrix, cellular receptors, and morphogenetic signaling molecules such as
20 peptide growth factors. The molecular regulatory signals and in particular the role of transcriptional factors in branching morphogenesis and lung injury/repair are an important source of information for the treatment of injury. Furthermore, because the lungs continue to undergo development after birth, untimely activation of alternative morphogenetic signals released by tissue injury or repair or both may potentially derail normal morphogenesis and
25 result in structural and functional aberrations characteristic of neonatal lung disease.

It is demonstrated herein that *hedgehog* proteins, such as *Shh*, is essential for development of the respiratory system. In *Shh* null mutants, for example, the trachea and esophagus do not separate properly and the lungs form a rudimentary sac due to failure of branching and growth after formation of the primary lung buds. Interestingly, normal

proximo-distal differentiation of the airway epithelium occurs, indicating that Shh is not needed for differentiation events. In addition, the transcription of several mesenchymally expressed downstream targets of Shh is abolished. These results highlight the importance of epithelially derived Shh in regulating branching morphogenesis of the lung, and establish a role for *hedgehog* in lung morphogenesis, disease and repair, and suggest that SHH normally regulates lung mesenchymal cell proliferation *in vivo*.

I. Overview

The present application is directed to the discovery that preparations of *hedgehog* polypeptides can be used to control the formation and/or maintenance of lung tissue. As described in the appended examples, *hedgehog* proteins are implicated in the proliferation and differentiation of lung mesenchymal and epithelial cells and provide early signals that regulate the formation and maintenance of lung tissues. The present invention provides a method for regulating the growth state of lung tissue, e.g., either in *in vitro* or *in vivo*. In general, the method of the present invention comprises contacting lung tissue, or cells derived therefrom, with an amount of a *hedgehog* therapeutic (defined *infra*) which produces a non-toxic response by the cell of induction or inhibition of the formation of lung tissue microarchitecture, e.g., depending on the whether the *hedgehog* therapeutic is a sufficient *hedgehog* agonist or *hedgehog* antagonist. The subject method can be carried out on lung cells which may be either dispersed in culture or a part of an intact tissue or organ. Moreover, the method can be performed on cells which are provided in culture (*in vitro*), or on cells in a whole animal (*in vivo*).

Without wishing to be bound by any particular theory, the ability of *hedgehog* proteins to regulate the growth state of lung tissue may be due at least in part to the ability of these proteins to antagonize (directly or indirectly) *patched*-mediated regulation of gene expression and other physiological effects mediated by that protein. The *patched* gene product, a cell surface protein, is understood to signal through a pathway which causes transcriptional repression of members of the Wnt and Dpp/BMP families of morphogens, proteins which impart positional information. In development of the CNS and patterning of

limbs in vertebrates, the introduction of *hedgehog* relieves (derepresses) this inhibition conferred by *patched*, allowing expression of particular gene programs.

Recently, it has been reported that mutations in the human version of *patched*, a gene first identified in a fruit fly developmental pathway, cause a hereditary skin cancer and may contribute to sporadic skin cancers. See, for example, Hahn et al. (1996) *Cell* 86:841-851; and Johnson et al. (1996) *Science* 272:1668-1671. The demonstration that nevoid basal-cell carcinoma (NBCC) results from mutations in the human *patched* gene provided an example of the roles *patched* plays in post-embryonic development. These observations have led the art to understand one activity of *patched* to be a tumor suppressor gene, which may act by inhibiting proliferative signals from *hedgehog*. Our observations set forth below reveal potential new roles for the *hedgehog/patched* pathway in maintenance of proliferation and differentiation of lung tissue. Accordingly, the present invention contemplates the use of other agents which are capable of mimicking the effect of the *hedgehog* protein on *patched* signalling, e.g., as may be identified from the drug screening assays described below.

Moreover, we demonstrate that *fgf-10* is an important component of the *hedgehog* regulatory network present in the embryonic lung, controlling proliferation, differentiation and pattern formation. Accordingly, Applicants contemplate that agonists and antagonist of *fgf-10* activity.

II. Definitions

For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

The term "*hedgehog* therapeutic" refers to various forms of *hedgehog* polypeptides, as well as peptidomimetics, which can modulate the proliferation/differentiation state of lung cells by, as will be clear from the context of individual examples, mimicking or potentiating (agonizing) or inhibiting (antagonizing) the effects of a naturally-occurring *hedgehog* protein. A *hedgehog* therapeutic which mimics or potentiates the activity of a wild-type *hedgehog* protein is a "*hedgehog* agonist". Conversely, a *hedgehog* therapeutic which inhibits the activity of a wild-type *hedgehog* protein is a "*hedgehog* antagonist".

In particular, the term "*hedgehog* polypeptide" encompasses preparations of *hedgehog* proteins and peptidyl fragments thereof, both agonist and antagonist forms as the specific context will make clear.

As used herein the term "bioactive fragment of a *hedgehog* protein" refers to a fragment of a full-length *hedgehog* polypeptide, wherein the fragment specifically agonizes or antagonizes inductive events mediated by wild-type *hedgehog* proteins. The *hedgehog* bioactive fragment preferably is a soluble extracellular portion of a *hedgehog* protein, where solubility is with reference to physiologically compatible solutions. Exemplary bioactive fragments are described in PCT publications WO 95/18856 and WO 96/17924.

The term "*patched*" or "*ptc*" refers to a family of related transmembrane proteins which have been implicated in the signal transduction induced by contacting a cell with a *hedgehog* protein. For example, the mammalian *ptc* family includes *ptc1* and *ptc2*. In addition to references set out below, see also Takabatake et al. (1997) *FEBS Lett* 410:485 and GenBank AB000847 for examples of *ptc2*. Unless otherwise evident from the context, it will be understood that embodiments described in the context of *ptc1* (or just *ptc*) also refer to equivalent embodiments involving other *ptc* homologs like *ptc2*.

The term "*ptc* therapeutic" refers to agents which either (i) mimic the effect of *hedgehog* proteins on *patched* signalling, e.g., which antagonize the cell-cycle inhibitory activity of *patched*, or (ii) activate or potentiate *patched* signalling. In other embodiments, the *ptc* therapeutic can be a *hedgehog* antagonist. The *ptc* therapeutic can be, e.g., a peptide, a nucleic acid, a carbohydrate, a small organic molecule, or natural product extract (or fraction thereof).

The term "*fgf-10* therapeutic" refers to agents which mimic or antagonize, as appropriate, the effect of *fgf-10* proteins on proliferation and differentiation of lung tissue. Such agents also include small organic molecules which bind to the *fgf-10* receptor and either inhibit or agonize *fgf-10* signalling.

A "proliferative" form of a *ptc*, *hedgehog* or *fgf-10* therapeutic is one which induces proliferation of lung cells, e.g., directly or indirectly, mesenchymal or epithelial cells. Conversely, an "antiproliferative" form of a *ptc*, *hedgehog* or *fgf-10* therapeutic is one which

inhibits proliferation of lung cells, preferably in a non-toxic manner, e.g., by promoting or maintaining a differentiated phenotype or otherwise promoting quiescence.

By way of example, though not wishing to be bound by a particular theory, proliferative *hedgehog* polypeptide will generally be a form of the protein which derepresses
5 *patched*-mediated cell-cycle arrest, e.g., the polypeptide mimics the effect of a naturally occurring *hedgehog* protein effect on lung tissues. A proliferative *ptc* therapeutic includes other agents which depress *patched*-mediated cell-cycle arrest, and may act extracellularly or intracellularly.

An illustrative antiproliferative *ptc* therapeutic agent may potentiate *patched*-mediated
10 cell-cycle arrest. Such agents can be small molecules that inhibit, e.g., *hedgehog* binding to *patched*, as well as agents which stimulate and/or potentiate a signal transduction pathway of the *patched* protein.

As used herein, "proliferating" and "proliferation" refer to cells undergoing mitosis.

As used herein, "transformed cells" refers to cells which have spontaneously
15 converted to a state of unrestrained growth, i.e., they have acquired the ability to grow through an indefinite number of divisions in culture. Transformed cells may be characterized by such terms as neoplastic, anaplastic and/or hyperplastic, with respect to their loss of growth control.

As used herein, "immortalized cells" refers to cells which have been altered via
20 chemical and/or recombinant means such that the cells have the ability to grow through an indefinite number of divisions in culture.

A "patient" or "subject" to be treated by the subject method can mean either a human or non-human animal.

An "effective amount" of, e.g., a *hedgehog* therapeutic, with respect to the subject
25 method of treatment, refers to an amount of, e.g., a *hedgehog* polypeptide in a preparation which, when applied as part of a desired dosage regimen brings about a change in the rate of cell proliferation and/or the state of differentiation of a cell so as to produce (or inhibit as the case may be) proliferation of lung cells in an amount according to clinically acceptable standards for the disorder to be treated or the cosmetic purpose.

The "growth state" of a cell refers to the rate of proliferation of the cell and the state of differentiation of the cell.

"Homology" and "identity" each refer to sequence similarity between two polypeptide sequences, with identity being a more strict comparison. Homology and identity can each be determined by comparing a position in each sequence which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same amino acid residue, then the polypeptides can be referred to as identical at that position; when the equivalent site is occupied by the same amino acid (e.g., identical) or a similar amino acid (e.g., similar in steric and/or electronic nature), then the molecules can be referred to as homologous at that position. A percentage of homology or identity between sequences is a function of the number of matching or homologous positions shared by the sequences. An "unrelated" or "non-homologous" sequence shares less than 40 percent identity, though preferably less than 25 percent identity, with a *hedgehog* sequence disclosed herein.

The term "corresponds to", when referring to a particular polypeptide or nucleic acid sequence is meant to indicate that the sequence of interest is identical or homologous to the reference sequence to which it is said to correspond.

The terms "recombinant protein", "heterologous protein" and "exogenous protein" are used interchangeably throughout the specification and refer to a polypeptide which is produced by recombinant DNA techniques, wherein generally, DNA encoding the polypeptide is inserted into a suitable expression construct which is in turn used to transform a host cell to produce the heterologous protein. That is, the polypeptide is expressed from a heterologous nucleic acid.

A "chimeric protein" or "fusion protein" is a fusion of a first amino acid sequence encoding a *hedgehog* polypeptide with a second amino acid sequence defining a domain foreign to and not substantially homologous with any domain of *hh* protein. A chimeric protein may present a foreign domain which is found (albeit in a different protein) in an organism which also expresses the first protein, or it may be an "interspecies", "intergenic", etc. fusion of protein structures expressed by different kinds of organisms. In general, a fusion protein can be represented by the general formula $(X)_n-(hh)_m-(Y)_n$, wherein *hh* represents all or a portion of the *hedgehog* protein, X and Y each independently represent an

amino acid sequences which are not naturally found as a polypeptide chain contiguous with the *hedgehog* sequence, *m* is an integer greater than or equal to 1, and each occurrence of *n* is, independently, 0 or an integer greater than or equal to 1 (*n* and *m* are preferably no greater than 5 or 10).

5

III. Exemplary Applications of Method and Compositions

The subject method has wide applicability to the treatment or prophylaxis of disorders afflicting lung tissue, as well as in *in vitro* cultures. In general, the method can be characterized as including a step of administering to an animal an amount of a *ptc*, *hedgehog* or *fgf-10* therapeutic effective to alter the growth state of a treated lung tissue. The mode of administration and dosage regimens will vary depending on the phenotype of, and desired effect on the target lung tissue. Likewise, as described in further detail below, the use of a particular *ptc*, *hedgehog* or *fgf-10* therapeutic, e.g., an agonist or antagonist, will depend on whether proliferation of cells in the treated lung tissue is desired or intended to be prevented.

15 In one aspect, the present invention provides pharmaceutical preparations and methods for controlling the proliferation of lung tissue utilizing, as an active ingredient, a *hedgehog* polypeptide or a mimetic thereof. The invention also relates to methods of controlling proliferation of mesenchymal and epithelial cells of the tissue by use of the pharmaceutical preparations of the invention.

20 The formulations of the present invention may be used as part of regimens in the treatment of disorders of, surgical repair of, or transplantation of lung tissues and whole organs. The methods and compositions disclosed herein also provide for the treatment of a variety of proliferative cancerous disorders effecting lung tissue. For instance, the subject method can be used to control wound healing processes, as for example may be desirable in connection with any surgery involving lung tissue.

25

In certain embodiments, the subject compositions can be used to inhibit, rather than promote, growth of lung-derived tissue. For instance, certain of the compositions disclosed herein may be applied to the treatment or prevention of a variety hyperplastic or neoplastic conditions. The method can find application for the treatment or prophylaxis of, e.g., used to

inhibit the growth and metastasis of lung cancer cells. For instance, inhibitory forms of the the subject *ptc*, *hedgehog* and *fgf-10* therapeutics may be used as part of a treatment program for small cell lung cancer (SCLC), as well as non-small cell lung cancer (NSCLC), such as adenocarcinoma, lung cell carcinoma and squamous cell carcinoma.

5 In other embodiments, the subject method can be used to treat rheumatoid lung disease, which may be marked by pleural thickening, adhesions, and pleural effusions. Such lung (pulmonary) manifestations can occur in both adult and juvenile forms of rheumatoid arthritis.

10 In other embodiments, the subject method can be used to treat, or lessen the severity of, damage to lung tissue as a complication of respiratory diseases such as broncho-pneumonia, chronic bronchitis, cystic fibrosis and asthma, and bronchospasm, or other apical interstitial lung diseases, such as cystic fibrosis, ankylosing spondylitis, sarcoidosis, silicosis, eosinophilic granuloma, tuberculosis, and lung infections.

15 In certain embodiments, the subject method can be used to treat or prevent damage to lung tissue resulting from allergic rhinitis, asthma, emphysema, chronic bronchitis, pneumoconiosis, respiratory distress syndrome, idiopathic pulmonary fibrosis and primary pulmonary hypertension

20 The subject method can be used in the treatment or prevention of occupational lung disease such as asbestos-related diseases, silicosis, occupational asthma, coal worker's pneumoconiosis, berylliosis, and industrial bronchitis.

In still other embodiments, the subject method can be used to treat certain health consequences of smoking which may result in degeneration of lung tissue.

25 The subject *hedgehog* treatments are effective on both human and animal subjects afflicted with these conditions. Animal subjects to which the invention is applicable extend to both domestic animals and livestock, raised either as pets or for commercial purposes. Examples are dogs, cats, cattle, horses, sheep, hogs and goats.

Still another aspect of the present invention provides a method of stimulating the growth and regulating the differentiation of epithelial tissue in tissue culture.

In one embodiment, the subject method can be used to regulate the proliferation and/or differentiation of lung mesenchymal progenitor cells.

The maintenance of lung tissues and whole organs *ex vivo* is also highly desirable. Lung and heart-lung transplantation therapy is well established in the treatment of certain human disease. The subject method can be used to maintain the tissue structure of lung tissue *ex vivo*, and in certain embodiments to accelerate the growth of certain lung tissue *in vitro*. The present method can also be used for improving the "take rate" of a lung transplants *in vivo*.

10 IV. Exemplary hedgehog therapeutic compounds.

The *hedgehog* therapeutic compositions of the subject method can be generated by any of a variety of techniques, including purification of naturally occurring proteins, recombinantly produced proteins and synthetic chemistry. Polypeptide forms of the *hedgehog* therapeutics are preferably derived from vertebrate *hedgehog* proteins, e.g., have sequences corresponding to naturally occurring *hedgehog* proteins, or fragments thereof, from vertebrate organisms. However, it will be appreciated that the *hedgehog* polypeptide can correspond to a *hedgehog* protein (or fragment thereof) which occurs in any metazoan organism.

The various naturally-occurring *hedgehog* proteins from which the subject therapeutics can be derived are characterized by a signal peptide, a highly conserved N-terminal region, and a more divergent C-terminal domain. In addition to signal sequence cleavage in the secretory pathway (Lee, J.J. *et al.* (1992) *Cell* 71:33-50; Tabata, T. *et al.* (1992) *Genes Dev.* 2635-2645; Chang, D.E. *et al.* (1994) *Development* 120:3339-3353), *hedgehog* precursor proteins naturally undergo an internal autoproteolytic cleavage which depends on conserved sequences in the C-terminal portion (Lee *et al.* (1994) *Science* 266:1528-1537; Porter *et al.* (1995) *Nature* 374:363-366). This autocleavage leads to a 19 kD N-terminal peptide and a C-terminal peptide of 26-28 kD (Lee *et al.* (1992) *supra*; Tabata *et al.* (1992) *supra*; Chang *et al.* (1994) *supra*; Lee *et al.* (1994) *supra*; Bumcrot, D.A., *et al.* (1995) *Mol. Cell. Biol.* 15:2294-2303; Porter *et al.* (1995) *supra*; Ekker, S.C. *et al.* (1995)

Curr. Biol. 5:944-955; Lai, C.J. *et al.* (1995) *Development* 121:2349-2360). The N-terminal peptide stays tightly associated with the surface of cells in which it was synthesized, while the C-terminal peptide is freely diffusible both *in vitro* and *in vivo* (Lee *et al.* (1994) *supra*; Bumcrot *et al.* (1995) *supra*; Mart', E. *et al.* (1995) *Development* 121:2537-2547; Roelink, H. *et al.* (1995) *Cell* 81:445-455). Cell surface retention of the N-terminal peptide is dependent on autocleavage, as a truncated form of *hedgehog* encoded by an RNA which terminates precisely at the normal position of internal cleavage is diffusible *in vitro* (Porter *et al.* (1995) *supra*) and *in vivo* (Porter, J.A. *et al.* (1996) *Cell* 86, 21-34). Biochemical studies have shown that the autoproteolytic cleavage of the *hedgehog* precursor protein proceeds through an internal thioester intermediate which subsequently is cleaved in a nucleophilic substitution. It is suggested that the nucleophile is a small lipophilic molecule, more particularly cholesterol, which becomes covalently bound to the C-terminal end of the N-peptide (Porter *et al.* (1996) *supra*), tethering it to the cell surface.

The vertebrate family of *hedgehog* genes includes at least four members, e.g., paralogs of the single drosophila *hedgehog* gene (SEQ ID No. 19). Three of these members, herein referred to as Desert *hedgehog* (*Dhh*), Sonic *hedgehog* (*Shh*) and Indian *hedgehog* (*Ihh*), apparently exist in all vertebrates, including fish, birds, and mammals. A fourth member, herein referred to as tiggie-winkle *hedgehog* (*Thh*), appears specific to fish. According to the appended sequence listing, (see also Table 1) a chicken *Shh* polypeptide is encoded by SEQ ID No:1; a mouse *Dhh* polypeptide is encoded by SEQ ID No:2; a mouse *Ihh* polypeptide is encoded by SEQ ID No:3; a mouse *Shh* polypeptide is encoded by SEQ ID No:4; a zebrafish *Shh* polypeptide is encoded by SEQ ID No:5; a human *Shh* polypeptide is encoded by SEQ ID No:6; a human *Ihh* polypeptide is encoded by SEQ ID No:7; a human *Dhh* polypeptide is encoded by SEQ ID No. 8; and a zebrafish *Thh* is encoded by SEQ ID No. 9.

Table 1

Guide to *hedgehog* sequences in Sequence Listing

	Nucleotide	Amino Acid
Chicken <i>Shh</i>	SEQ ID No. 1	SEQ ID No. 10
Mouse <i>Dhh</i>	SEQ ID No. 2	SEQ ID No. 11
Mouse <i>Ihh</i>	SEQ ID No. 3	SEQ ID No. 12
Mouse <i>Shh</i>	SEQ ID No. 4	SEQ ID No. 13
Zebrafish <i>Shh</i>	SEQ ID No. 5	SEQ ID No. 14
Human <i>Shh</i>	SEQ ID No. 6	SEQ ID No. 15
Human <i>Ihh</i>	SEQ ID No. 7	SEQ ID No. 16
Human <i>Dhh</i>	SEQ ID No. 8	SEQ ID No. 17
Zebrafish <i>Thh</i>	SEQ ID No. 9	SEQ ID No. 18
Drosophila <i>HH</i>	SEQ ID No. 19	SEQ ID No. 20

5 In addition to the sequence variation between the various *hedgehog* homologs, the *hedgehog* proteins are apparently present naturally in a number of different forms, including a pro-form, a full-length mature form, and several processed fragments thereof. The pro-form includes an N-terminal signal peptide for directed secretion of the extracellular domain, while the full-length mature form lacks this signal sequence.

10 As described above, further processing of the mature form occurs in some instances to yield biologically active fragments of the protein. For instance, *sonic hedgehog* undergoes additional proteolytic processing to yield two peptides of approximately 19 kDa and 27 kDa, the 19kDa fragment corresponding to an proteolytic N-terminal portion of the mature protein.

In addition to proteolytic fragmentation, the vertebrate *hedgehog* proteins can also be
15 modified post-translationally, such as by glycosylation and/or addition of lipophilic moieties,

such as stents, fatty acids, etc., though bacterially produced (e.g. unmodified) forms of the proteins still maintain certain of the bioactivities of the native protein. Bioactive fragments of *hedgehog* polypeptides of the present invention have been generated and are described in great detail in, e.g., PCT publications WO 95/18856 and WO 96/17924.

5 There are a wide range of lipophilic moieties with which *hedgehog* polypeptides can be derivatived. The term "lipophilic group", in the context of being attached to a *hedgehog* polypeptide, refers to a group having high hydrocarbon content thereby giving the group high affinity to lipid phases. A lipophilic group can be, for example, a relatively long chain alkyl or cycloalkyl (preferably n-alkyl) group having approximately 7 to 30 carbons. The alkyl
10 group may terminate with a hydroxy or primary amine "tail". To further illustrate, lipophilic molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, sterols, esters and alcohols, other lipid molecules, cage structures such as adamantane and buckminsterfullerenes, and aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene, naphthalene, pyrene, chrysene, and naphthacene.

15 In one embodiment, the *hedgehog* polypeptide is modified with one or more sterol moieties, such as cholesterol. See, for example, PCT publication WO 96/17924. In certain embodiments, the cholesterol is preferably added to the C-terminal glycine where the *hedgehog* polypeptide corresponds to the naturally-occurring N-terminal proteolytic fragment.

20 In another embodiment, the *hedgehog* polypeptide can be modified with a fatty acid moiety, such as a myristoyl, palmitoyl, stearoyl, or arachidoyl moiety. See, e.g., Pepinsky et al. (1998) J Biol. Chem 273: 14037.

25 In addition to those effects seen by cholesterol-addition to the C-terminus or fatty acid addition to the N-terminus of extracellular fragments of the protein, at least certain of the biological activities of the *hedgehog* gene products can be potentiated by derivatization of the protein with lipophilic moieties at other sites on the protein and/or by moieties other than cholesterol or fatty acids. Certain aspects of the invention are directed to the use of preparations of *hedgehog* polypeptides which are modified at sites other than N-terminal or C-terminal residues of the natural processed form of the protein, and/or which are modified at

such terminal residues with lipophilic moieties other than a sterol at the C-terminus or fatty acid at the N-terminus.

Particularly useful as lipophilic molecules are alicyclic hydrocarbons, saturated and unsaturated fatty acids and other lipid and phospholipid moieties, waxes, cholesterol, isoprenoids, terpenes and polyalicyclic hydrocarbons including adamantane and buckminsterfullerenes, vitamins, polyethylene glycol or oligoethylene glycol, (C1-C18)-alkyl phosphate diesters, -O-CH₂-CH(OH)-O-(C12-C18)-alkyl, and in particular conjugates with pyrene derivatives. The lipophilic moiety can be a lipophilic dye suitable for use in the invention include, but are not limited to, diphenylhexatriene, Nile Red, N-phenyl-1-naphthylamine, Prodan, Laurodan, Pyrene, Perylene, rhodamine, rhodamine B, tetramethylrhodamine, Texas Red, sulforhodamine, 1,1'-didodecyl-3,3',3',3'-tetramethylindocarbocyanine perchlorate, octadecyl rhodamine B and the BODIPY dyes available from Molecular Probes Inc.

Other exemplary lipophilic moieties include aliphatic carbonyl radical groups include 1- or 2-adamantylacetyl, 3-methyladamant-1-ylacetyl, 3-methyl-3-bromo-1-adamantylacetyl, 1-decalinacetyl, camphoracetyl, camphaneacetyl, noradamantylacetyl, norbornaneacetyl, bicyclo[2.2.2.]-oct-5-eneacetyl, 1-methoxybicyclo[2.2.2.]-oct-5-ene-2-carbonyl, cis-5-norbornene-endo-2,3-dicarbonyl, 5-norbornen-2-ylacetyl, (1R)-(-)-myrtenaneacetyl, 2-norbornaneacetyl, anti-3-oxo-tricyclo[2.2.1.0<2,6>]-heptane-7-carbonyl, decanoyl, dodecanoyl, dodecenoyl, tetradecadienoyl, decynoyl or dodecynoyl.

The *hedgehog* polypeptide can be linked to the hydrophobic moiety in a number of ways including by chemical coupling means, or by genetic engineering.

Moreover, mutagenesis can be used to create modified *hh* polypeptides, e.g., for such purposes as enhancing therapeutic or prophylactic efficacy, or stability (e.g., *ex vivo* shelf life and resistance to proteolytic degradation *in vivo*). Such modified peptides can be produced, for instance, by amino acid substitution, deletion, or addition. Modified *hedgehog* polypeptides can also include those with altered post-translational processing relative to a naturally occurring *hedgehog* protein, e.g., altered glycosylation, cholesterolization, prenylation and the like.

In one embodiment, the *hedgehog* therapeutic is a polypeptide encodable by a nucleotide sequence that hybridizes under stringent conditions to a *hedgehog* coding sequence represented in one or more of SEQ ID Nos:1-7. Appropriate stringency conditions which promote DNA hybridization, for example, 6.0 x sodium chloride/sodium citrate (SSC) at about 45°C, followed by a wash of 2.0 x SSC at 50°C, are known to those skilled in the art or can be found in *Current Protocols in Molecular Biology*, John Wiley & Sons, N.Y. (1989), 6.3.1-6.3.6. For example, the salt concentration in the wash step can be selected from a low stringency of about 2.0 x SSC at 50°C to a high stringency of about 0.2 x SSC at 50°C. In addition, the temperature in the wash step can be increased from low stringency conditions at room temperature, about 22°C, to high stringency conditions at about 65°C.

As described in the literature, genes for other *hedgehog* proteins, e.g., from other animals, can be obtained from mRNA or genomic DNA samples using techniques well known in the art. For example, a cDNA encoding a *hedgehog* protein can be obtained by isolating total mRNA from a cell, e.g. a mammalian cell, e.g. a human cell, including embryonic cells. Double stranded cDNAs can then be prepared from the total mRNA, and subsequently inserted into a suitable plasmid or bacteriophage vector using any one of a number of known techniques. The gene encoding a *hedgehog* protein can also be cloned using established polymerase chain reaction techniques.

Preferred nucleic acids encode a *hedgehog* polypeptide comprising an amino acid sequence at least 60% homologous or identical, more preferably 70% homologous or identical, and most preferably 80% homologous or identical with an amino acid sequence selected from the group consisting of SEQ ID Nos:8-14. Nucleic acids which encode polypeptides at least about 90%, more preferably at least about 95%, and most preferably at least about 98-99% homology or identity with an amino acid sequence represented in one of SEQ ID Nos:8-14 are also within the scope of the invention.

In addition to native *hedgehog* proteins, *hedgehog* polypeptides preferred by the present invention are at least 60% homologous or identical, more preferably 70% homologous or identical and most preferably 80% homologous or identical with an amino acid sequence represented by any of SEQ ID Nos:8-14. Polypeptides which are at least 90%, more preferably at least 95%, and most preferably at least about 98-99% homologous or

identical with a sequence selected from the group consisting of SEQ ID Nos:8-14 are also within the scope of the invention. The only prerequisite is that the *hedgehog* polypeptide is capable of modulating the growth of lung cells.

The term "recombinant protein" refers to a polypeptide of the present invention which is produced by recombinant DNA techniques, wherein generally, DNA encoding a *hedgehog* polypeptide is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the heterologous protein. Moreover, the phrase "derived from", with respect to a recombinant *hedgehog* gene, is meant to include within the meaning of "recombinant protein" those proteins having an amino acid sequence of a native *hedgehog* protein, or an amino acid sequence similar thereto which is generated by mutations including substitutions and deletions (including truncation) of a naturally occurring form of the protein.

The method of the present invention can also be carried out using variant forms of the naturally occurring *hedgehog* polypeptides, e.g., mutational variants.

As is known in the art, *hedgehog* polypeptides can be produced by standard biological techniques or by chemical synthesis. For example, a host cell transfected with a nucleic acid vector directing expression of a nucleotide sequence encoding the subject polypeptides can be cultured under appropriate conditions to allow expression of the peptide to occur. The polypeptide *hedgehog* may be secreted and isolated from a mixture of cells and medium containing the recombinant *hedgehog* polypeptide. Alternatively, the peptide may be retained cytoplasmically by removing the signal peptide sequence from the recombinant *hedgehog* gene and the cells harvested, lysed and the protein isolated. A cell culture includes host cells, media and other byproducts. Suitable media for cell culture are well known in the art. The recombinant *hedgehog* polypeptide can be isolated from cell culture medium, host cells, or both using techniques known in the art for purifying proteins including ion-exchange chromatography, gel filtration chromatography, ultrafiltration, electrophoresis, and immunoaffinity purification with antibodies specific for such peptide. In a preferred embodiment, the recombinant *hedgehog* polypeptide is a fusion protein containing a domain which facilitates its purification, such as an *hedgehog*/GST fusion protein. The host cell may be any prokaryotic or eukaryotic cell.

Recombinant *hedgehog* genes can be produced by ligating nucleic acid encoding an *hedgehog* protein, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Expression vectors for production of recombinant forms of the subject *hedgehog* polypeptides include plasmids and other vectors. For instance, suitable vectors for the expression of a *hedgehog* polypeptide include plasmids of the types: pBR322-derived plasmids, pEMBL-derived plasmids, pEX-derived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as *E. coli*.

A number of vectors exist for the expression of recombinant proteins in yeast. For instance, YEP24, YIP5, YEP51, YEP52, pYES2, and YRP17 are cloning and expression vehicles useful in the introduction of genetic constructs into *S. cerevisiae* (see, for example, Broach *et al.* (1983) in *Experimental Manipulation of Gene Expression*, ed. M. Inouye Academic Press, p. 83, incorporated by reference herein). These vectors can replicate in *E. coli* due to the presence of the pBR322 ori, and in *S. cerevisiae* due to the replication determinant of the yeast 2 micron plasmid. In addition, drug resistance markers such as ampicillin can be used. In an illustrative embodiment, an *hedgehog* polypeptide is produced recombinantly utilizing an expression vector generated by sub-cloning the coding sequence of one of the *hedgehog* genes represented in SEQ ID Nos:1-7.

The preferred mammalian expression vectors contain both prokaryotic sequences, to facilitate the propagation of the vector in bacteria, and one or more eukaryotic transcription units that are expressed in eukaryotic cells. The pcDNAI/amp, pcDNAI/neo, pRc/CMV, pSV2gpt, pSV2neo, pSV2-dhfr, pTk2, pRSVneo, pMSG, pSVT7, pko-neo and pHyg derived vectors are examples of mammalian expression vectors suitable for transfection of eukaryotic cells. Some of these vectors are modified with sequences from bacterial plasmids, such as pBR322, to facilitate replication and drug resistance selection in both prokaryotic and eukaryotic cells. Alternatively, derivatives of viruses such as the bovine papillomavirus (BPV-1), or Epstein-Barr virus (pHEBo, pREP-derived and p205) can be used for transient expression of proteins in eukaryotic cells. The various methods employed in the preparation of the plasmids and transformation of host organisms are well known in the art. For other suitable expression systems for both prokaryotic and eukaryotic cells, as well as general recombinant procedures, see *Molecular Cloning A Laboratory Manual*, 2nd Ed., ed. by

Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1989) Chapters 16 and 17.

In some instances, it may be desirable to express the recombinant *hedgehog* polypeptide by the use of a baculovirus expression system. Examples of such baculovirus expression systems include pVL-derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as pAcUW1), and pBlueBac-derived vectors (such as the β -gal containing pBlueBac III).

When it is desirable to express only a portion of an *hedgehog* protein, such as a form lacking a portion of the N-terminus, i.e. a truncation mutant which lacks the signal peptide, it may be necessary to add a start codon (ATG) to the oligonucleotide fragment containing the desired sequence to be expressed. It is well known in the art that a methionine at the N-terminal position can be enzymatically cleaved by the use of the enzyme methionine aminopeptidase (MAP). MAP has been cloned from *E. coli* (Ben-Bassat et al. (1987) *J. Bacteriol.* 169:751-757) and *Salmonella typhimurium* and its *in vitro* activity has been demonstrated on recombinant proteins (Miller et al. (1987) *PNAS* 84:2718-1722). Therefore, removal of an N-terminal methionine, if desired, can be achieved either *in vivo* by expressing *hedgehog*-derived polypeptides in a host which produces MAP (e.g., *E. coli* or CM89 or *S. cerevisiae*), or *in vitro* by use of purified MAP (e.g., procedure of Miller et al., *supra*).

Alternatively, the coding sequences for the polypeptide can be incorporated as a part of a fusion gene including a nucleotide sequence encoding a different polypeptide. It is widely appreciated that fusion proteins can also facilitate the expression of proteins, and accordingly, can be used in the expression of the *hedgehog* polypeptides of the present invention. For example, *hedgehog* polypeptides can be generated as glutathione-S-transferase (GST-fusion) proteins. Such GST-fusion proteins can enable easy purification of the *hedgehog* polypeptide, as for example by the use of glutathione-derivatized matrices (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. (N.Y.: John Wiley & Sons, 1991)). In another embodiment, a fusion gene coding for a purification leader sequence, such as a poly-(His)/enterokinase cleavage site sequence, can be used to replace the signal sequence which naturally occurs at the N-terminus of the *hedgehog* protein (e.g. of the pro-form, in order to permit purification of the poly(His)-*hedgehog* protein by affinity

chromatography using a Ni^{2+} metal resin. The purification leader sequence can then be subsequently removed by treatment with enterokinase (e.g., see Hochuli et al. (1987) *J. Chromatography* 411:177; and Janknecht et al. *PNAS* 88:8972).

Techniques for making fusion genes are known to those skilled in the art. Essentially, the joining of various DNA fragments coding for different polypeptide sequences is performed in accordance with conventional techniques, employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers which give rise to complementary overhangs between two consecutive gene fragments which can subsequently be annealed to generate a chimeric gene sequence (see, for example, *Current Protocols in Molecular Biology*, eds. Ausubel et al. John Wiley & Sons: 1992).

Hedgehog polypeptides may also be chemically modified to create *hedgehog* derivatives by forming covalent or aggregate conjugates with other chemical moieties, such as glycosyl groups, cholesterol, isoprenoids, lipids, phosphate, acetyl groups and the like. Covalent derivatives of *hedgehog* proteins can be prepared by linking the chemical moieties to functional groups on amino acid sidechains of the protein or at the N-terminus or at the C-terminus of the polypeptide.

For instance, *hedgehog* proteins can be generated to include a moiety, other than sequence naturally associated with the protein, that binds a component of the extracellular matrix and enhances localization of the analog to cell surfaces. For example, sequences derived from the fibronectin "type-III repeat", such as a tetrapeptide sequence R-G-D-S (Pierschbacher et al. (1984) *Nature* 309:30-3; and Kornblihtt et al. (1985) *EMBO* 4:1755-9) can be added to the *hedgehog* polypeptide to support attachment of the chimeric molecule to a cell through binding ECM components (Ruoslahti et al. (1987) *Science* 238:491-497; Pierschbacher et al. (1987) *J. Biol. Chem.* 262:17294-8.; Hynes (1987) *Cell* 48:549-54; and Hynes (1992) *Cell* 69:11-25).

In a preferred embodiment, the *hedgehog* polypeptide is isolated from, or is otherwise substantially free of, other cellular proteins, especially other extracellular or cell surface associated proteins which may normally be associated with the *hedgehog* polypeptide, unless provided in the form of fusion protein with the *hedgehog* polypeptide. The term "substantially free of other cellular or extracellular proteins" (also referred to herein as "contaminating proteins") or "substantially pure preparations" or "purified preparations" are defined as encompassing preparations of *hedgehog* polypeptides having less than 20% (by dry weight) contaminating protein, and preferably having less than 5% contaminating protein. By "purified", it is meant that the indicated molecule is present in the substantial absence of other biological macromolecules, such as other proteins. The term "purified" as used herein preferably means at least 80% by dry weight, more preferably in the range of 95-99% by weight, and most preferably at least 99.8% by weight, of biological macromolecules of the same type present (but water, buffers, and other small molecules, especially molecules having a molecular weight of less than 5000, can be present). The term "pure" as used herein preferably has the same numerical limits as "purified" immediately above.

As described above for recombinant polypeptides, isolated *hedgehog* polypeptides can include all or a portion of the amino acid sequences represented in any of SEQ ID Nos:10-18 or 20, or a homologous sequence thereto. Preferred fragments of the subject *hedgehog* proteins correspond to the N-terminal and C-terminal proteolytic fragments of the mature protein. Bioactive fragments of *hedgehog* polypeptides are described in great detail in PCT publications WO 95/18856 and WO 96/17924.

With respect to bioactive fragments of *hedgehog* polypeptide, preferred *hedgehog* therapeutics include at least 50 (contiguous) amino acid residues of a *hedgehog* polypeptide, more preferably at least 100 (contiguous), and even more preferably at least 150 (contiguous) residues.

Another preferred *hedgehog* polypeptide which can be included in the *hedgehog* therapeutic is an N-terminal fragment of the mature protein having a molecular weight of approximately 19 kDa.

Preferred human *hedgehog* proteins include N-terminal fragments corresponding approximately to residues 24-197 of SEQ ID No. 15, 28-202 of SEQ ID No. 16, and 23-198

of SEQ ID No. 17. By "corresponding approximately" it is meant that the sequence of interest is at most 20 amino acid residues different in length to the reference sequence, though more preferably at most 5, 10 or 15 amino acid different in length.

As described above for recombinant polypeptides, isolated *hedgehog* polypeptides
5 can include all or a portion of the amino acid sequences represented in SEQ ID No:8, SEQ ID No:9, SEQ ID No:10, SEQ ID No:11, SEQ ID No:12, SEQ ID No:13 or SEQ ID No:14, or a homologous sequence thereto. Preferred fragments of the subject *hedgehog* proteins correspond to the N-terminal and C-terminal proteolytic fragments of the mature protein. Bioactive fragments of *hedgehog* polypeptides are described in great detail in PCT
10 publications WO 95/18856 and WO 96/17924.

Still other preferred *hedgehog* polypeptides includes an amino acid sequence represented by the formula A-B wherein: (i) A represents all or the portion of the amino acid sequence designated by residues 1-168 of SEQ ID No:21; and B represents at least one amino acid residue of the amino acid sequence designated by residues 169-221 of SEQ ID No:21;
15 (ii) A represents all or the portion of the amino acid sequence designated by residues 24-193 of SEQ ID No:15; and B represents at least one amino acid residue of the amino acid sequence designated by residues 194-250 of SEQ ID No:15; (iii) A represents all or the portion of the amino acid sequence designated by residues 25-193 of SEQ ID No:13; and B represents at least one amino acid residue of the amino acid sequence designated by residues
20 194-250 of SEQ ID No:13; (iv) A represents all or the portion of the amino acid sequence designated by residues 23-193 of SEQ ID No:11; and B represents at least one amino acid residue of the amino acid sequence designated by residues 194-250 of SEQ ID No:11; (v) A represents all or the portion of the amino acid sequence designated by residues 28-197 of SEQ ID No:12; and B represents at least one amino acid residue of the amino acid sequence
25 designated by residues 198-250 of SEQ ID No:12; (vi) A represents all or the portion of the amino acid sequence designated by residues 29-197 of SEQ ID No:16; and B represents at least one amino acid residue of the amino acid sequence designated by residues 198-250 of SEQ ID No:16; or (vii) A represents all or the portion of the amino acid sequence designated by residues 23-193 of SEQ ID No. 17, and B represents at least one amino acid residue of the
30 amino acid sequence designated by residues 194-250 of SEQ ID No. 17. In certain preferred

embodiments, A and B together represent a contiguous polypeptide sequence designated sequence, A represents at least 25, 50, 75, 100, 125 or 150 (contiguous) amino acids of the designated sequence, and B represents at least 5, 10, or 20 (contiguous) amino acid residues of the amino acid sequence designated by corresponding entry in the sequence listing, and A
5 and B together preferably represent a contiguous sequence corresponding to the sequence listing entry. Similar fragments from other *hedgehog* also contemplated, e.g., fragments which correspond to the preferred fragments from the sequence listing entries which are enumerated above. In preferred embodiments, the *hedgehog* polypeptide includes a C-terminal glycine (or other appropriate residue) which is derivatized with a cholesterol.

10 Isolated peptidyl portions of *hedgehog* proteins can be obtained by screening peptides recombinantly produced from the corresponding fragment of the nucleic acid encoding such peptides. In addition, fragments can be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, a *hedgehog* polypeptide of the present invention may be arbitrarily divided into fragments of
15 desired length with no overlap of the fragments, or preferably divided into overlapping fragments of a desired length. The fragments can be produced (recombinantly or by chemical synthesis) and tested to identify those peptidyl fragments which can function as either agonists or antagonists of a wild-type (e.g., "authentic") *hedgehog* protein. For example, Román et al. (1994) *Eur J Biochem* 222:65-73 describe the use of competitive-binding assays
20 using short, overlapping synthetic peptides from larger proteins to identify binding domains.

The recombinant *hedgehog* polypeptides of the present invention also include homologs of the authentic *hedgehog* proteins, such as versions of those protein which are resistant to proteolytic cleavage, as for example, due to mutations which alter potential cleavage sequences or which inactivate an enzymatic activity associated with the protein.

25 *Hedgehog* homologs of the present invention also include proteins which have been post-translationally modified in a manner different than the authentic protein. Exemplary derivatives of *hedgehog* proteins include polypeptides which lack N-glycosylation sites (e.g. to produce an unglycosylated protein), which lack sites for cholesterolization, and/or which lack N-terminal and/or C-terminal sequences.

Modification of the structure of the subject *hedgehog* polypeptides can also be for such purposes as enhancing therapeutic or prophylactic efficacy, or stability (e.g., *ex vivo* shelf life and resistance to proteolytic degradation *in vivo*). Such modified peptides, when designed to retain at least one activity of the naturally-occurring form of the protein, are
5 considered functional equivalents of the *hedgehog* polypeptides described in more detail herein. Such modified peptides can be produced, for instance, by amino acid substitution, deletion, or addition.

It is well known in the art that one could reasonably expect that certain isolated replacements of amino acids, e.g., replacement of an amino acid residue with another related
10 amino acid (i.e. isosteric and/or isoelectric mutations), can be carried out without major effect on the biological activity of the resulting molecule. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids can be divided into four families: (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine; (3) nonpolar = alanine, valine, leucine, isoleucine,
15 proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar = glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In similar fashion, the amino acid repertoire can be grouped as (1) acidic = aspartate, glutamate; (2) basic = lysine, arginine, histidine, (3) aliphatic = glycine, alanine, valine, leucine, isoleucine, serine,
20 threonine, with serine and threonine optionally be grouped separately as aliphatic-hydroxyl; (4) aromatic = phenylalanine, tyrosine, tryptophan; (5) amide = asparagine, glutamine; and (6) sulfur -containing = cysteine and methionine. (see, for example, *Biochemistry*, 2nd ed., Ed. by L. Stryer, WH Freeman and Co.: 1981). Whether a change in the amino acid sequence of a peptide results in a functional *hedgehog* homolog (e.g. functional in the sense
25 that it acts to mimic or antagonize the wild-type form) can be readily determined by assessing the ability of the variant peptide to produce a response in cells in a fashion similar to the wild-type protein, or competitively inhibit such a response. Polypeptides in which more than one replacement has taken place can readily be tested in the same manner.

It is specifically contemplated that the methods of the present invention can be carried
30 using homologs of naturally occurring *hedgehog* proteins. In one embodiment, the invention

contemplates using *hedgehog* polypeptides generated by combinatorial mutagenesis. Such methods, as are known in the art, are convenient for generating both point and truncation mutants, and can be especially useful for identifying potential variant sequences (e.g. homologs) that are functional in binding to a receptor for *hedgehog* proteins. The purpose of screening such combinatorial libraries is to generate, for example, novel *hedgehog* homologs which can act as either agonists or antagonist. To illustrate, *hedgehog* homologs can be engineered by the present method to provide more efficient binding to a cognate receptor, such as *patched*, yet still retain at least a portion of an activity associated with *hedgehog*. Thus, combinatorially-derived homologs can be generated to have an increased potency relative to a naturally occurring form of the protein. Likewise, *hedgehog* homologs can be generated by the present combinatorial approach to act as antagonists, in that they are able to mimic, for example, binding to other extracellular matrix components (such as receptors), yet not induce any biological response, thereby inhibiting the action of authentic *hedgehog* or *hedgehog* agonists. Moreover, manipulation of certain domains of *hedgehog* by the present method can provide domains more suitable for use in fusion proteins, such as one that incorporates portions of other proteins which are derived from the extracellular matrix and/or which bind extracellular matrix components.

To further illustrate the state of the art of combinatorial mutagenesis, it is noted that the review article of Gallop et al. (1994) *J Med Chem* 37:1233 describes the general state of the art of combinatorial libraries as of the earlier 1990's. In particular, Gallop et al state at page 1239 "[s]creening the analog libraries aids in determining the minimum size of the active sequence and in identifying those residues critical for binding and intolerant of substitution". In addition, the Ladner et al. PCT publication WO90/02809, the Goeddel et al. U.S. Patent 5,223,408, and the Markland et al. PCT publication WO92/15679 illustrate specific techniques which one skilled in the art could utilize to generate libraries of *hedgehog* variants which can be rapidly screened to identify variants/fragments which retained a particular activity of the *hedgehog* polypeptides. These techniques are exemplary of the art and demonstrate that large libraries of related variants/truncants can be generated and assayed to isolate particular variants without undue experimentation. Gustin et al. (1993) *Virology* 193:653, and Bass et al. (1990) *Proteins: Structure, Function and Genetics* 8:309-314

also describe other exemplary techniques from the art which can be adapted as means for generating mutagenic variants of *hedgehog* polypeptides.

Indeed, it is plain from the combinatorial mutagenesis art that large scale mutagenesis of *hedgehog* proteins, without any preconceived ideas of which residues were critical to the biological function, and generate wide arrays of variants having equivalent biological activity. Indeed, it is the ability of combinatorial techniques to screen billions of different variants by high throughout analysis that removes any requirement of *a priori* understanding or knowledge of critical residues.

To illustrate, the amino acid sequences for a population of *hedgehog* homologs or other related proteins are aligned, preferably to promote the highest homology possible. Such a population of variants can include, for example, *hedgehog* homologs from one or more species. Amino acids which appear at each position of the aligned sequences are selected to create a degenerate set of combinatorial sequences. In a preferred embodiment, the variegated library of *hedgehog* variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For instance, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential *hedgehog* sequences are expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g. for phage display) containing the set of *hedgehog* sequences therein.

As illustrated in PCT publication WO 95/18856, to analyze the sequences of a population of variants, the amino acid sequences of interest can be aligned relative to sequence homology. The presence or absence of amino acids from an aligned sequence of a particular variant is relative to a chosen consensus length of a reference sequence, which can be real or artificial.

In an illustrative embodiment, alignment of exons 1, 2 and a portion of exon 3 encoded sequences (e.g. the N-terminal approximately 221 residues of the mature protein) of each of the *Shh* clones produces a degenerate set of *Shh* polypeptides represented by the general formula:

C-G-P-G-R-G-X(1)-G-X(2)-R-R-H-P-K-K-L-T-P-L-A-Y-K-Q-F-I-P-N-V-A-
 E-K-T-L-G-A-S-G-R-Y-E-G-K-I-X(3)-R-N-S-E-R-F-K-E-L-T-P-N-Y-N-P-D-
 I-I-F-K-D-E-E-N-T-G-A-D-R-L-M-T-Q-R-C-K-D-K-L-N-X(4)-L-A-I-S-V-
 M-N-X(5)-W-P-G-V-X(6)-L-R-V-T-E-G-W-D-E-D-G-H-H-X(7)-E-E-S-L-H-
 5 Y-E-G-R-A-V-D-I-T-T-S-D-R-D-X(8)-S-K-Y-G-X(9)-L-X(10)-R-L-A-V-E-
 A-G-F-D-W-V-Y-Y-E-S-K-A-H-I-H-C-S-V-K-A-E-N-S-V-A-A-K-S-G-G-C-
 F-P-G-S-A-X(11)-V-X(12)-L-X(13)-X(14)-G-G-X(15)-K-X(16)-V-K-D-L-
 X(17)-P-G-D-X(18)-V-L-A-A-D-X(19)-X(20)-G-X(21)-L-X(22)-X(23)-S-D-
 F-X(24)-X(25)-F-X(26)-D-R (SEQ ID No: 21)

- 10 wherein each of the degenerate positions "X" can be an amino acid which occurs in that position in one of the human, mouse, chicken or zebrafish *Shh* clones, or, to expand the library, each X can also be selected from amongst amino acid residue which would be conservative substitutions for the amino acids which appear naturally in each of those positions. For instance, Xaa(1) represents Gly, Ala, Val, Leu, Ile, Phe, Tyr or Trp ; Xaa(2)
- 15 represents Arg, His or Lys; Xaa(3) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(4) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(5) represents Lys, Arg, His, Asn or Gln; Xaa(6) represents Lys, Arg or His; Xaa(7) represents Ser, Thr, Tyr, Trp or Phe; Xaa(8) represents Lys, Arg or His; Xaa(9) represents Met, Cys, Ser or Thr; Xaa(10) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(11) represents Leu, Val, Met, Thr or Ser; Xaa(12)
- 20 represents His, Phe, Tyr, Ser, Thr, Met or Cys; Xaa(13) represents Gln, Asn, Glu, or Asp; Xaa(14) represents His, Phe, Tyr, Thr, Gln, Asn, Glu or Asp; Xaa(15) represents Gln, Asn, Glu, Asp, Thr, Ser, Met or Cys; Xaa(16) represents Ala, Gly, Cys, Leu, Val or Met; Xaa(17) represents Arg, Lys, Met, Ile, Asn, Asp, Glu, Gln, Ser, Thr or Cys; Xaa(18) represents Arg, Lys, Met or Ile; Xaa(19) represents Ala, Gly, Cys, Asp, Glu, Gln, Asn, Ser, Thr or Met;
- 25 Xaa(20) represents Ala, Gly, Cys, Asp, Asn, Glu or Gln; Xaa(21) represents Arg, Lys, Met, Ile, Asn, Asp, Glu or Gln; Xaa(22) represent Leu, Val, Met or Ile; Xaa(23) represents Phe, Tyr, Thr, His or Trp; Xaa(24) represents Ile, Val, Leu or Met; Xaa(25) represents Met, Cys, Ile, Leu, Val, Thr or Ser; Xaa(26) represents Leu, Val, Met, Thr or Ser. In an even more expansive library, each X can be selected from any amino acid.

In similar fashion, alignment of each of the human, mouse, chicken and zebrafish *hedgehog* clones, can provide a degenerate polypeptide sequence represented by the general formula:

5 C-G-P-G-R-G-X(1)-X(2)-X(3)-R-R-X(4)-X(5)-X(6)-P-K-X(7)-L-X(8)-P-L-
X(9)-Y-K-Q-F-X(10)-P-X(11)-X(12)-X(13)-E-X(14)-T-L-G-A-S-G-X(15)-
X(16)-E-G-X(17)-X(18)-X(19)-R-X(20)-S-E-R-F-X(21)-X(22)-L-T-P-N-Y-
N-P-D-I-I-F-K-D-E-E-N-X(23)-G-A-D-R-L-M-T-X(24)-R-C-K-X(25)-X(26)-
X(27)-N-X(28)-L-A-I-S-V-M-N-X(29)-W-P-G-V-X(30)-L-R-V-T-E-G-
X(31)-D-E-D-G-H-H-X(32)-X(33)-X(34)-S-L-H-Y-E-G-R-A-X(35)-D-I-T-T-
10 S-D-R-D-X(36)-X(37)-K-Y-G-X(38)-L-X(39)-R-L-A-V-E-A-G-F-D-W-V-Y-
Y-E-S-X(40)-X(41)-H-X(42)-H-X(43)-S-V-K-X(44)-X(45) (SEQ IDNo:22

wherein, as above, each of the degenerate positions "X" can be an amino acid which occurs in a corresponding position in one of the wild-type clones, and may also include amino acid residue which would be conservative substitutions, or each X can be any amino acid residue.

15 In an exemplary embodiment, Xaa(1) represents Gly, Ala, Val, Leu, Ile, Pro, Phe or Tyr; Xaa(2) represents Gly, Ala, Val, Leu or Ile; Xaa(3) represents Gly, Ala, Val, Leu, Ile, Lys, His or Arg; Xaa(4) represents Lys, Arg or His; Xaa(5) represents Phe, Trp, Tyr or an amino acid gap; Xaa(6) represents Gly, Ala, Val, Leu, Ile or an amino acid gap; Xaa(7) represents Asn, Gln, His, Arg or Lys; Xaa(8) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(9)
20 represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(10) represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(11) represents Ser, Thr, Gln or Asn; Xaa(12) represents Met, Cys, Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(13) represents Gly, Ala, Val, Leu, Ile or Pro; Xaa(14) represents Arg, His or Lys; Xaa(15) represents Gly, Ala, Val, Leu, Ile, Pro, Arg, His or Lys; Xaa(16) represents Gly, Ala, Val, Leu, Ile, Phe or Tyr; Xaa(17) represents Arg, His or Lys; Xaa(18)
25 represents Gly, Ala, Val, Leu, Ile, Ser or Thr; Xaa(19) represents Thr or Ser; Xaa(20) represents Gly, Ala, Val, Leu, Ile, Asn or Gln; Xaa(21) represents Arg, His or Lys; Xaa(22) represents Asp or Glu; Xaa(23) represents Ser or Thr; Xaa(24) represents Glu, Asp, Gln or Asn; Xaa(25) represents Glu or Asp; Xaa(26) represents Arg, His or Lys; Xaa(27) represents Gly, Ala, Val, Leu or Ile; Xaa(28) represents Gly, Ala, Val, Leu, Ile, Thr or Ser; Xaa(29)
30 represents Met, Cys, Gln, Asn, Arg, Lys or His; Xaa(30) represents Arg, His or Lys; Xaa(31)

represents Trp, Phe, Tyr, Arg, His or Lys; Xaa(32) represents Gly, Ala, Val, Leu, Ile, Ser, Thr, Tyr or Phe; Xaa(33) represents Gln, Asn, Asp or Glu; Xaa(34) represents Asp or Glu; Xaa(35) represents Gly, Ala, Val, Leu, or Ile; Xaa(36) represents Arg, His or Lys; Xaa(37) represents Asn, Gln, Thr or Ser; Xaa(38) represents Gly, Ala, Val, Leu, Ile, Ser, Thr, Met or Cys; Xaa(39) represents Gly, Ala, Val, Leu, Ile, Thr or Ser; Xaa(40) represents Arg, His or Lys; Xaa(41) represents Asn, Gln, Gly, Ala, Val, Leu or Ile; Xaa(42) represents Gly, Ala, Val, Leu or Ile; Xaa(43) represents Gly, Ala, Val, Leu, Ile, Ser, Thr or Cys; Xaa(44) represents Gly, Ala, Val, Leu, Ile, Thr or Ser; and Xaa(45) represents Asp or Glu.

There are many ways by which the library of potential *hedgehog* homologs can be generated from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The purpose of a degenerate set of genes is to provide, in one mixture, all of the sequences encoding the desired set of potential *hedgehog* sequences. The synthesis of degenerate oligonucleotides is well known in the art (see for example, Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos. Macromolecules*, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249:404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

A wide range of techniques are known in the art for screening gene products of combinatorial libraries made by point mutations, and for screening cDNA libraries for gene products having a certain property. Such techniques will be generally adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of *hedgehog* homologs. The most widely used techniques for screening large gene libraries typically comprises cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates relatively easy isolation of

the vector encoding the gene whose product was detected. Each of the illustrative assays described below are amenable to high through-put analysis as necessary to screen large numbers of degenerate *hedgehog* sequences created by combinatorial mutagenesis techniques.

5 In one embodiment, the combinatorial library is designed to be secreted (e.g. the polypeptides of the library all include a signal sequence but no transmembrane or cytoplasmic domains), and is used to transfect a eukaryotic cell that can be co-cultured with lung cells, e.g., lung mesenchymal or epithelial cells. A functional *hedgehog* protein secreted by the cells expressing the combinatorial library will diffuse to the neighboring lung cells and
10 induce a particular biological response, such as proliferation. The pattern of detection of proliferation will resemble a gradient function, and will allow the isolation (generally after several repetitive rounds of selection) of cells producing *hedgehog* homologs active as proliferative agents with respect to the lung cells. Likewise, *hedgehog* antagonists can be selected in similar fashion by the ability of the cell producing a functional antagonist to
15 protect neighboring cells (e.g., to inhibit proliferation) from the effect of wild-type *hedgehog* added to the culture media.

To illustrate, target lung cells are cultured in 24-well microtitre plates. Other eukaryotic cells are transfected with the combinatorial *hedgehog* gene library and cultured in cell culture inserts (e.g. Collaborative Biomedical Products, Catalog #40446) that are able to
20 fit into the wells of the microtitre plate. The cell culture inserts are placed in the wells such that recombinant *hedgehog* homologs secreted by the cells in the insert can diffuse through the porous bottom of the insert and contact the target cells in the microtitre plate wells. After a period of time sufficient for functional forms of a *hedgehog* protein to produce a measurable response in the target cells, such as proliferation, the inserts are removed and the
25 effect of the variant *hedgehog* proteins on the target cells determined. Cells from the inserts corresponding to wells which score positive for activity can be split and re-cultured on several inserts, the process being repeated until the active clones are identified.

In yet another screening assay, the candidate *hedgehog* gene products are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to
30 associate with a *hedgehog*-binding moiety (such as the *patched* protein or other *hedgehog*

receptor) via this gene product is detected in a "panning assay". Such panning steps can be carried out on cells cultured from embryos. For instance, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) *Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In a similar fashion, fluorescently labeled molecules which bind *hedgehog* can be used to score for potentially functional *hedgehog* homologs. Cells can be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, separated by a fluorescence-activated cell sorter.

In an alternate embodiment, the gene library is expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at very high concentrations, large number of phage can be screened at one time. Second, since each infectious phage displays the combinatorial gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E.coli* filamentous phages M13, fd, and f1 are most often used in phage display libraries, as either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) *J. Biol. Chem.* 267:16007-16010; Griffiths et al. (1993) *EMBO J* 12:725-734; Clackson et al. (1991) *Nature* 352:624-628; and Barbas et al. (1992) *PNAS* 89:4457-4461).

In an illustrative embodiment, the recombinant phage antibody system (RPAS, Pharmacia Catalog number 27-9400-01) can be easily modified for use in expressing and screening *hedgehog* combinatorial libraries. For instance, the pCANTAB 5 phagemid of the RPAS kit contains the gene which encodes the phage gIII coat protein. The *hedgehog* combinatorial gene library can be cloned into the phagemid adjacent to the gIII signal sequence such that it will be expressed as a gIII fusion protein. After ligation, the phagemid is used to transform competent *E. coli* TG1 cells. Transformed cells are subsequently

infected with M13KO7 helper phage to rescue the phagemid and its candidate *hedgehog* gene insert. The resulting recombinant phage contain phagemid DNA encoding a specific candidate *hedgehog*, and display one or more copies of the corresponding fusion coat protein. The phage-displayed candidate *hedgehog* proteins which are capable of binding an *hedgehog* receptor are selected or enriched by panning. For instance, the phage library can be applied to cells which express the *patched* protein and unbound phage washed away from the cells. The bound phage is then isolated, and if the recombinant phage express at least one copy of the wild type gIII coat protein, they will retain their ability to infect *E. coli*. Thus, successive rounds of reinfection of *E. coli*, and panning will greatly enrich for *hedgehog* homologs, which can then be screened for further biological activities in order to differentiate agonists and antagonists.

Combinatorial mutagenesis has a potential to generate very large libraries of mutant proteins, e.g., in the order of 10^{26} molecules. Combinatorial libraries of this size may be technically challenging to screen even with high throughput screening assays such as phage display. To overcome this problem, a new technique has been developed recently, recursive ensemble mutagenesis (REM), which allows one to avoid the very high proportion of non-functional proteins in a random library and simply enhances the frequency of functional proteins, thus decreasing the complexity required to achieve a useful sampling of sequence space. REM is an algorithm which enhances the frequency of functional mutants in a library when an appropriate selection or screening method is employed (Arkin and Yourvan, 1992, *PNAS USA* 89:7811-7815; Yourvan et al., 1992, *Parallel Problem Solving from Nature*, 2., In Maenner and Manderick, eds., Elsevir Publishing Co., Amsterdam, pp. 401-410; Delgrave et al., 1993, *Protein Engineering* 6(3):327-331).

The invention also provides for reduction of the *hedgehog* protein to generate mimetics, e.g. peptide or non-peptide agents, which are able to disrupt binding of a *hedgehog* polypeptide of the present invention with an *hedgehog* receptor. Thus, such mutagenic techniques as described above are also useful to map the determinants of the *hedgehog* proteins which participate in protein-protein interactions involved in, for example, binding of the subject *hedgehog* polypeptide to other extracellular matrix components. To illustrate, the critical residues of a subject *hedgehog* polypeptide which are involved in molecular

recognition of an *hedgehog* receptor such as *patched* can be determined and used to generate *hedgehog*-derived peptidomimetics which competitively inhibit binding of the authentic *hedgehog* protein with that moiety. By employing, for example, scanning mutagenesis to map the amino acid residues of each of the subject *hedgehog* proteins which are involved in binding other extracellular proteins, peptidomimetic compounds can be generated which mimic those residues of the *hedgehog* protein which facilitate the interaction. Such mimetics may then be used to interfere with the normal function of a *hedgehog* protein. For instance, non-hydrolyzable peptide analogs of such residues can be generated using benzodiazepine (e.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans* 1:1231), and β -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71).

Recombinantly produced forms of the *hedgehog* proteins can be produced using, e.g., expression vectors containing a nucleic acid encoding a *hedgehog* polypeptide, operably linked to at least one transcriptional regulatory sequence. Operably linked is intended to mean that the nucleotide sequence is linked to a regulatory sequence in a manner which allows expression of the nucleotide sequence. Regulatory sequences are art-recognized and are selected to direct expression of a *hedgehog* polypeptide. Accordingly, the term transcriptional regulatory sequence includes promoters, enhancers and other expression control elements. Such regulatory sequences are described in Goeddel; *Gene Expression Technology: Methods in Enzymology* 185, Academic Press, San Diego, CA (1990). For instance, any of a wide variety of expression control sequences, sequences that control the expression of a DNA sequence when operatively linked to it, may be used in these vectors to express DNA sequences encoding *hedgehog* polypeptide. Such useful expression control

sequences, include, for example, a viral LTR, such as the LTR of the Moloney murine leukemia virus, the early and late promoters of SV40, adenovirus or cytomegalovirus immediate early promoter, the lac system, the trp system, the TAC or TRC system, T7 promoter whose expression is directed by T7 RNA polymerase, the major operator and promoter regions of phage λ , the control regions for fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α -mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. It should be understood that the design of the expression vector may depend on such factors as the choice of the host cell to be transformed and/or the type of protein desired to be expressed. Moreover, the vector's copy number, the ability to control that copy number and the expression of any other proteins encoded by the vector, such as antibiotic markers, should also be considered.

In addition to providing a ready source of *hedgehog* polypeptides for purification, the gene constructs of the present invention can also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of a *hedgehog* polypeptide. Thus, another aspect of the invention features expression vectors for *in vivo* transfection of a *hedgehog* polypeptide in particular cell types so as cause ectopic expression of a *hedgehog* polypeptide in lung tissue.

Formulations of such expression constructs may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the recombinant gene to cells *in vivo*. Approaches include insertion of the *hedgehog* coding sequence in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO_4 precipitation carried out *in vivo*. It will be appreciated that because transduction of appropriate target cells represents the critical first

step in gene therapy, choice of the particular gene delivery system will depend on such factors as the phenotype of the intended target and the route of administration, e.g. locally or systemically. Furthermore, it will be recognized that the particular gene construct provided for *in vivo* transduction of *hedgehog* expression are also useful for *in vitro* transduction of cells, such as for use in the *ex vivo* tissue culture systems described below.

A preferred approach for *in vivo* introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding the particular form of the *hedgehog* polypeptide desired. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery system of choice for the transfer of exogenous genes *in vivo*, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. A major prerequisite for the use of retroviruses is to ensure the safety of their use, particularly with regard to the possibility of the spread of wild-type virus in the cell population. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased the utility of retroviruses for gene therapy, and defective retroviruses are well characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). Thus, recombinant retrovirus can be constructed in which part of the retroviral coding sequence (*gag*, *pol*, *env*) has been replaced by nucleic acid encoding a *hedgehog* polypeptide and renders the retrovirus replication defective. The replication defective retrovirus is then packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells *in vitro* or *in vivo* with such viruses can be found in Current Protocols in Molecular Biology, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are well known to those skilled in the art. Examples of suitable packaging virus lines

for preparing both ecotropic and amphotropic retroviral systems include Crip, Cre, 2 and Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including lung cells, *in vitro* and/or *in vivo* (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; 5 Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Furthermore, it has been shown that it is possible to limit the infection spectrum of retroviruses and consequently of retroviral-based vectors, by modifying the viral packaging 15 proteins on the surface of the viral particle (see, for example PCT publications WO93/25234 and WO94/06920). For instance, strategies for the modification of the infection spectrum of retroviral vectors include: coupling antibodies specific for cell surface antigens to the viral *env* protein (Roux et al. (1989) *PNAS* 86:9079-9083; Julian et al. (1992) *J. Gen Virol* 73:3251-3255; and Goud et al. (1983) *Virology* 163:251-254); or coupling cell surface 20 receptor ligands to the viral *env* proteins (Neda et al. (1991) *J Biol Chem* 266:14143-14146). Coupling can be in the form of the chemical cross-linking with a protein or other variety (e.g. lactose to convert the *env* protein to an asialoglycoprotein), as well as by generating fusion proteins (e.g. single-chain antibody/*env* fusion proteins). This technique, while useful to limit or otherwise direct the infection to certain tissue types, can also be used to convert an 25 ecotropic vector in to an amphotropic vector.

Moreover, use of retroviral gene delivery can be further enhanced by the use of tissue- or cell-specific transcriptional regulatory sequences which control expression of the *hedgehog* gene of the retroviral vector.

Another viral gene delivery system useful in the present method utilizes adenovirus- 30 derived vectors. The genome of an adenovirus can be manipulated such that it encodes and

expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See for example Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are well known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they can be used to infect a wide variety of cell types, including lung cells (Rosenfeld et al. (1992) cited *supra*). Furthermore, the virus particle is relatively stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis in situations where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267). Most replication-defective adenoviral vectors currently in use and therefore favored by the present invention are deleted for all or parts of the viral E1 and E3 genes but retain as much as 80% of the adenoviral genetic material (see, e.g., Jones et al. (1979) *Cell* 16:683; Berkner et al., *supra*; and Graham et al. in Methods in Molecular Biology, E.J. Murray, Ed. (Humana, Clifton, NJ, 1991) vol. 7. pp. 109-127). Expression of the inserted *hedgehog* gene can be under control of, for example, the E1A promoter, the major late promoter (MLP) and associated leader sequences, the E3 promoter, or exogenously added promoter sequences.

In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a *hedgehog* polypeptide in the tissue of an animal. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the *hedgehog* polypeptide gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes.

In clinical settings, the gene delivery systems for the therapeutic *hedgehog* gene can be introduced into a patient by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) *PNAS* 91: 3054-3057). A *hedgehog* expression construct can be delivered in a gene therapy construct to dermal cells by, e.g., electroporation using techniques described, for example, by Dev et al. ((1994) *Cancer Treat Rev* 20:105-115).

The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.

In yet another embodiment, the *ptc*, *hedgehog* or *fgf-10* therapeutic can be a "gene activation" construct which, by homologous recombination with a genomic DNA, alters the transcriptional regulatory sequences of an endogenous gene. For instance, the gene activation construct can replace the endogenous promoter of a *hedgehog* gene with a heterologous promoter, e.g., one which causes constitutive expression of the *hedgehog* gene or which causes inducible expression of the gene under conditions different from the normal expression pattern of the gene. Other genes in the *patched* signaling pathway can be similarly targeted. A variety of different formats for the gene activation constructs are available. See, for example, the Transkaryotic Therapies, Inc PCT publications WO93/09222, WO95/31560, WO96/29411, WO95/31560 and WO94/12650.

In preferred embodiments, the nucleotide sequence used as the gene activation construct can be comprised of (1) DNA from some portion of the endogenous *hedgehog* gene (exon sequence, intron sequence, promoter sequences, etc.) which direct recombination and (2) heterologous transcriptional regulatory sequence(s) which is to be operably linked to the coding sequence for the genomic *hedgehog* gene upon recombination of the gene activation construct. For use in generating cultures of *hedgehog* producing cells, the construct may further include a reporter gene to detect the presence of the knockout construct in the cell.

The gene activation construct is inserted into a cell, and integrates with the genomic DNA of the cell in such a position so as to provide the heterologous regulatory sequences in operative association with the native *hedgehog* gene. Such insertion occurs by homologous recombination, i.e., recombination regions of the activation construct that are homologous to the endogenous *hedgehog* gene sequence hybridize to the genomic DNA and recombine with the genomic sequences so that the construct is incorporated into the corresponding position of the genomic DNA.

The terms "recombination region" or "targeting sequence" refer to a segment (i.e., a portion) of a gene activation construct having a sequence that is substantially identical to or substantially complementary to a genomic gene sequence, e.g., including 5' flanking sequences of the genomic gene, and can facilitate homologous recombination between the genomic sequence and the targeting transgene construct.

As used herein, the term "replacement region" refers to a portion of a activation construct which becomes integrated into an endogenous chromosomal location following homologous recombination between a recombination region and a genomic sequence.

The heterologous regulatory sequences, e.g., which are provided in the replacement region, can include one or more of a variety elements, including: promoters (such as constitutive or inducible promoters), enhancers, negative regulatory elements, locus control regions, transcription factor binding sites, or combinations thereof. Promoters/enhancers which may be used to control the expression of the targeted gene *in vivo* include, but are not limited to, the cytomegalovirus (CMV) promoter/enhancer (Karasuyama et al., 1989, *J. Exp. Med.*, 169:13), the human β -actin promoter (Gunning et al. (1987) *PNAS* 84:4831-4835), the glucocorticoid-inducible promoter present in the mouse mammary tumor virus long terminal

repeat (MMTV LTR) (Klessig et al. (1984) *Mol. Cell Biol.* 4:1354-1362), the long terminal repeat sequences of Moloney murine leukemia virus (MuLV LTR) (Weiss et al. (1985) *RNA Tumor Viruses*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York), the SV40 early or late region promoter (Bernoist et al. (1981) *Nature* 290:304-310; Templeton et al. (1984) *Mol. Cell Biol.*, 4:817; and Sprague et al. (1983) *J. Virol.*, 45:773), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (RSV) (Yamamoto et al., 1980, *Cell*, 22:787-797), the herpes simplex virus (HSV) thymidine kinase promoter/enhancer (Wagner et al. (1981) *PNAS* 82:3567-71), and the herpes simplex virus LAT promoter (Wolfe et al. (1992) *Nature Genetics*, 1:379-384).

In an exemplary embodiment, portions of the 5' flanking region of the human *Shh* gene are amplified using primers which add restriction sites, to generate the following fragments

5'-gcgcgcttcgaaGCGAGGCAGCCAGCGAGGGAGAGAGCGAGCGGGCGAGCCGGAGC-GAGGAAatcgatgcgcgcg (primer 1)

5'-gcgcgcgagatctGGGAAAGCGCAAGAGAGAGCGCACACGCACACACCCGCCGCGCG-CACTCGggatccgcgcgcg (primer 2)

As illustrated, primer 1 includes a 5' non-coding region of the human *Shh* gene and is flanked by an *Asu*II and *Cla*I restriction sites. Primer 2 includes a portion of the 5' non-coding region immediately 3' to that present in primer 1. The *hedgehog* gene sequence is flanked by *Xho*II and *Bam*HI restriction sites. The purified amplimers are cut with each of the enzymes as appropriate.

The vector pCDNA1.1 (Invitrogen) includes a CMV promoter. The plasmid is cut with with *Asu*II, which cleaves just 3' to the CMV promoter sequence. The *Asu*II/*Cla*I fragment of primer 1 is ligated to the *Asu*II cleavage site of the pCDNA vector. The *Cla*I/*Asu*II ligation destroys the *Asu*II site at the 3' end of a properly inserted primer 1.

The vector is then cut with BamHI, and an XhoII/BamHI fragment of primer 2 is ligated to the BamHI cleavage site. As above, the BamHI/XhoII ligation destroys the BamHI site at the 5' end of a properly inserted primer 2.

Individual colonies are selected, cut with AsuII and BamHI, and the size of the AsuII/BamHI fragment determined. Colonies in which both the primer 1 and primer 2 sequences are correctly inserted are further amplified, and cut with AsuII and BamHI to produce the gene activation construct

```
cgaagcgaggcagccagcgagggagagagcgagcgggagcgagccggagcgaggaaATCGAAGG
TTCGAATCCTTCCCCACCACCATCACTTTCAAAGTCCGAAAGAATCTGCTCCCTGCTTGT
10 GTGTTGGAGGTGCTGAGTAGTGCGGAGTAAATTTAAGCTACAACAAGGCAAGGCTTGAC
CGACAATTGCATGAAGAATCTGCTTAGGGTTAGGCGTTTTGCGCTGCTTCGCGATGTACGGG
CCAGATATACGCGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCA
TTAGTTCATAGCCCATATATGGAGTTCGCGGTTACATAACTTACGGTAAATGGCCCGCCTGG
CTGACCGCCCAACGACCCCGCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGC
15 CAATAGGGACTTTCCATTGACGTCAATGGGTGGACTATTTACGGTAAACTGCCCACTTGCGA
GTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCC
CGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACG
TATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAG
CGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATGACGTCAATGGGAGTTTGTTTTG
20 GCACCAAATCAACGGGACTTTCCAAATGTCGTAACAACTCCGCCCCATTGACGCAAATGG
GCGGTAGGCGTGACGGTGGGAGGTCTATATAAGCAGAGCTCTCTGGCTAACTAGAGAACCC
ACTGCTTACTGGCTTATCGAAATTAATACGACTCACTATAGGGAGACCCAAGCTTGGTACCG
AGCTCGGATCgatctgggaaagcgcaagagagagcgcacacgcacacacccgccgcgcgcac
tcgg
```

In this construct, the flanking primer 1 and primer 2 sequences provide the recombination region which permits the insertion of the CMV promoter in front of the coding sequence for the human *Shh* gene. Other heterologous promoters (or other transcriptional regulatory sequences) can be inserted in a genomic *hedgehog* gene by a similar method.

In still other embodiments, the replacement region merely deletes a negative transcriptional control element of the native gene, e.g., to activate expression, or ablates a positive control element, e.g., to inhibit expression of the targeted gene.

V. Exemplary ptc therapeutic compounds.

In another embodiment, the subject method is carried out using a *ptc* therapeutic composition. Such compositions can be generated with, for example, compounds which bind to *patched* and alter its signal transduction activity, compounds which alter the binding and/or enzymatic activity of a protein (e.g., intracellular) involved in *patched* signal pathway, and compounds which alter the level of expression of a *hedgehog* protein, a *patched* protein or a protein involved in the intracellular signal transduction pathway of *patched*.

The availability of purified and recombinant *hedgehog* polypeptides facilitates the generation of assay systems which can be used to screen for drugs, such as small organic molecules, which are either agonists or antagonists of the normal cellular function of a *hedgehog* and/or *patched* protein, particularly their role in the pathogenesis of proliferation and/or differentiation of various lung cells and maintenance of lung tissue. In one embodiment, the assay evaluates the ability of a compound to modulate binding between a *hedgehog* polypeptide and a *hedgehog* receptor such as *patched*. In other embodiments, the assay merely scores for the ability of a test compound to alter the signal transduction activity of the *patched* protein. In this manner, a variety of *hedgehog* and/or *ptc* therapeutics, both proliferative and anti-proliferative in activity, can be identified. A variety of assay formats will suffice and, in light of the present disclosure, will be comprehended by skilled artisan.

In many drug screening programs which test libraries of compounds and natural extracts, high throughput assays are desirable in order to maximize the number of compounds surveyed in a given period of time. Assays which are performed in cell-free systems, such as may be derived with purified or semi-purified proteins, are often preferred as "primary" screens in that they can be generated to permit rapid development and relatively easy detection of an alteration in a molecular target which is mediated by a test compound. Moreover, the effects of cellular toxicity and/or bioavailability of the test compound can be generally ignored in the *in vitro* system, the assay instead being focused primarily on the

effect of the drug on the molecular target as may be manifest in an alteration of binding affinity with receptor proteins.

Accordingly, in an exemplary screening assay for *ptc* therapeutics, the compound of interest is contacted with a mixture including a *hedgehog* receptor protein (e.g., a cell expressing the *patched* receptor) and a *hedgehog* protein under conditions in which it is ordinarily capable of binding the *hedgehog* protein. To the mixture is then added a composition containing a test compound. Detection and quantification of receptor/*hedgehog* complexes provides a means for determining the test compound's efficacy at inhibiting (or potentiating) complex formation between the receptor protein and the *hedgehog* polypeptide. The efficacy of the compound can be assessed by generating dose response curves from data obtained using various concentrations of the test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. In the control assay, isolated and purified *hedgehog* polypeptide is added to the receptor protein, and the formation of receptor/*hedgehog* complex is quantitated in the absence of the test compound.

In other embodiments, a *ptc* therapeutic of the present invention is one which disrupts the association of *patched* with *smoothened*.

Agonist and antagonists of cell growth can be distinguished, and the efficacy of the compound can be assessed, by subsequent testing with certain lung cells, e.g., in culture.

In an illustrative embodiment, the polypeptide utilized as a *hedgehog* receptor can be generated from the *patched* protein. Accordingly, an exemplary screening assay includes all or a suitable portion of the *patched* protein which can be obtained from, for example, the human *patched* gene (GenBank U43148) or other vertebrate sources (see GenBank Accession numbers U40074 for chicken *patched* and U46155 for mouse *patched*), as well as from *drosophila* (GenBank Accession number M28999) or other invertebrate sources. The *patched* protein can be provided in the screening assay as a whole protein (preferably expressed on the surface of a cell), or alternatively as a fragment of the full length protein which binds to *hedgehog* polypeptides, e.g., as one or both of the substantial extracellular domains (e.g. corresponding to residues Asn120-Ser438 and/or Arg770-Trp1027 of the human *patched* protein - which are also potential antagonists of *hedgehog*-dependent signal transduction). For instance, the *patched* protein can be provided in soluble form, as for

example a preparation of one of the extracellular domains, or a preparation of both of the extracellular domains which are covalently connected by an unstructured linker (see, for example, Huston et al. (1988) PNAS 85:4879; and U.S. Patent No. 5,091,513). In other embodiments, the protein can be provided as part of a liposomal preparation or expressed on the surface of a cell. The *patched* protein can be derived from a recombinant gene, e.g., being ectopically expressed in a heterologous cell. For instance, the protein can be expressed on oocytes, mammalian cells (e.g., COS, CHO, 3T3 or the like), or yeast cell by standard recombinant DNA techniques. These recombinant cells can be used for receptor binding, signal transduction or gene expression assays. Marigo et al. (1996) *Development* 122:1225-1233 illustrates a binding assay of human *hedgehog* to chick *patched* protein ectopically expressed in *Xenopus laevis* oocytes. The assay system of Marigo et al. can be adapted to the present drug screening assays. As illustrated in that reference, *Shh* binds to the *patched* protein in a selective, saturable, dose-dependent manner, thus demonstrating that *patched* is a receptor for *Shh*.

Complex formation between the *hedgehog* polypeptide and a *hedgehog* receptor may be detected by a variety of techniques. For instance, modulation of the formation of complexes can be quantitated using, for example, detectably labelled proteins such as radiolabelled, fluorescently labelled, or enzymatically labelled *hedgehog* polypeptides, by immunoassay, or by chromatographic detection.

Typically, for cell-free assays, it will be desirable to immobilize either the *hedgehog* receptor or the *hedgehog* polypeptide to facilitate separation of receptor/*hedgehog* complexes from uncomplexed forms of one of the proteins, as well as to accommodate automation of the assay. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase/receptor (GST/receptor) fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the *hedgehog* polypeptide, e.g. an ³⁵S-labeled *hedgehog* polypeptide, and the test compound and incubated under conditions conducive to complex formation, e.g. at physiological conditions for salt and pH, though slightly more stringent conditions may be desired. Following incubation, the beads are washed to remove any unbound *hedgehog*

polypeptide, and the matrix bead-bound radiolabel determined directly (e.g. beads placed in scintillant), or in the supernatant after the receptor/*hedgehog* complexes are dissociated. Alternatively, the complexes can be dissociated from the bead, separated by SDS-PAGE gel, and the level of *hedgehog* polypeptide found in the bead fraction quantitated from the gel using standard electrophoretic techniques.

Other techniques for immobilizing proteins on matrices are also available for use in the subject assay. For instance, soluble portions of the *hedgehog* receptor protein can be immobilized utilizing conjugation of biotin and streptavidin. For instance, biotinylated receptor molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well known in the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, IL), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with the *hedgehog* receptor but which do not interfere with *hedgehog* binding can be derivatized to the wells of the plate, and the receptor trapped in the wells by antibody conjugation. As above, preparations of a *hedgehog* polypeptide and a test compound are incubated in the receptor-presenting wells of the plate, and the amount of receptor/*hedgehog* complex trapped in the well can be quantitated. Exemplary methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the *hedgehog* polypeptide, or which are reactive with the receptor protein and compete for binding with the *hedgehog* polypeptide; as well as enzyme-linked assays which rely on detecting an enzymatic activity associated with the *hedgehog* polypeptide. In the instance of the latter, the enzyme can be chemically conjugated or provided as a fusion protein with the *hedgehog* polypeptide. To illustrate, the *hedgehog* polypeptide can be chemically cross-linked or genetically fused with alkaline phosphatase, and the amount of *hedgehog* polypeptide trapped in the complex can be assessed with a chromogenic substrate of the enzyme, e.g. paranitrophenylphosphate. Likewise, a fusion protein comprising the *hedgehog* polypeptide and glutathione-S-transferase can be provided, and complex formation quantitated by detecting the GST activity using 1-chloro-2,4-dinitrobenzene (Habig et al (1974) *J Biol Chem* 249:7130).

For processes which rely on immunodetection for quantitating one of the proteins trapped in the complex, antibodies against the protein, such as the anti-*hedgehog* antibodies described herein, can be used. Alternatively, the protein to be detected in the complex can be "epitope tagged" in the form of a fusion protein which includes, in addition to the *hedgehog* polypeptide or *hedgehog* receptor sequence, a second polypeptide for which antibodies are readily available (e.g. from commercial sources). For instance, the GST fusion proteins described above can also be used for quantification of binding using antibodies against the GST moiety. Other useful epitope tags include myc-epitopes (e.g., see Ellison et al. (1991) *J Biol Chem* 266:21150-21157) which includes a 10-residue sequence from c-myc, as well as the pFLAG system (International Biotechnologies, Inc.) or the pEZZ-protein A system (Pharmacia, NJ).

Where the desired portion of the *hedgehog* receptor (or other *hedgehog* binding molecule) cannot be provided in soluble form, liposomal vesicles can be used to provide manipulatable and isolatable sources of the receptor. For example, both authentic and recombinant forms of the *patched* protein can be reconstituted in artificial lipid vesicles (e.g. phosphatidylcholine liposomes) or in cell membrane-derived vesicles (see, for example, Bear et al. (1992) *Cell* 68:809-818; Newton et al. (1983) *Biochemistry* 22:6110-6117; and Reber et al. (1987) *J Biol Chem* 262:11369-11374).

In addition to cell-free assays, such as described above, the readily available source of *hedgehog* proteins provided by the art also facilitates the generation of cell-based assays for identifying small molecule agonists/antagonists and the like. Analogous to the cell-based assays described above for screening combinatorial libraries, cells which are sensitive to *hedgehog* induction, e.g. *patched*-expressing cells or other lung-derived cells sensitive to *hedgehog* induction, can be contacted with a *hedgehog* protein and a test agent of interest, with the assay scoring for anything from simple binding to the cell to modulation in *hedgehog* inductive responses by the target cell in the presence and absence of the test agent. As with the cell-free assays, agents which produce a statistically significant change in *hedgehog* activities (either inhibition or potentiation) can be identified.

In other emdodiments, the cell-based assay scores for agents which disrupt association of *patched* and *smoothened* proteins, e.g., in the cell surface membrane or liposomal preparation.

In addition to characterizing cells that naturally express the *patched* protein, cells
5 which have been genetically engineered to ectopically express *patched* can be utilized for drug screening assays. As an example, cells which either express low levels or lack expression of the *patched* protein, e.g. *Xenopus laevis* oocytes, COS cells or yeast cells, can be genetically modified using standard techniques to ectopically express the *patched* protein. (see Marigo et al., *supra*).

10 The resulting recombinant cells, e.g., which express a functional *patched* receptor, can be utilized in receptor binding assays to identify agonist or anatagonsts of *hedgehog* binding. Binding assays can be performed using whole cells. Furthermore, the recombinant cells of the present invention can be engineered to include other heterolgous genes encoding proteins involved in *hedgehog*-dependent siganl pathways. For example, the gene products
15 of one or more of *smoothened*, *costal-2* and/or *fused* can be co-expressed with *patched* in the reagent cell, with assays being sensitive to the functional reconstituion of the *hedgehog* signal transduction cascade.

Alternatively, liposomal preparations using reconstituted *patched* protein can be utilized. *Patched* protein purified from detergent extracts from both authentic and
20 recombinant origins can be reconstituted in in artificial lipid vesicles (e.g. phosphatidylcholine liposomes) or in cell membrane-derived vesicles (see, for example, Bear et al. (1992) *Cell* 68:809-818; Newton et al. (1983) *Biochemistry* 22:6110-6117; and Reber et al. (1987) *J Biol Chem* 262:11369-11374). The lamellar structure and size of the resulting liposomes can be characterized using electron microscopy. External orientation of the
25 *patched* protein in the reconstituted membranes can be demonstrated, for example, by immunoelectron microscopy. The *hedgehog* protein binding activity of liposomes containing *patched* and liposomes without the protein in the presence of candidate agents can be compared in order to identify potential modulators of the *hedgehog-patched* interaction.

The *hedgehog* protein used in these cell-based assays can be provided as a purified
30 source (natural or recombinant in origin), or in the form of cells/tissue which express the

protein and which are co-cultured with the target cells. As in the cell-free assays, where simple binding (rather than induction) is the *hedgehog* activity scored for in the assay, the protein can be labelled by any of the above-mentioned techniques, e.g., fluorescently, enzymatically or radioactively, or detected by immunoassay.

5 In addition to binding studies, functional assays can be used to identify modulators, i.e., agonists or antagonists, of *hedgehog* or *patched* activities. By detecting changes in intracellular signals, such as alterations in second messengers or gene expression, in *patched*-expressing cells contacted with a test agent, candidate agonists and antagonists to *patched* signaling can be identified.

10 A number of gene products have been implicated in *patched*-mediated signal transduction, including *patched*, the transcription factor *cubitus interruptus* (*ci*), the serine/threonine kinase *fused* (*fu*) and the gene products of *costal-2*, *smoothened* and *suppressor of fused*.

The interaction of a *hedgehog* protein with *patched* sets in motion a cascade involving
15 the activation and inhibition of downstream effectors, the ultimate consequence of which is, in some instances, a detectable change in the transcription or translation of a gene. Potential transcriptional targets of *patched* signaling are the *patched* gene itself (Hidalgo and Ingham, 1990 *Development* 110, 291-301; Marigo et al., 1996) and the vertebrate homologs of the *drosophila cubitus interruptus* gene, the *GLI* genes (Hui et al. (1994) *Dev Biol* 162:402-413).

20 *Patched* gene expression has been shown to be induced in cells of the limb bud and the neural plate that are responsive to *Shh*. (Marigo et al. (1996) *PNAS*; Marigo et al. (1996) *Development* 122:1225-1233). The *GLI* genes encode putative transcription factors having zinc finger DNA binding domains (Orenic et al. (1990) *Genes & Dev* 4:1053-1067; Kinzler et al. (1990) *Mol Cell Biol* 10:634-642). Transcription of the *GLI* gene has been reported to
25 be upregulated in response to *hedgehog* in limb buds, while transcription of the *GLI3* gene is downregulated in response to *hedgehog* induction (Marigo et al. (1996) *Development* 122:1225-1233). By selecting transcriptional regulatory sequences from such target genes, e.g. from *patched* or *GLI* genes, that are responsible for the up- or down regulation of these genes in response to *patched* signalling, and operatively linking such promoters to a reporter
30 gene, one can derive a transcription based assay which is sensitive to the ability of a specific

test compound to modify *patched* signalling pathways. Expression of the reporter gene, thus, provides a valuable screening tool for the development of compounds that act as agonists or antagonists of *ptc* induction of differentiation/quiescence.

Reporter gene based assays of this invention measure the end stage of the above described cascade of events, e.g., transcriptional modulation. Accordingly, in practicing one embodiment of the assay, a reporter gene construct is inserted into the reagent cell in order to generate a detection signal dependent on *ptc* signaling. To identify potential regulatory elements responsive to *ptc* signaling present in the transcriptional regulatory sequence of a target gene, nested deletions of genomic clones of the target gene can be constructed using standard techniques. See, for example, Current Protocols in Molecular Biology, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989); U.S. Patent 5,266,488; Sato et al. (1995) *J Biol Chem* 270:10314-10322; and Kube et al. (1995) *Cytokine* 7:1-7. A nested set of DNA fragments from the gene's 5'-flanking region are placed upstream of a reporter gene, such as the luciferase gene, and assayed for their ability to direct reporter gene expression in *patched* expressing cells. Host cells transiently transfected with reporter gene constructs can be scored for the induction of expression of the reporter gene in the presence and absence of *hedgehog* to determine regulatory sequences which are responsive to *patched*-dependent signalling.

In practicing one embodiment of the assay, a reporter gene construct is inserted into the reagent cell in order to generate a detection signal dependent on second messengers generated by induction with *hedgehog* protein. Typically, the reporter gene construct will include a reporter gene in operative linkage with one or more transcriptional regulatory elements responsive to the *hedgehog* activity, with the level of expression of the reporter gene providing the *hedgehog*-dependent detection signal. The amount of transcription from the reporter gene may be measured using any method known to those of skill in the art to be suitable. For example, mRNA expression from the reporter gene may be detected using RNase protection or RNA-based PCR, or the protein product of the reporter gene may be identified by a characteristic stain or an intrinsic activity. The amount of expression from the reporter gene is then compared to the amount of expression in either the same cell in the absence of the test compound (or *hedgehog*) or it may be compared with the amount of

transcription in a substantially identical cell that lacks the target receptor protein. Any statistically or otherwise significant difference in the amount of transcription indicates that the test compound has in some manner altered the signal transduction of the *patched* protein, e.g., the test compound is a potential *ptc* therapeutic.

5 As described in further detail below, in preferred embodiments the gene product of the reporter is detected by an intrinsic activity associated with that product. For instance, the reporter gene may encode a gene product that, by enzymatic activity, gives rise to a detection signal based on color, fluorescence, or luminescence. In other preferred embodiments, the reporter or marker gene provides a selective growth advantage, e.g., the reporter gene may
10 enhance cell viability, relieve a cell nutritional requirement, and/or provide resistance to a drug.


Preferred reporter genes are those that are readily detectable. The reporter gene may also be included in the construct in the form of a fusion gene with a gene that includes desired transcriptional regulatory sequences or exhibits other desirable properties. Examples
15 of reporter genes include, but are not limited to CAT (chloramphenicol acetyl transferase) (Alton and Vapnek (1979), Nature 282: 864-869) luciferase, and other enzyme detection systems, such as beta-galactosidase; firefly luciferase (deWet et al. (1987), Mol. Cell. Biol. 7:725-737); bacterial luciferase (Engebrecht and Silverman (1984), PNAS 1: 4154-4158; Baldwin et al. (1984), Biochemistry 23: 3663-3667); alkaline phosphatase (Toh et al. (1989)
20 Eur. J. Biochem. 182: 231-238, Hall et al. (1983) J. Mol. Appl. Gen. 2: 101), human placental secreted alkaline phosphatase (Cullen and Malim (1992) Methods in Enzymol. 216:362-368).

Transcriptional control elements which may be included in a reporter gene construct include, but are not limited to, promoters, enhancers, and repressor and activator binding
25 sites. Suitable transcriptional regulatory elements may be derived from the transcriptional regulatory regions of genes whose expression is induced after modulation of a *patched* signal transduction pathway. The characteristics of preferred genes from which the transcriptional control elements are derived include, but are not limited to, low or undetectable expression in quiescent cells, rapid induction at the transcriptional level within minutes of extracellular
30 simulation, induction that is transient and independent of new protein synthesis, subsequent

shut-off of transcription requires new protein synthesis, and mRNAs transcribed from these genes have a short half-life. It is not necessary for all of these properties to be present.

In yet other embodiments, second messenger generation can be measured directly in the detection step, such as mobilization of intracellular calcium, phospholipid metabolism or adenylate cyclase activity are quantitated, for instance, the products of phospholipid hydrolysis IP_3 , DAG or cAMP could be measured. For example, recent studies have implicated protein kinase A (PKA) as a possible component of *hedgehog/patched* signaling (Hammerschmidt et al. (1996) *Genes & Dev* 10:647). High PKA activity has been shown to antagonize *hedgehog* signaling in these systems. Although it is unclear whether PKA acts directly downstream or in parallel with *hedgehog* signaling, it is possible that *hedgehog* signalling occurs via inhibition of PKA activity. Thus, detection of PKA activity provides a potential readout for the instant assays.

In a preferred embodiment, the *ptc* therapeutic is a PKA inhibitor. A variety of PKA inhibitors are known in the art, including both peptidyl and organic compounds. For instance, the *ptc* therapeutic can be a 5-isoquinolinesulfonamide, such as represented in the general formula:



wherein,

R_1 and R_2 each can independently represent hydrogen, and as valence and stability permit a lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, $-(CH_2)_m-R_8$, $-(CH_2)_m-OH$, $-(CH_2)_m-O$ -lower alkyl, $-(CH_2)_m-O$ -

lower alkenyl, $-(CH_2)_n-O-(CH_2)_m-R_8$, $-(CH_2)_m-SH$, $-(CH_2)_m-S$ -lower alkyl, $-(CH_2)_m-S$ -lower alkenyl, $-(CH_2)_n-S-(CH_2)_m-R_8$, or

R_1 and R_2 taken together with N form a heterocycle (substituted or unsubstituted);


R_3 is absent or represents one or more substitutions to the isoquinoline ring such as a

- 5 lower alkyl, a lower alkenyl, a lower alkynyl, a carbonyl (such as a carboxyl, an ester, a formate, or a ketone), a thiocarbonyl (such as a thioester, a thioacetate, or a thioformate), an amino, an acylamino, an amido, a cyano, a nitro, an azido, a sulfate, a sulfonate, a sulfonamido, $-(CH_2)_m-R_8$, $-(CH_2)_m-OH$, $-(CH_2)_m-O$ -lower alkyl, $-(CH_2)_m-O$ -lower alkenyl, $-(CH_2)_n-O-(CH_2)_m-R_8$, $-(CH_2)_m-SH$, $-(CH_2)_m-S$ -lower alkyl, $-(CH_2)_m-S$ -lower alkenyl,
 10 $-(CH_2)_n-S-(CH_2)_m-R_8$;


R_8 represents a substituted or unsubstituted aryl, aralkyl, cycloalkyl, cycloalkenyl, or heterocycle; and

n and m are independently for each occurrence zero or an integer in the range of 1 to 6.


- 15 In a preferred embodiment, the PKA inhibitor is N-[2-((p-bromocinnamyl)amino)ethyl]-5-isoquinolinesulfonamide (H-89; Calbiochem Cat. No. 371963), e.g., having the formula:





In another embodiment, the PKA inhibitor is 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7; Calbiochem Cat. No. 371955), e.g., having the formula:



In still other embodiments, the PKA inhibitor is KT5720 (Calbiochem Cat. No. 420315), having the structure



- 5 A variety of nucleoside analogs are also useful as PKA inhibitors. For example, the subject method can be carried out cyclic AMP analogs which inhibit the kinase activity of PKA, as for example, 8-bromo-cAMP or dibutyryl-cAMP



Exemplary peptidyl inhibitors of PKA activity include the PKA Heat Stable Inhibitor (isoform α ; see, for example, Calbiochem Cat. No. 539488, and Wen et al. (1995) *J Biol Chem* 270:2041).

Certain *hedehog* receptors may stimulate the activity of phospholipases. Inositol
5 lipids can be extracted and analyzed using standard lipid extraction techniques. Water soluble derivatives of all three inositol lipids (IP₁, IP₂, IP₃) can also be quantitated using radiolabelling techniques or HPLC.

The mobilization of intracellular calcium or the influx of calcium from outside the cell may be a response to *hedehog* stimulation or lack thereof. Calcium flux in the reagent
10 cell can be measured using standard techniques. The choice of the appropriate calcium indicator, fluorescent, bioluminescent, metallochromic, or Ca⁺⁺-sensitive microelectrodes depends on the cell type and the magnitude and time constant of the event under study (Borle (1990) *Environ Health Perspect* 84:45-56). As an exemplary method of Ca⁺⁺ detection, cells could be loaded with the Ca⁺⁺-sensitive fluorescent dye fura-2 or indo-1, using standard
15 methods, and any change in Ca⁺⁺ measured using a fluorometer.

In certain embodiments of the assay, it may be desirable to screen for changes in cellular phosphorylation. As an example, the drosophila gene *fused* (fu) which encodes a serine/threonine kinase has been identified as a potential downstream target in *hedehog* signaling. (Preat et al., 1990 *Nature* 347, 87-89; Therond et al. 1993, *Mech. Dev.* 44. 65-80).
20 The ability of compounds to modulate serine/threonine kinase activation could be screened using colony immunoblotting (Lyons and Nelson (1984) *Proc. Natl. Acad. Sci. USA* 81:7426-7430) using antibodies against phosphorylated serine or threonine residues. Reagents for performing such assays are commercially available, for example, phosphoserine and phosphothreonine specific antibodies which measure increases in phosphorylation of those
25 residues can be purchased from commercial sources.

In yet another embodiment, the *ptc* therapeutic is an antisense molecule which inhibits expression of a protein involved in a *patched*-mediated signal transduction pathway. To illustrate, by inhibiting the expression of a protein which are involved in *patched* signals,

such as fused, costal-2, smoothened and/or Gli genes, the ability of the *patched* signal pathway(s) to inhibit proliferation of a cell can be altered, e.g., potentiated or repressed.

As used herein, "antisense" therapy refers to administration or *in situ* generation of oligonucleotide probes or their derivatives which specifically hybridize (e.g. bind) under cellular conditions with cellular mRNA and/or genomic DNA encoding a *hedgehog* protein, *patched*, or a protein involved in *patched*-mediated signal transduction. The hybridization should inhibit expression of that protein, e.g. by inhibiting transcription and/or translation. The binding may be by conventional base pair complementarity, or, for example, in the case of binding to DNA duplexes, through specific interactions in the major groove of the double helix. In general, "antisense" therapy refers to the range of techniques generally employed in the art, and includes any therapy which relies on specific binding to oligonucleotide sequences.

An antisense construct of the present invention can be delivered, for example, as an expression plasmid which, when transcribed in the cell, produces RNA which is complementary to at least a unique portion of the target cellular mRNA. Alternatively, the antisense construct is an oligonucleotide probe which is generated *ex vivo* and which, when introduced into the cell causes inhibition of expression by hybridizing with the mRNA and/or genomic sequences of a target gene. Such oligonucleotide probes are preferably modified oligonucleotide which are resistant to endogenous nucleases, e.g. exonucleases and/or endonucleases, and is therefore stable *in vivo*. Exemplary nucleic acid molecules for use as antisense oligonucleotides are phosphoramidate, phosphothioate and methylphosphonate analogs of DNA (see also U.S. Patents 5,176,996; 5,264,564; and 5,256,775). Additionally, general approaches to constructing oligomers useful in antisense therapy have been reviewed, for example, by Van der Krol et al. (1988) *Biotechniques* 6:958-976; and Stein et al. (1988) *Cancer Res* 48:2659-2668.

Several considerations should be taken into account when constructing antisense oligonucleotides for the use in the methods of the invention: (1) oligos should have a GC content of 50% or more; (2) avoid sequences with stretches of 3 or more G's; and (3) oligonucleotides should not be longer than 25-26 mers. When testing an antisense oligonucleotide, a mismatched control can be constructed. The controls can be generated by

reversing the sequence order of the corresponding antisense oligonucleotide in order to conserve the same ratio of bases.

In an illustrative embodiment, the *ptc* therapeutic can be an antisense construct for inhibiting the expression of *patched*, e.g., to mimic the inhibition of *patched* by *hedgehog*.

5 Exemplary antisense constructs include:

5'-GTCCTGGCGCCGCCGCCGCGTCGCC

5'-TTCCGATGACCGGCCTTTCGCGGTGA

5'-GTGCACGGAAAGGTGCAGGCCACACT

10 VI. Exemplary pharmaceutical preparations of *hedgehog* and *ptc* therapeutics

The source of the *hedgehog* and *ptc* therapeutics to be formulated will depend on the particular form of the agent. Small organic molecules and peptidyl fragments can be chemically synthesized and provided in a pure form suitable for pharmaceutical/cosmetic usage. Products of natural extracts can be purified according to techniques known in the art.

15 For example, the Cox et al. U.S. Patent 5,286,654 describes a method for purifying naturally occurring forms of a secreted protein and can be adapted for purification of *hedgehog* polypeptides. Recombinant sources of *hedgehog* polypeptides are also available. For example, the gene encoding *hedgehog* polypeptides, are known, *inter alia*, from PCT publications WO 95/18856 and WO 96/17924.

20 Those of skill in treating lung tissues can determine the effective amount of an *ptc*, *hedgehog* or *fgf-10* therapeutic to be formulated in a pharmaceutical or cosmetic preparation.

The *ptc*, *hedgehog* or *fgf-10* therapeutic formulations used in the method of the invention are most preferably applied in the form of appropriate compositions. As appropriate compositions there may be cited all compositions usually employed for systemically or
25 topically administering drugs. The pharmaceutically acceptable carrier should be substantially inert, so as not to act with the active component. Suitable inert carriers include water, alcohol polyethylene glycol, mineral oil or petroleum gel, propylene glycol and the like.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular *ptc*, *hedgehog* or *fgf-10* therapeutic as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirable in unitary dosage form suitable, particularly, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represents the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. Also included are solid form preparations which are intended to be converted, shortly before use, to liquid form preparations. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.

In addition to the direct topical application of the preparations they can be topically administered by other methods, for example, encapsulated in a temperature and/or pressure sensitive matrix or in film or solid carrier which is soluble in body fluids and the like for subsequent release, preferably sustained-release of the active component.

As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering therapeutics, e.g., creams, gellies, dressings, shampoos, tinctures, pastes, ointments, salves, powders, liquid or semiliquid

formulation and the like. Application of said compositions may be by aerosol e.g. with a propellant such as nitrogen carbon dioxide, a freon, or without a propellant such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab. In particular compositions, semisolid compositions such as salves, creams, pastes, gellies, ointments and the like will conveniently be used.

It is especially advantageous to formulate the subject compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powders packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

The pharmaceutical preparations of the present invention can be used, as stated above, for the many applications which can be considered cosmetic uses. Cosmetic compositions known in the art, preferably hypoallergic and pH controlled are especially preferred, and include toilet waters, packs, lotions, skin milks or milky lotions. The preparations contain, besides the *ptc*, *hedgehog* or *fgf-10* therapeutic, components usually employed in such preparations. Examples of such components are oils, fats, waxes, surfactants, humectants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dyestuffs, lower alkanols, and the like. If desired, further ingredients may be incorporated in the compositions, e.g. antiinflammatory agents, antibacterials, antifungals, disinfectants, vitamins, sunscreens, antibiotics, or other anti-acne agents.

Examples of oils comprise fats and oils such as olive oil and hydrogenated oils; waxes such as beeswax and lanolin; hydrocarbons such as liquid paraffin, ceresin, and squalane; fatty acids such as stearic acid and oleic acid; alcohols such as cetyl alcohol, stearyl alcohol, lanolin alcohol, and hexadecanol; and esters such as isopropyl myristate, isopropyl palmitate and butyl stearate. As examples of surfactants there may be cited anionic surfactants such as sodium stearate, sodium cetylsulfate, polyoxyethylene laurylether phosphate, sodium N-acyl glutamate; cationic surfactants such as stearyldimethylbenzylammonium chloride and

stearyltrimethylammonium chloride; ampholytic surfactants such as alkylaminoethylglycine hydrochloride solutions and lecithin; and nonionic surfactants such as glycerin monostearate, sorbitan monostearate, sucrose fatty acid esters, propylene glycol monostearate, polyoxyethylene oleylether, polyethylene glycol monostearate, polyoxyethylene sorbitan
5 monopalmitate, polyoxyethylene coconut fatty acid monoethanolamide, polyoxypropylene glycol (e.g. the materials sold under the trademark "Pluronic"), polyoxyethylene castor oil, and polyoxyethylene lanolin. Examples of humectants include glycerin, 1,3-butylene glycol, and propylene glycol; examples of lower alcohols include ethanol and isopropanol; examples of thickening agents include xanthan gum, hydroxypropyl cellulose, hydroxypropyl methyl
10 cellulose, polyethylene glycol and sodium carboxymethyl cellulose; examples of antioxidants comprise butylated hydroxytoluene, butylated hydroxyanisole, propyl gallate, citric acid and ethoxyquin; examples of chelating agents include disodium edetate and ethanehydroxy diphosphate; examples of buffers comprise citric acid, sodium citrate, boric acid, borax, and disodium hydrogen phosphate; and examples of preservatives are methyl
15 parahydroxybenzoate, ethyl parahydroxybenzoate, dehydroacetic acid, salicylic acid and benzoic acid.

For preparing ointments, creams, toilet waters, skin milks, and the like, typically from 0.01 to 10% in particular from 0.1 to 5% and more in particular from 0.2 to 2.5% of the active ingredient, e.g., of the *ptc*, *hedgehog* or *fgf-10* therapeutic, will be incorporated in the
20 compositions. In ointments or creams, the carrier for example consists of 1 to 20%, in particular 5 to 15% of a humectant, 0.1 to 10% in particular from 0.5 to 5% of a thickener and water; or said carrier may consist of 70 to 99%, in particular 20 to 95% of a surfactant, and 0 to 20%, in particular 2.5 to 15% of a fat; or 80 to 99.9% in particular 90 to 99% of a thickener; or 5 to 15% of a surfactant, 2-15% of a humectant, 0 to 80% of an oil, very small (
25 < 2%) amounts of preservative, coloring agent and/or perfume, and water. In a toilet water, the carrier for example consists of 2 to 10% of a lower alcohol, 0.1 to 10% or in particular 0.5 to 1% of a surfactant, 1 to 20%, in particular 3 to 7% of a humectant, 0 to 5% of a buffer, water and small amounts (< 2%) of preservative, dyestuff and/or perfume. In a skin milk, the carrier typically consists of 10-50% of oil, 1 to 10% of surfactant, 50-80% of water and 0 to
30 3% of preservative and/or perfume. In the aforementioned preparations, all % symbols refer to weight by weight percentage.

Particular compositions for use in the method of the present invention are those wherein the *ptc*, *hedgehog* or *fgf-10* therapeutic is formulated in liposome-containing compositions. Liposomes are artificial vesicles formed by amphiphatic molecules such as polar lipids, for example, phosphatidyl cholines, ethanolamines and serines, sphingomyelins, 5 cardiolipins, plasmalogens, phosphatidic acids and cerebiosides. Liposomes are formed when suitable amphiphatic molecules are allowed to swell in water or aqueous solutions to form liquid crystals usually of multilayer structure comprised of many bilayers separated from each other by aqueous material (also referred to as coarse liposomes). Another type of liposome known to be consisting of a single bilayer encapsulating aqueous material is 10 referred to as a unilamellar vesicle. If water-soluble materials are included in the aqueous phase during the swelling of the lipids they become entrapped in the aqueous layer between the lipid bilayers.

Water-soluble active ingredients such as, for example, various salt forms of a *hedgehog* polypeptide, are encapsulated in the aqueous spaces between the molecular layers. 15 The lipid soluble active ingredient of *ptc*, *hedgehog* or *fgf-10* therapeutic, such as an organic mimetic, is predominantly incorporated into the lipid layers, although polar head groups may protude from the layer into the aqueous space. The encapsulation of these compounds can be achieved by a number of methods. The method most commonly used involves casting a thin film of phospholipid onto the walls of a flask by evaporation from an organic solvent. When 20 this film is dispersed in a suitable aqueous medium, multilamellar liposomes are formed. Upon suitable sonication, the coarse liposomes form smaller similarly closed vesicles.

Water-soluble active ingredients are usually incorporated by dispersing the cast film with an aqueous solution of the compound. The unencapsulated compound is then removed by centrifugation, chromatography, dialysis or other art-known suitable procedures. The 25 lipid-soluble active ingredient is usually incorporated by dissolving it in the organic solvent with the phospholipid prior to casting the film. If the solubility of the material in the lipid phase is not exceeded or the amount present is not in excess of that which can be bound to the lipid, liposomes prepared by the above method usually contain most of the material bound in the lipid bilayers; separation of the liposomes from unencapsulated material is not required.

A particularly convenient method for preparing liposome formulated forms of *hedgehog* and *ptc* therapeutics is the method described in EP-A-253,619, incorporated herein by reference. In this method, single bilayered liposomes containing encapsulated active ingredients are prepared by dissolving the lipid component in an organic medium, injecting
5 the organic solution of the lipid component under pressure into an aqueous component while simultaneously mixing the organic and aqueous components with a high speed homogenizer or mixing means, whereupon the liposomes are formed spontaneously.

The single bilayered liposomes containing the encapsulated *ptc*, *hedgehog* or *fgf-10* therapeutic can be employed directly or they can be employed in a suitable pharmaceutically
10 acceptable carrier for topical administration. The viscosity of the liposomes can be increased by the addition of one or more suitable thickening agents such as, for example xanthan gum, hydroxypropyl cellulose, hydroxypropyl methylcellulose and mixtures thereof. The aqueous component may consist of water alone or it may contain electrolytes, buffered systems and other ingredients, such as, for example, preservatives. Suitable electrolytes which can be
15 employed include metal salts such as alkali metal and alkaline earth metal salts. The preferred metal salts are calcium chloride, sodium chloride and potassium chloride. The concentration of the electrolyte may vary from zero to 260 mM, preferably from 5 mM to 160 mM. The aqueous component is placed in a suitable vessel which can be adapted to effect homogenization by effecting great turbulence during the injection of the organic component.
20 Homogenization of the two components can be accomplished within the vessel, or, alternatively, the aqueous and organic components may be injected separately into a mixing means which is located outside the vessel. In the latter case, the liposomes are formed in the mixing means and then transferred to another vessel for collection purpose.

The organic component consists of a suitable non-toxic, pharmaceutically acceptable
25 solvent such as, for example ethanol, glycerol, propylene glycol and polyethylene glycol, and a suitable phospholipid which is soluble in the solvent. Suitable phospholipids which can be employed include lecithin, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, phosphatidylinositol, lysophosphatidylcholine and phosphatidyl glycerol, for example. Other lipophilic additives may be employed in order to selectively modify the

characteristics of the liposomes. Examples of such other additives include stearylamine, phosphatidic acid, tocopherol, cholesterol and lanolin extracts.

In addition, other ingredients which can prevent oxidation of the phospholipids may be added to the organic component. Examples of such other ingredients include tocopherol, butylated hydroxyanisole, butylated hydroxytoluene, ascorbyl palmitate and ascorbyl oleate. Preservatives such as benzoic acid, methyl paraben and propyl paraben may also be added.

Apart from the above-described compositions, use may be made of covers, e.g. plasters, bandages, dressings, gauze pads and the like, containing an appropriate amount of a *ptc*, *hedgehog* or *fgf-10* therapeutic. In some cases use may be made of plasters, bandages, dressings, gauze pads and the like which have been impregnated with a topical formulation containing the therapeutic formulation.

Exemplification

The invention now being generally described, it will be more readily understood by reference to the following examples which are included merely for purposes of illustration of certain aspects and embodiments of the present invention, and are not intended to limit the invention.

The mammalian lung, like many other organs, develops by branching morphogenesis of an epithelium [see ref. 1]. Development initiates with evagination of two ventral buds of foregut endoderm into the underlying splanchnic mesoderm. As they extend, they send out lateral branches at precise, invariant positions establishing the primary airways and the lobes of each lung. Dichotomous branching leads to further extension of the airways. Grafting studies have demonstrated the importance of bronchial mesenchyme in inducing epithelial branching, but the significance of epithelial signaling is largely unstudied. The morphogen *Sonic hedgehog* (*Shh*) is widely expressed in the foregut endoderm and is specifically up-regulated in the distal epithelium of the lung where branching is occurring [see ref. 2]. Ectopic expression of *Shh* disrupts branching and increases proliferation suggesting that local *Shh* signaling regulates lung development [see ref. 2]. We report here that *Shh* is essential for

development of the respiratory system. In *Shh* null mutants, the trachea and esophagus do not separate properly and the lungs form a rudimentary sac due to failure of branching and growth after formation of the primary lung buds. Interestingly, normal proximo-distal differentiation of the airway epithelium occurs, indicating that *Shh* is not needed for differentiation events. In addition, the transcription of several mesenchymally expressed downstream targets of *Shh* is abolished. These results highlight the importance of epithelially derived *Shh* in regulating branching morphogenesis of the lung.

Results and discussion

To address the role of *Shh* in respiratory tract development, we examined a null mutant of the gene (3). At 10.5 days *post coitum* (dpc) of embryonic mouse development, the lung of wild- type (wt) siblings consists of a left and right bud [see ref. 1]. By 12.5 dpc, the trachea epithelium has separated ventrally from the esophageal component of the foregut and the two lung buds have formed several lateral branches which will give rise to primary airways of the lung lobes (Figure 1a-c). In contrast, the esophageal and tracheal tubes remain closely associated in *Shh* mutants (Figure 1d,e) and although left and right buds form, they either have not branched or possess one abnormally positioned branch point (Figure 1f). Wild- type lungs undergo considerable growth and branching in organ culture. However, in explant culture of lungs from *Shh* mutants, bronchial mesenchyme cells detach from the endoderm and the epithelium fails to grow, or branch extensively (data not shown). We conclude that the defect in branching morphogenesis is independent of other *Shh*-expressing organs (i.e., the gut), and that the observed branching phenotype reflects an absence of *Shh* signaling which is normally associated with the branching process.

To determine if branching is merely delayed and whether *Shh* plays a role in differentiation, we examined lungs removed at 15.5 (data not shown) and 18.5 dpc (Figure 1g,h). At this time, five well-developed lobes are evident in the wild-type (four right, one left), and highly branched airways form a ramifying epithelial network, the respiratory tree (Figure 1i,k,l). To mediate gas exchange in the alveolar sacs, the respiratory surface is well vascularized (Figure 1g). In contrast, *Shh* mutants form only a rudimentary respiratory organ with a few large, poorly vascularized airways (Figure 1h). Trachea and esophagus are so

closely juxtaposed that their tubes share some common epithelium (Figure 1e) and a fistula-like fusion of the alimentary and respiratory tract is formed, mirroring a lethal anomaly well described in human pathology [see ref. 4,5] (Figure 1j,m).

Remarkably, despite the absence of branching, evidence of normal proximo-distal epithelial differentiation can be observed. Most proximally, the pulmonary epithelium forms a columnar epithelium typical of the mainstem bronchi (Figure 1m) and expresses *CCSP* [see ref. 6], a marker for terminally differentiated secretory Clara cells (Figure 1q). More distally, the epithelium consists of a mixture of columnar and cuboidal epithelium as observed in the bronchioles (Figure 1n), and alveolar air sacs are formed which correspondingly express *SP-C* [see ref. 7], a type II pneumocyte marker (Figure 1r).

In summary, *Shh* is not required for proximo-distal differentiation of lung epithelium, but is essential for three different events of regional morphogenesis of the foregut endoderm, formation of the tracheoesophageal septum, lung lobation and generation of the respiratory tree, all of which are essential in forming a functional lung.

The exact role for *Shh* in branching processes remains to be determined. Grafting studies indicate that, whereas budding can be supported by mesenchyme from many different sources, only bronchial mesenchyme can induce organotypic branching morphogenesis [see ref. 8]. The requirement for *Shh* in the epithelium suggests that regulation of its expression may be a reciprocal epithelial response to mesenchymal signaling.

To examine in more detail how *Shh* might regulate early branching of the lung epithelium, we performed digoxigenin *in situ* hybridization with probes recognizing general targets of *Hedgehog* signaling (Figure 2a-e and data not shown), or genes specifically implicated in lung morphogenesis (Figure 2f-k). As *Shh* mutants are growth retarded and show a general delay in lung budding, we compared expression of these markers at 12.5 dpc with wild type embryos collected at 11.5 and 12.5 dpc.

Patched genes encode proteins thought to be *Hedgehog* receptors, while *Gli*-genes encode transcriptional mediators of *Hedgehog* signaling [see ref. 9]. Both *Ptc-1* and *Gli-1* are up-regulated when *Shh* is ectopically expressed in the lung indicating that here, as elsewhere in the embryo, they are transcriptional targets of *Shh* signaling [see ref. 9,10]. Consistent with

this model, *Ptc-1* and *Gli-1* are normally expressed in the mesenchyme of wild-type embryos with highest levels at the distal branch points mirroring epithelial *Shh* expression [see ref. 10] (Figure 2a,c). In *Shh* mutants, only basal levels of expression of both genes are detected (Figure 2a,c). *Gli-3* which shows more wide-spread expression in the mesenchyme is also
5 down-regulated (Figure 2e). In contrast, *Ptc-2* which is expressed at higher levels in the epithelium and *Gli-2*, which is normally expressed more uniformly in the mesenchyme are not altered (Figure 2b,d). These data indicate that the lung mesenchyme, not the epithelium, is most likely the direct cellular target of *Shh* signaling. Further, they suggest that modulation of *Gli-1* and *Gli-3* transcription may be a critical aspect of lung morphogenesis. As *Gli-1*
10 mutants do not have a lung phenotype, the *Shh* phenotype cannot simply be ascribed to a loss of *Gli-1* transcriptional activity [see ref. 10]. Given that post-transcriptional processing regulates *Gli* (*Ci*) activity in invertebrates [see ref. 11], we cannot rule out that *Gli-2* is expressed, but posttranscriptionally inactivated. *Gli* genes are clearly involved in lung development, as evidenced by the relatively weak lobular hypoplasia observed in *Gli-3*
15 mutants [see ref. 10], but revealing the full extent of *Gli* action may require the generation of compound mutants.

Several lines of evidence indicate that *hedgehog* signaling regulates the expression of *Bmp*, *Wnt* and *FGF* family members [see ref. 11]. In the lung, *Bmp-4* is strongly expressed in the distal-most tips of the epithelium. Ectopic expression results in decreased epithelial
20 proliferation, disrupted branching and reduced differentiation of distal cell types in the airway [see ref. 12]. In *Shh* mutants, *Bmp 4* is expressed in the normal position but at higher levels (Figure 2f), suggesting that enhanced *Bmp 4* signaling could contribute to the block in branching. *Wnt-7b* is normally expressed in the lung epithelium and is required for normal branching (S. Lee, W. Cardoso, B. Parr & A. McMahon; unpublished), whereas *Wnt-2* is
25 expressed in the underlying mesenchyme suggesting a role in epithelial maintenance [see ref. 2]. In *Shh* mutants, *Wnt-7b* expression is not altered (Figure 2g) but *Wnt-2* expression is down-regulated (Figure 2h). This observation lends further support to the model that the lung mesenchyme is the primary target of *Shh* signaling and indicates that mesenchymal signaling is abnormal in *Shh* mutants. However, no role for *Wnt-2* in lung development has been
30 reported in *Wnt-2* mutants [see ref. 13].

Ectopic expression of a dominant negative form of *FGF-R2* in the lung epithelium arrests branching after formation of left and right buds which then grow caudally as tubes, differentiating into proximal epithelial structures only [see ref. 14]. An arrest in branching after initial budding is reminiscent of *Shh* mutants, but there are clearly differences in subsequent morphogenesis and differentiation which is largely unaffected in *Shh* mutants. The recent observation that *Fgf10* is expressed in mesenchyme cells preceding branch formation and can induce branching of lung epithelium in culture, points to its role as a putative ligand [see ref. 15]. In *Shh* mutants, expression of *FGF-R2* is unaltered (Figure 2I). In contrast, *Fgf10* which in wild-type embryos is highly localized to small patches of mesenchyme at a distance from the lung epithelium (arrows in Figure 2j), is expressed broadly in mesenchyme immediately adjacent to the epithelium in the mutant lung. These results indicate that *Shh* is not required for *Fgf10* expression. Further, they suggest that Shh signaling may spatially restrict *Fgf10* expression to the distal mesenchyme. Such an inhibitory role for Shh in the local regulation of *Fgf10* expression is supported by transgenic studies [see ref. 16]. The intriguing possibility that the altered position of *Fgf10* expression then disrupts branching remains to be determined.

HNF-3 β and *Nkx-2.1* are specific transcriptional effectors of Shh signaling in the neural tube. In the gut, *HNF-3b* is widely expressed in the epithelium, including the lung, whereas *Nkx-2.1* expression is specific to the lung epithelium and a few other endodermal derivatives [see ref. 17]. Mice lacking *Nkx 2.1* develop cystic unbranched lungs indicating that it is essential for lung morphogenesis [see ref. 17]. Expression of both genes is unaltered in the epithelium of *Shh* mutant lungs suggesting that in this organ their expression is independent of the Shh signaling pathway (Figure 2k and data not shown).

As loss of *Shh* activity predominantly affects the expression of mesenchyme markers, we analyzed late mesenchyme differentiation. Formation of cartilage rings, albeit disorganized, occurs in the mutant (Figure 3a), while the layer of smooth muscle typically lining the proximal epithelium is absent (Figure 3b). The observation that Shh is required for formation of smooth muscle is in agreement with previous studies [see ref. 18].

In summary, the results reported here establish Shh as a regulator of foregut development and more specifically as a key factor in the control of branching morphogenesis

in the mouse lung. They also indicate that the genetic control of growth and branching in the lung epithelium is most likely a complex process involving both epithelial and mesenchymal interactions at the branch points, and that the downstream targets of Shh signaling in this organ are primarily mesenchymally expressed genes.

5

Materials and methods

Shh mutants

Generation of the *Shh* mutants has been described elsewhere [see ref. 3]. Mice homozygous for the null allele appear phenotypically identical to those reported in [see ref.

10 19].

Histological/in situ analysis

Tissue was processed for standard histology, or a modified *in situ* hybridization procedure [see ref. 20].

15

Antibody staining

Antibody staining with a monoclonal antibody against smooth muscle actin (Sigma) was carried out according to the manufacturer's instructions.

20 References cited in Examples

1. Ten Have-Opbroek AAW: *Lung development in the mouse embryo. Exp Lung Res* 1992, 17:111-130.
2. Bellusci S et al.: *Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. Development* 1997, 124: 53-63.
- 25 3. St.-Jacques B, Dassule H, Karavanova I, Botchkarev VA, Li J, Danielian P, McMahon JA, Paus R, Lewis P, McMahon AP: *Shh signaling is essential for hair development. Curr Biol.*, in press.

4. Sutliff KS, Hutchins GM: *Septation of the respiratory and digestive tracts in human embryos: crucial role of the tracheoesophageal sulcus. Anatom Record* 1994, 238:237-247.
5. Skandalakis JE et al: *The trachea and the lungs. Embr for Surgeons.* 1994, 414-450.
- 5 6. Hackett BP, Gitlin JD: *Cell-specific expression of a Clara cell secretory protein-human growth hormone gene in the bronchiolar epithelium of transgenic mice. Proc Natl Acad USA* 1992, 89:9079-9083.
7. Bachurski CJ, Pryhuber GS, Glasser SW, Kelly SE, Whitsett JA: *Tumor necrosis factor-alpha inhibits surfactant protein C gene transcription. J Biol Chem* 1995, 270:19402-19407.
- 10 8. Spooner BS, Wessells NK *Mammalian lung development: interactions in primordium formation and bronchial morphogenesis. J Exp Zool* 1970, 175: 445-454.
9. Tabin CJ, McMahon AP: *Recent advances in hedgehog signaling. Trends Cell Biol* 1997, 7:442-445.
- 15 10. Grindley JC, Bellusci S, Perkins D, Hogan BLM: *Evidence for the involvement of the Gli gene family in embryonic mouse lung development. Dev Biol* 1997, 188: 337-348.
11. Hammerschmidt M, Brook A, McMahon AP: *The world according to hedgehog. TIGs* 1997, 13: 14-21.
12. Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan BLM: *Evidence from normal expression and targeted misexpression that Bone Morphogenetic Protein-4 (Bmp-4) plays a role in mouse embryonic lung morphogenesis. Development* 1996, 122: 1693-1702.
- 20 13. Monkley SJ, et al.: *Targeted disruption of the Wnt2 gene results in placentation defects. Development* 1996, 122: 3343-3353.
- 25 14. Peters K, Werner S, Liao X, Whitsett J, Williams S: *Targeted expression of a dominant negative FGF receptor blocks branching morphogenesis and epithelial differentiation of the mouse lung. EMBO J* 1996, 13:3296-3301.

15. Bellusci S. et al.: *Fibroblast Growth Factor 10 and branching morphogenesis in the embryonic mouse lung. Development* 1997, 124: 4867-4878.
16. Ang SL, Rossant J: *HNF-3beta is essential for node and notochord formation in mouse development. Cell* 1994, 78:561-574.
- 5 17. Kimura S et al.: *The T/ebp null mouse: thyroid-specific enhancer-binding protein is essential for the organogenesis of the thyroid, lung, ventral forebrain, and pituitary. Genes Dev* 1996, 10:60-69.
18. Apelqvist A, Ahlgren U, Edlund H: *Sonic hedgehog directs specialized mesoderm differentiation in the intestine and pancreas. Curr Biol* 1997, 7:801-804.
- 10 19. Chiang C et al.: *Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. Nature* 1996, 383: 407-413.
20. Chen H et al.: *Limb and kidney defects in Lmx1b mutant mice suggest and involvement of LMX1B in human nail patella syndrome. Nature Genetics* 1998, 19:51-55.
- 15 All of the above-cited references and publications are hereby incorporated by reference.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than
20 routine experimentation, numerous equivalents to the specific polypeptides, nucleic acids, methods, assays and reagents described herein. Such equivalents are considered to be within the scope of this invention.

We claim:

1. A method for modulating the growth state of lung tissue, or cells derived therefrom, comprising ectopically contacting the tissue with an amount of an agent effective to
5 alter the rate of proliferation of the lung tissue, wherein the agent is selected from the group consisting of a *hedgehog* therapeutic, a *ptc* therapeutic and an *fgf-10* therapeutic.
2. A method for inducing the formation of, or the maintenance or functiona performance of lung tissue, comprising contacting the lung tissue with an amount of an agent effective to induce the formation of new lung tissue, wherein the agent is selected from
10 the group consisting of a *hedgehog* therapeutic, a *ptc* therapeutic and an *fgf-10* therapeutic.
3. The method of claim 1, wherein the lung tissue is in culture, and the agent is provided as a cell culture additive.
4. The method of claim 1, wherein the cell is treated in an animal and the agent is
15 administered to the animal as a therapeutic composition.
5. The method of claim 1, wherein the agent is a *hedgehog* therapeutic.
6. The method of claim 5, wherein the *hedgehog* therapeutic is a polypeptide including a *hedgehog* polypeptide sequence of at least a bioactive extracellular portion of a *hedgehog* protein.
- 20 7. The method of claim 6, wherein the polypeptide includes at least 50 amino acids residues of an N-terminal half of the *hedgehog* protein
8. The method of claim 6, wherein the polypeptide includes at least 100 amino acids of an extracellular domain of the *hedgehog* protein.
9. The method of claim 6, wherein the polypeptide includes at least a portion of the
25 *hedgehog* protein corresponding to a 19kd fragment of an extracellular domain of the *hedgehog* protein.
10. The method of claim 6, wherein the *hedgehog* protein is encoded by a gene of a vertebrate organism.

11. The method of claim 6, wherein the polypeptide includes a *hedgehog* polypeptide sequence represented in the general formula of SEQ ID No. 21.
12. The method of claim 6, wherein the polypeptide includes a *hedgehog* polypeptide sequence represented in the general formula of SEQ ID No. 22.
- 5 13. The method of claim 6, wherein the *hedgehog* protein is encoded by a human *hedgehog* gene.
14. The method of claim 6, wherein the *hedgehog* polypeptide sequence is at least 60 percent identical to an amino acid sequence of a *hedgehog* protein selected from the group consisting of SEQ ID No:9, SEQ ID No:10, SEQ ID No:11, SEQ ID No:12, SEQ
10 ID No:13, SEQ ID No:14, SEQ ID No:15 and SEQ ID No:16.
15. The method of claim 6, wherein the *hedgehog* polypeptide sequence is encodable by a nucleotide sequence which hybridizes under stringent conditions to a sequence selected from the group consisting of SEQ ID No:1, SEQ ID No:2, SEQ ID No:3, SEQ ID No:4, SEQ ID No:5, SEQ ID No:6, SEQ ID No:7 and SEQ ID No:8.
- 15 16. The method of claim 6, wherein the *hedgehog* polypeptide sequence is an amino acid sequence of a *hedgehog* protein selected from the group consisting of SEQ ID No:9, SEQ ID No:10, SEQ ID No:11, SEQ ID No:12, SEQ ID No:13, SEQ ID No:14, SEQ ID No:15 and SEQ ID No:16.
17. The method of claim 6, wherein the *hedgehog* polypeptide sequence is an amino acid
20 sequence of a Sonic *hedgehog* protein.
18. The method of claim 1, wherein the agent is a *ptc* therapeutic.
19. The method of claim 18, wherein the *ptc* therapeutic is a small organic molecule which binds to a *patched* protein and derepresses *patched*-mediated inhibition of mitosis.
20. The method of claims 18, wherein the *ptc* therapeutic binds to *patched* and mimics
25 *hedgehog*-mediated *patched* signal transduction.
21. The method of claim 20, wherein the *ptc* therapeutic is a small organic molecule.




Fig. 1A




Fig. 1D




Fig. 1B




Fig. 1E




Fig. 1C




Fig. 1F




Fig. 1G




Fig. 1H

2/5

WILD-TYPE




Fig. 1I

WILD-TYPE



Fig. 1K

WILD-TYPE



Fig. 1L

WILD-TYPE



Fig. 1O

WILD-TYPE



Fig. 1P

-/-



Fig. 1J

-/-



Fig. 1M

-/-



Fig. 1N

-/-



Fig. 1Q

-/-



Fig. 1R

3/5




Fig. 2A




Fig. 2B



Fig. 2C




Fig. 2D




Fig. 2E




Fig. 2F




Fig. 2G




Fig. 2H




Fig. 2I




Fig. 2J




Fig. 2K

5/5




Fig. 3A



Fig. 3B

SEQUENCE LISTING

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- 5 (A) LENGTH: 1277 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

10 (ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..1275

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ATG GTC GAA ATG CTG CTG TTG ACA AGA ATT CTC TTG GTG GGC TTC ATC 48

Met Val Glu Met Leu Leu Leu Thr Arg Ile Leu Leu Val Gly Phe Ile

20 1 5 10 15

TGC GCT CTT TTA GTC TCC TCT GGG CTG ACT TGT GGA CCA GGC AGG GGC 96

Cys Ala Leu Leu Val Ser Ser Gly Leu Thr Cys Gly Pro Gly Arg Gly

20 25 30

25

ATT GGA AAA AGG AGG CAC CCC AAA AAG CTG ACC CCG TTA GCC TAT AAG 144

Ile Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys

35 40 45

30 CAG TTT ATT CCC AAT GTG GCA GAG AAG ACC CTA GGG GCC AGT GGA AGA 192

Gln Phe Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg

50 55 60

TAT GAA GGG AAG ATC ACA AGA AAC TCC GAG AGA TTT AAA GAA CTA ACC 240

35 Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr

65 70 75 80

CCA AAT TAC AAC CCT GAC ATT ATT TTT AAG GAT GAA GAG AAC ACG GGA 288

Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly

	85	90	95	
	GCT GAC AGA CTG ATG ACT CAG CGC TGC AAG GAC AAG CTG AAT GCC CTG			336
	Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu			
5	100	105	110	
	GCG ATC TCG GTG ATG AAC CAG TGG CCC GGG GTG AAG CTG CGG GTG ACC			384
	Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr			
	115	120	125	
10	GAG GGC TGG GAC GAG GAT GGC CAT CAC TCC GAG GAA TCG CTG CAC TAC			432
	Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr			
	130	135	140	
15	GAG GGT CGC GCC GTG GAC ATC ACC ACG TCG GAT CGG GAC CGC AGC AAG			480
	Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys			
	145	150	155	160
	TAC GGA ATG CTG GCC CGC CTC GCC GTC GAG GCC GGC TTC GAC TGG GTC			528
20	Tyr Gly Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val			
	165	170	175	
	TAC TAC GAG TCC AAG GCG CAC ATC CAC TGC TCC GTC AAA GCA GAA AAC			576
	Tyr Tyr Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn			
25	180	185	190	
	TCA GTG GCA GCG AAA TCA GGA GGC TGC TTC CCT GGC TCA GCC ACA GTG			624
	Ser Val Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val			
	195	200	205	
30	CAC CTG GAG CAT GGA GGC ACC AAG CTG GTG AAG GAC CTG AGC CCT GGG			672
	His Leu Glu His Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly			
	210	215	220	
35	GAC CGC GTG CTG GCT GCT GAC GCG GAC GGC CGG CTG CTC TAC AGT GAC			720
	Asp Arg Val Leu Ala Ala Asp Ala Asp Gly Arg Leu Leu Tyr Ser Asp			
	225	230	235	240
	TTC CTC ACC TTC CTC GAC CGG ATG GAC AGC TCC CGA AAG CTC TTC TAC			768

	Phe	Leu	Thr	Phe	Leu	Asp	Arg	Met	Asp	Ser	Ser	Arg	Lys	Leu	Phe	Tyr	
					245					250					255		
	GTC	ATC	GAG	ACG	CGG	CAG	CCC	CGG	GCC	CGG	CTG	CTA	CTG	ACG	GCG	GCC	816
5	Val	Ile	Glu	Thr	Arg	Gln	Pro	Arg	Ala	Arg	Leu	Leu	Leu	Thr	Ala	Ala	
					260					265					270		
	CAC	CTG	CTC	TTT	GTG	GCC	CCC	CAG	CAC	AAC	CAG	TCG	GAG	GCC	ACA	GGG	864
	His	Leu	Leu	Phe	Val	Ala	Pro	Gln	His	Asn	Gln	Ser	Glu	Ala	Thr	Gly	
10					275					280					285		
	TCC	ACC	AGT	GGC	CAG	GCG	CTC	TTC	GCC	AGC	AAC	GTG	AAG	CCT	GGC	CAA	912
	Ser	Thr	Ser	Gly	Gln	Ala	Leu	Phe	Ala	Ser	Asn	Val	Lys	Pro	Gly	Gln	
					290					295					300		
15																	
	CGT	GTC	TAT	GTG	CTG	GGC	GAG	GGC	GGG	CAG	CAG	CTG	CTG	CCG	GCG	TCT	960
	Arg	Val	Tyr	Val	Leu	Gly	Glu	Gly	Gly	Gln	Gln	Leu	Leu	Pro	Ala	Ser	
	305					310					315				320		
20	GTC	CAC	AGC	GTC	TCA	TTG	CGG	GAG	GAG	GCG	TCC	GGA	GCC	TAC	GCC	CCA	1008
	Val	His	Ser	Val	Ser	Leu	Arg	Glu	Glu	Ala	Ser	Gly	Ala	Tyr	Ala	Pro	
						325					330				335		
	CTC	ACC	GCC	CAG	GGC	ACC	ATC	CTC	ATC	AAC	CGG	GTG	TTG	GCC	TCC	TGC	1056
25	Leu	Thr	Ala	Gln	Gly	Thr	Ile	Leu	Ile	Asn	Arg	Val	Leu	Ala	Ser	Cys	
					340						345				350		
	TAC	GCC	GTC	ATC	GAG	GAG	CAC	AGT	TGG	GCC	CAT	TGG	GCC	TTC	GCA	CCA	1104
	Tyr	Ala	Val	Ile	Glu	Glu	His	Ser	Trp	Ala	His	Trp	Ala	Phe	Ala	Pro	
30					355						360				365		
	TTC	CGC	TTG	GCT	CAG	GGG	CTG	CTG	GCC	GCC	CTC	TGC	CCA	GAT	GGG	GCC	1152
	Phe	Arg	Leu	Ala	Gln	Gly	Leu	Leu	Ala	Ala	Leu	Cys	Pro	Asp	Gly	Ala	
					370						375				380		
35																	
	ATC	CCT	ACT	GCC	GCC	ACC	ACC	ACC	ACT	GGC	ATC	CAT	TGG	TAC	TCA	CGG	1200
	Ile	Pro	Thr	Ala	Ala	Thr	Thr	Thr	Thr	Gly	Ile	His	Trp	Tyr	Ser	Arg	
	385					390					395				400		
	CTC	CTC	TAC	CGC	ATC	GGC	AGC	TGG	GTG	CTG	GAT	GGT	GAC	GCG	CTG	CAT	1248

Leu Leu Tyr Arg Ile Gly Ser Trp Val Leu Asp Gly Asp Ala Leu His
 405 410 415

CCG CTG GGC ATG GTG GCA CCG GCC AGC TG

1277

5 Pro Leu Gly Met Val Ala Pro Ala Ser
 420 425

(2) INFORMATION FOR SEQ ID NO:2:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1190 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

20

(A) NAME/KEY: CDS

(B) LOCATION: 1..1191

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

25 ATG GCT CTG CCG GCC AGT CTG TTG CCC CTG TGC TGC TTG GCA CTC TTG 48
 Met Ala Leu Pro Ala Ser Leu Leu Pro Leu Cys Cys Leu Ala Leu Leu
 1 5 10 15

GCA CTA TCT GCC CAG AGC TGC GGG CCG GGC CGA GGA CCG GTT GGC CGG 96
 30 Ala Leu Ser Ala Gln Ser Cys Gly Pro Gly Arg Gly Pro Val Gly Arg
 20 25 30

CGG CGT TAT GTG CGC AAG CAA CTT GTG CCT CTG CTA TAC AAG CAG TTT 144
 Arg Arg Tyr Val Arg Lys Gln Leu Val Pro Leu Leu Tyr Lys Gln Phe
 35 35 40 45

GTG CCC AGT ATG CCC GAG CGG ACC CTG GGC GCG AGT GGG CCA GCG GAG 192
 Val Pro Ser Met Pro Glu Arg Thr Leu Gly Ala Ser Gly Pro Ala Glu
 50 55 60

GGG AGG GTA ACA AGG GGG TCG GAG CGC TTC CGG GAC CTC GTA CCC AAC 240
 Gly Arg Val Thr Arg Gly Ser Glu Arg Phe Arg Asp Leu Val Pro Asn
 65 70 75 80

5

TAC AAC CCC GAC ATA ATC TTC AAG GAT GAG GAG AAC AGC GGC GCA GAC 288
 Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp
 85 90 95

10

CGC CTG ATG ACA GAG CGT TGC AAA GAG CGG GTG AAC GCT CTA GCC ATC 336
 Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile
 100 105 110

GCG GTG ATG AAC ATG TGG CCC GGA GTA CGC CTA CGT GTG ACT GAA GGC 384
 15 Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly
 115 120 125

TGG GAC GAG GAC GGC CAC CAC GCA CAG GAT TCA CTC CAC TAC GAA GGC 432
 Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly
 20 130 135 140

CGT GCC TTG GAC ATC ACC ACG TCT GAC CGT GAC CGT AAT AAG TAT GGT 480
 Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly
 145 150 155 160

25

TTG TTG GCG CGC CTA GCT GTG GAA GCC GGA TTC GAC TGG GTC TAC TAC 528
 Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr
 165 170 175

30

GAG TCC CGC AAC CAC ATC CAC GTA TCG GTC AAA GCT GAT AAC TCA CTG 576
 Glu Ser Arg Asn His Ile His Val Ser Val Lys Ala Asp Asn Ser Leu
 180 185 190

GCG GTC CGA GCC GGA GGC TGC TTT CCG GGA AAT GCC ACG GTG CGC TTG 624
 35 Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu
 195 200 205

CGG AGC GGC GAA CGG AAG GGG CTG AGG GAA CTA CAT CGT GGT GAC TGG 672
 Arg Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp

	210	215	220	
	GTA CTG GCC GCT GAT GCA GCG GGC CGA GTG GTA CCC ACG CCA GTG CTG			720
	Val Leu Ala Ala Asp Ala Ala Gly Arg Val Val Pro Thr Pro Val Leu			
5	225	230	235	240
	CTC TTC CTG GAC CGG GAT CTG CAG CGC CGC GCC TCG TTC GTG GCT GTG			768
	Leu Phe Leu Asp Arg Asp Leu Gln Arg Arg Ala Ser Phe Val Ala Val			
		245	250	255
10	GAG ACC GAG CGG CCT CCG CGC AAA CTG TTG CTC ACA CCC TGG CAT CTG			816
	Glu Thr Glu Arg Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp His Leu			
		260	265	270
15	GTG TTC GCT GCT CGC GGG CCA GCG CCT GCT CCA GGT GAC TTT GCA CCG			864
	Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp Phe Ala Pro			
		275	280	285
	GTG TTC GCG CGC CGC TTA CGT GCT GGC GAC TCG GTG CTG GCT CCC GGC			912
20	Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val Leu Ala Pro Gly			
		290	295	300
	GGG GAC GCG CTC CAG CCG GCG CGC GTA GCC CGC GTG GCG CGC GAG GAA			960
	Gly Asp Ala Leu Gln Pro Ala Arg Val Ala Arg Val Ala Arg Glu Glu			
25	305	310	315	320
	GCC GTG GGC GTG TTC GCA CCG CTC ACT GCG CAC GGG ACG CTG CTG GTC			1008
	Ala Val Gly Val Phe Ala Pro Leu Thr Ala His Gly Thr Leu Leu Val			
		325	330	335
30	AAC GAC GTC CTC GCC TCC TGC TAC GCG GTT CTA GAG AGT CAC CAG TGG			1056
	Asn Asp Val Leu Ala Ser Cys Tyr Ala Val Leu Glu Ser His Gln Trp			
		340	345	350
35	GCC CAC CGC GCC TTC GCC CCT TTG CGG CTG CTG CAC GCG CTC GGG GCT			1104
	Ala His Arg Ala Phe Ala Pro Leu Arg Leu Leu His Ala Leu Gly Ala			
		355	360	365
	CTG CTC CCT GGG GGT GCA GTC CAG CCG ACT GGC ATG CAT TGG TAC TCT			1152

Leu Leu Pro Gly Gly Ala Val Gln Pro Thr Gly Met His Trp Tyr Ser
 370 375 380

CGC CTC CTT TAC CGC TTG GCC GAG GAG TTA ATG GGC TG 1190
 5 Arg Leu Leu Tyr Arg Leu Ala Glu Glu Leu Met Gly
 385 390 395

(2) INFORMATION FOR SEQ ID NO:3:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1281 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1233

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

25

ATG TCT CCC GCC TGG CTC CGG CCC CGA CTG CGG TTC TGT CTG TTC CTG 48
 Met Ser Pro Ala Trp Leu Arg Pro Arg Leu Arg Phe Cys Leu Phe Leu
 1 5 10 15

30

CTG CTG CTG CTT CTG GTG CCG GCG GCG CGG GGC TGC GGG CCG GGC CGG 96
 Leu Leu Leu Leu Leu Val Pro Ala Ala Arg Gly Cys Gly Pro Gly Arg
 20 25 30

35

GTG GTG GGC AGC CGC CGG AGG CCG CCT CGC AAG CTC GTG CCT CTT GCC 144
 Val Val Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala
 35 40 45

TAC AAG CAG TTC AGC CCC AAC GTG CCG GAG AAG ACC CTG GGC GCC AGC 192
 Tyr Lys Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser

	50		55		60		
	GGG CGC TAC GAA GGC AAG ATC GCG CGC AGC TCT GAG CGC TTC AAA GAG	240					
	Gly Arg Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu						
5	65		70		75		80
	CTC ACC CCC AAC TAC AAT CCC GAC ATC ATC TTC AAG GAC GAG GAG AAC	288					
	Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn						
		85		90		95	
10							
	ACG GGT GCC GAC CGC CTC ATG ACC CAG CGC TGC AAG GAC CGT CTG AAC	336					
	Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn						
		100		105		110	
	TCA CTG GCC ATC TCT GTC ATG AAC CAG TGG CCT GGT GTG AAA CTG CGG	384					
15	Ser Leu Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg						
		115		120		125	
	GTG ACC GAA GGC CGG GAT GAA GAT GGC CAT CAC TCA GAG GAG TCT TTA	432					
20	Val Thr Glu Gly Arg Asp Glu Asp Gly His His Ser Glu Glu Ser Leu						
		130		135		140	
	CAC TAT GAG GGC CGC GCG GTG GAT ATC ACC ACC TCA GAC CGT GAC CGA	480					
	His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg						
25	145		150		155		160
	AAT AAG TAT GGA CTG CTG GCG CGC TTA GCA GTG GAG GCC GGC TTC GAC	528					
	Asn Lys Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp						
		165		170		175	
30							
	TGG GTG TAT TAC GAG TCC AAG GCC CAC GTG CAT TGC TCT GTC AAG TCT	576					
	Trp Val Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser						
		180		185		190	
	GAG CAT TCG GCC GCT GCC AAG ACA GGT GGC TGC TTT CCT GCC GGA GCC	624					
35	Glu His Ser Ala Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala						
		195		200		205	
	CAG GTG CGC CTA GAG AAC GGG GAG CGT GTG GCC CTG TCA GCT GTA AAG	672					

	Gln Val Arg Leu Glu Asn Gly Glu Arg Val Ala Leu Ser Ala Val Lys	
	210 215 220	
	CCA GGA GAC CGG GTG CTG GCC ATG GGG GAG GAT GGG ACC CCC ACC TTC	720
5	Pro Gly Asp Arg Val Leu Ala Met Gly Glu Asp Gly Thr Pro Thr Phe	
	225 230 235 240	
	AGT GAT GTG CTT ATT TTC CTG GAC CGC GAG CCA AAC CGG CTG AGA GCT	768
10	Ser Asp Val Leu Ile Phe Leu Asp Arg Glu Pro Asn Arg Leu Arg Ala	
	245 250 255	
	TTC CAG GTC ATC GAG ACT CAG GAT CCT CCG CGT CGG CTG GCG CTC ACG	816
	Phe Gln Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr	
	260 265 270	
15	CCT GCC CAC CTG CTC TTC ATT GCG GAC AAT CAT ACA GAA CCA GCA GCC	864
	Pro Ala His Leu Leu Phe Ile Ala Asp Asn His Thr Glu Pro Ala Ala	
	275 280 285	
20	CAC TTC CGG GCC ACA TTT GCC AGC CAT GTG CAA CCA GGC CAA TAT GTG	912
	His Phe Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val	
	290 295 300	
	CTG GTA TCA GGG GTA CCA GGC CTC CAG CCT GCT CGG GTG GCA GCT GTC	960
25	Leu Val Ser Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val	
	305 310 315 320	
	TCC ACC CAC GTG GCC CTT GGG TCC TAT GCT CCT CTC ACA AGG CAT GGG	1008
30	Ser Thr His Val Ala Leu Gly Ser Tyr Ala Pro Leu Thr Arg His Gly	
	325 330 335	
	ACA CTT GTG GTG GAG GAT GTG GTG GCC TCC TGC TTT GCA GCT GTG GCT	1056
	Thr Leu Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala	
	340 345 350	
35	GAC CAC CAT CTG GCT CAG TTG GCC TTC TGG CCC CTG CGA CTG TTT CCC	1104
	Asp His His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe Pro	
	355 360 365	

AGT TTG GCA TGG GGC AGC TGG ACC CCA AGT GAG GGT GTT CAC TCC TAC 1152
 Ser Leu Ala Trp Gly Ser Trp Thr Pro Ser Glu Gly Val His Ser Tyr
 370 375 380

5 CCT CAG ATG CTC TAC CGC CTG GGG CGT CTC TTG CTA GAA GAG AGC ACC 1200
 Pro Gln Met Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Glu Ser Thr
 385 390 395 400

TTC CAT CCA CTG GGC ATG TCT GGG GCA GGA AGC TGAAGGGACT CTAACCACTG 1253
 10 Phe His Pro Leu Gly Met Ser Gly Ala Gly Ser
 405 410

CCCTCCTGGA ACTGCTGTGC GTGGATCC 1281

15

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1313 base pairs
 20 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

25

(ix) FEATURE:

(A) NAME/KEY: CDS
 (B) LOCATION: 1..1314

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

ATG CTG CTG CTG CTG GCC AGA TGT TTT CTG GTG ATC CTT GCT TCC TCG 48
 35 Met Leu Leu Leu Leu Ala Arg Cys Phe Leu Val Ile Leu Ala Ser Ser
 1 5 10 15

CTG CTG GTG TGC CCC GGG CTG GCC TGT GGG CCC GGC AGG GGG TTT GGA 96
 Leu Leu Val Cys Pro Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly

	20	25	30	
	AAG AGG CGG CAC CCC AAA AAG CTG ACC CCT TTA GCC TAC AAG CAG TTT	144		
	Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe			
5	35	40	45	
	ATT CCC AAC GTA GCC GAG AAG ACC CTA GGG GCC AGC GGC AGA TAT GAA	192		
	Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu			
	50	55	60	
10				
	GGG AAG ATC ACA AGA AAC TCC GAA CGA TTT AAG GAA CTC ACC CCC AAT	240		
	Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn			
	65	70	75	80
15				
	TAC AAC CCC GAC ATC ATA TTT AAG GAT GAG GAA AAC ACG GGA GCA GAC	288		
	Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp			
	85	90	95	
	CGG CTG ATG ACT CAG AGG TGC AAA GAC AAG TTA AAT GCC TTG GCC ATC	336		
20	Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile			
	100	105	110	
	TCT GTG ATG AAC CAG TGG CCT GGA GTG AGG CTG CGA GTG ACC GAG GGC	384		
	Ser Val Met Asn Gln Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly			
25	115	120	125	
	TGG GAT GAG GAC GGC CAT CAT TCA GAG GAG TCT CTA CAC TAT GAG GGT	432		
	Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly			
	130	135	140	
30				
	CGA GCA GTG GAC ATC ACC ACG TCC GAC CGG GAC CGC AGC AAG TAC GGC	480		
	Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly			
	145	150	155	160
35				
	ATG CTG GCT CGC CTG GCT GTG GAA GCA GGT TTC GAC TGG GTC TAC TAT	528		
	Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr			
	165	170	175	
	GAA TCC AAA GCT CAC ATC CAC TGT TCT GTG AAA GCA GAG AAC TCC GTG	576		

	Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val	
	180 185 190	
5	GCG GCC AAA TCC GGC GGC TGT TTC CCG GGA TCC GCC ACC GTG CAC CTG Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu	624
	195 200 205	
10	GAG CAG GGC GGC ACC AAG CTG GTG AAG GAC TTA CGT CCC GGA GAC CGC Glu Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Arg Pro Gly Asp Arg	672
	210 215 220	
15	GTG CTG GCG GCT GAC GAC CAG GGC CGG CTG CTG TAC AGC GAC TTC CTC Val Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu	720
	225 230 235 240	
	ACC TTC CTG GAC CGC GAC GAA GGC GCC AAG AAG GTC TTC TAC GTG ATC Thr Phe Leu Asp Arg Asp Glu Gly Ala Lys Lys Val Phe Tyr Val Ile	768
	245 250 255	
20	GAG ACC CTG GAG CCG CGC GAG CGC CTG CTG CTC ACC GCC GCG CAC CTG Glu Thr Leu Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu	816
	260 265 270	
25	CTC TTC GTG GCG CCG CAC AAC GAC TCG GGG CCC ACG CCC GGG CCA AGC Leu Phe Val Ala Pro His Asn Asp Ser Gly Pro Thr Pro Gly Pro Ser	864
	275 280 285	
30	GCG CTC TTT GCC AGC CGC GTG CGC CCC GGG CAG CGC GTG TAC GTG GTG Ala Leu Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val	912
	290 295 300	
35	GCT GAA CGC GGC GGG GAC CGC CGG CTG CTG CCC GCC GCG GTG CAC AGC Ala Glu Arg Gly Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser	960
	305 310 315 320	
	GTG ACG CTG CGA GAG GAG GAG GCG GGC GCG TAC GCG CCG CTC ACG GCG Val Thr Leu Arg Glu Glu Glu Ala Gly Ala Tyr Ala Pro Leu Thr Ala	1008
	325 330 335	

CAC GGC ACC ATT CTC ATC AAC CGG GTG CTC GCC TCG TGC TAC GCT GTC 1056
 His Gly Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val
 340 345 350

5 ATC GAG GAG CAC AGC TGG GCA CAC CGG GCC TTC GCG CCT TTC CGC CTG 1104
 Ile Glu Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu
 355 360 365

GCG CAC GCG CTG CTG GCC GCG CTG GCA CCC GCC CGC ACG GAC GGC GGG 1152
 10 Ala His Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Gly Gly
 370 375 380

GGC GGC GGC AGC ATC CCT GCA GCG CAA TCT GCA ACG GAA GCG AGG GGC 1200
 Gly Gly Gly Ser Ile Pro Ala Ala Gln Ser Ala Thr Glu Ala Arg Gly
 15 385 390 395 400

GCG GAG CCG ACT GCG GGC ATC CAC TGG TAC TCG CAG CTG CTC TAC CAC 1248
 Ala Glu Pro Thr Ala Gly Ile His Trp Tyr Ser Gln Leu Leu Tyr His
 405 410 415

20 ATT GGC ACC TGG CTG TTG GAC AGC GAG ACC ATG CAT CCC TTG GGA ATG 1296
 Ile Gly Thr Trp Leu Leu Asp Ser Glu Thr Met His Pro Leu Gly Met
 420 425 430

25 GCG GTC AAG TCC AGC TG 1313
 Ala Val Lys Ser Ser
 435

30 (2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1256 base pairs
 (B) TYPE: nucleic acid
 35 (C) STRANDEDNESS: both
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1257

5

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

	ATG CGG CTT TTG ACG AGA GTG CTG CTG GTG TCT CTT CTC ACT CTG TCC	48
10	Met Arg Leu Leu Thr Arg Val Leu Leu Val Ser Leu Leu Thr Leu Ser	
	1 5 10 15	
	TTG GTG GTG TCC GGA CTG GCC TGC GGT CCT GGC AGA GGC TAC GGC AGA	96
	Leu Val Val Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Tyr Gly Arg	
15	20 25 30	
	AGA AGA CAT CCG AAG AAG CTG ACA CCT CTC GCC TAC AAG CAG TTC ATA	144
	Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile	
	35 40 45	
20		
	CCT AAT GTC GCG GAG AAG ACC TTA GGG GCC AGC GGC AGA TAC GAG GGC	192
	Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly	
	50 55 60	
25	AAG ATA ACG CGC AAT TCG GAG AGA TTT AAA GAA CTT ACT CCA AAT TAC	240
	Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr	
	65 70 75 80	
	AAT CCC GAC ATT ATC TTT AAG GAT GAG GAG AAC ACG GGA GCG GAC AGG	288
30	Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg	
	85 90 95	
	CTC ATG ACA CAG AGA TGC AAA GAC AAG CTG AAC TCG CTG GCC ATC TCT	336
	Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ser Leu Ala Ile Ser	
35	100 105 110	
	GTA ATG AAC CAC TGG CCA GGG GTT AAG CTG CGT GTG ACA GAG GGC TGG	384
	Val Met Asn His Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp	
	115 120 125	

GAT GAG GAC GGT CAC CAT TTT GAA GAA TCA CTC CAC TAC GAG GGA AGA 432
 Asp Glu Asp Gly His His Phe Glu Glu Ser Leu His Tyr Glu Gly Arg
 130 135 140

5 GCT GTT GAT ATT ACC ACC TCT GAC CGA GAC AAG AGC AAA TAC GGG ACA 480
 Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Lys Ser Lys Tyr Gly Thr
 145 150 155 160

10 CTG TCT CGC CTA GCT GTG GAG GCT GGA TTT GAC TGG GTC TAT TAC GAG 528
 Leu Ser Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu
 165 170 175

15 TCC AAA GCC CAC ATT CAT TGC TCT GTC AAA GCA GAA AAT TCG GTT GCT 576
 Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala
 180 185 190

20 GCG AAA TCT GGG GGC TGT TTC CCA GGT TCC GCT CTG GTC TCG CTC CAG 624
 Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Leu Val Ser Leu Gln
 195 200 205

25 GAC GGA GGA CAG AAG GCC GTG AAG GAC CTG AAC CCC GGA GAC AAG GTG 672
 Asp Gly Gly Gln Lys Ala Val Lys Asp Leu Asn Pro Gly Asp Lys Val
 210 215 220

CTG GCG GCA GAC AGC GCG GGA AAC CTG GTG TTC AGC GAC TTC ATC ATG 720
 Leu Ala Ala Asp Ser Ala Gly Asn Leu Val Phe Ser Asp Phe Ile Met
 225 230 235 240

30 TTC ACA GAC CGA GAC TCC ACG ACG CGA CGT GTG TTT TAC GTC ATA GAA 768
 Phe Thr Asp Arg Asp Ser Thr Thr Arg Arg Val Phe Tyr Val Ile Glu
 245 250 255

35 ACG CAA GAA CCC GTT GAA AAG ATC ACC CTC ACC GCC GCT CAC CTC CTT 816
 Thr Gln Glu Pro Val Glu Lys Ile Thr Leu Thr Ala Ala His Leu Leu
 260 265 270

TTT GTC CTC GAC AAC TCA ACG GAA GAT CTC CAC ACC ATG ACC GCC GCG 864
 Phe Val Leu Asp Asn Ser Thr Glu Asp Leu His Thr Met Thr Ala Ala

	275	280	285	
	TAT GCC AGC AGT GTC AGA GCC GGA CAA AAG GTG ATG GTT GTT GAT GAT			912
	Tyr Ala Ser Ser Val Arg Ala Gly Gln Lys Val Met Val Val Asp Asp			
5	290	295	300	
	AGC GGT CAG CTT AAA TCT GTC ATC GTG CAG CGG ATA TAC ACG GAG GAG			960
	Ser Gly Gln Leu Lys Ser Val Ile Val Gln Arg Ile Tyr Thr Glu Glu			
	305	310	315	320
10	CAG CGG GGC TCG TTC GCA CCA GTG ACT GCA CAT GGG ACC ATT GTG GTC			1008
	Gln Arg Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile Val Val			
	325	330	335	
15	GAC AGA ATA CTG GCG TCC TGT TAC GCC GTA ATA GAG GAC CAG GGG CTT			1056
	Asp Arg Ile Leu Ala Ser Cys Tyr Ala Val Ile Glu Asp Gln Gly Leu			
	340	345	350	
	GCG CAT TTG GCC TTC GCG CCC GCC AGG CTC TAT TAT TAC GTG TCA TCA			1104
20	Ala His Leu Ala Phe Ala Pro Ala Arg Leu Tyr Tyr Tyr Val Ser Ser			
	355	360	365	
	TTC CTG TCC CCC AAA ACT CCA GCA GTC GGT CCA ATG CGA CTT TAC AAC			1152
	Phe Leu Ser Pro Lys Thr Pro Ala Val Gly Pro Met Arg Leu Tyr Asn			
25	370	375	380	
	AGG AGG GGG TCC ACT GGT ACT CCA GGC TCC TGT CAT CAA ATG GGA ACG			1200
	Arg Arg Gly Ser Thr Gly Thr Pro Gly Ser Cys His Gln Met Gly Thr			
	385	390	395	400
30	TGG CTT TTG GAC AGC AAC ATG CTT CAT CCT TTG GGG ATG TCA GTA AAC			1248
	Trp Leu Leu Asp Ser Asn Met Leu His Pro Leu Gly Met Ser Val Asn			
	405	410	415	
35	TCA AGC TG			1256
	Ser Ser			

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1425 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..1425

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

20	ATG CTG CTG CTG GCG AGA TGT CTG CTG CTA GTC CTC GTC TCC TCG CTG	48
	Met Leu Leu Leu Ala Arg Cys Leu Leu Leu Val Leu Val Ser Ser Leu	
	1 5 10 15	
25	CTG GTA TGC TCG GGA CTG GCG TGC GGA CCG GGC AGG GGG TTC GGG AAG	96
	Leu Val Cys Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly Lys	
	20 25 30	
30	AGG AGG CAC CCC AAA AAG CTG ACC CCT TTA GCC TAC AAG CAG TTT ATC	144
	Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile	
	35 40 45	
35	CCC AAT GTG GCC GAG AAG ACC CTA GGC GCC AGC GGA AGG TAT GAA GGG	192
	Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly	
	50 55 60	
35	AAG ATC TCC AGA AAC TCC GAG CGA TTT AAG GAA CTC ACC CCC AAT TAC	240
	Lys Ile Ser Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr	
	65 70 75 80	
	AAC CCC GAC ATC ATA TTT AAG GAT GAA GAA AAC ACC GGA GCG GAC AGG	288

	Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg	
	85 90 95	
5	CTG ATG ACT CAG AGG TGT AAG GAC AAG TTG AAC GCT TTG GCC ATC TCG Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile Ser	336
	100 105 110	
10	GTG ATG AAC CAG TGG CCA GGA GTG AAA CTG CGG GTG ACC GAG GGC TGG Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp	384
	115 120 125	
15	GAC GAA GAT GGC CAC CAC TCA GAG GAG TCT CTG CAC TAC GAG GGC CGC Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly Arg	432
	130 135 140	
	GCA GTG GAC ATC ACC ACG TCT GAC CGC GAC CGC AGC AAG TAC GGC ATG Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly Met	480
	145 150 155 160	
20	CTG GCC CGC CTG GCG GTG GAG GCC GGC TTC GAC TGG GTG TAC TAC GAG Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu	528
	165 170 175	
25	TCC AAG GCA CAT ATC CAC TGC TCG GTG AAA GCA GAG AAC TCG GTG GCG Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala	576
	180 185 190	
30	GCC AAA TCG GGA GGC TGC TTC CCG GGC TCG GCC ACG GTG CAC CTG GAG Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu Glu	624
	195 200 205	
35	CAG GGC GGC ACC AAG CTG GTG AAG GAC CTG AGC CCC GGG GAC CGC GTG Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly Asp Arg Val	672
	210 215 220	
	CTG GCG GCG GAC GAC CAG GGC CGG CTG CTC TAC AGC GAC TTC CTC ACT Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu Thr	720
	225 230 235 240	

	TTC CTG GAC CGC GAC GAC GGC GCC AAG AAG GTC TTC TAC GTG ATC GAG	768
	Phe Leu Asp Arg Asp Asp Gly Ala Lys Lys Val Phe Tyr Val Ile Glu	
	245 250 255	
5	ACG CGG GAG CCG CGC GAG CGC CTG CTG CTC ACC GCC GCG CAC CTG CTC	816
	Thr Arg Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu Leu	
	260 265 270	
10	TTT GTG GCG CCG CAC AAC GAC TCG GCC ACC GGG GAG CCC GAG GCG TCC	864
	Phe Val Ala Pro His Asn Asp Ser Ala Thr Gly Glu Pro Glu Ala Ser	
	275 280 285	
15	TCG GGC TCG GGG CCG CCT TCC GGG GGC GCA CTG GGG CCT CGG GCG CTG	912
	Ser Gly Ser Gly Pro Pro Ser Gly Gly Ala Leu Gly Pro Arg Ala Leu	
	290 295 300	
20	TTC GCC AGC CGC GTG CGC CCG GGC CAG CGC GTG TAC GTG GTG GCC GAG	960
	Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val Ala Glu	
	305 310 315 320	
25	CGT GAC GGG GAC CGC CGG CTC CTG CCC GCC GCT GTG CAC AGC GTG ACC	1008
	Arg Asp Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser Val Thr	
	325 330 335	
30	CTA AGC GAG GAG GCC GCG GGC GCC TAC GCG CCG CTC ACG GCC CAG GGC	1056
	Leu Ser Glu Glu Ala Ala Gly Ala Tyr Ala Pro Leu Thr Ala Gln Gly	
	340 345 350	
35	ACC ATT CTC ATC AAC CGG GTG CTG GCC TCG TGC TAC GCG GTC ATC GAG	1104
	Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val Ile Glu	
	355 360 365	
40	GAG CAC AGC TGG GCG CAC CGG GCC TTC GCG CCC TTC CGC CTG GCG CAC	1152
	Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu Ala His	
	370 375 380	
45	GCG CTC CTG GCT GCA CTG GCG CCC GCG CGC ACG GAC CGC GGC GGG GAC	1200
	Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Arg Gly Gly Asp	
	385 390 395 400	

AGC GGC GGC GGG GAC CGC GGG GGC GGC GGC GGC AGA GTA GCC CTA ACC 1248
 Ser Gly Gly Gly Asp Arg Gly Gly Gly Gly Gly Arg Val Ala Leu Thr
 405 410 415

5

GCT CCA GGT GCT GCC GAC GCT CCG GGT GCG GGG GCC ACC GCG GGC ATC 1296
 Ala Pro Gly Ala Ala Asp Ala Pro Gly Ala Gly Ala Thr Ala Gly Ile
 420 425 430

10

CAC TGG TAC TCG CAG CTG CTC TAC CAA ATA GGC ACC TGG CTC CTG GAC 1344
 His Trp Tyr Ser Gln Leu Leu Tyr Gln Ile Gly Thr Trp Leu Leu Asp
 435 440 445

AGC GAG GCC CTG CAC CCG CTG GGC ATG GCG GTC AAG TCC AGC NNN AGC 1392
 15 Ser Glu Ala Leu His Pro Leu Gly Met Ala Val Lys Ser Ser Xaa Ser
 450 455 460

CGG GGG GCC GGG GGA GGG GCG CGG GAG GGG GCC 1425
 Arg Gly Ala Gly Gly Gly Ala Arg Glu Gly Ala
 20 465 470 475

(2) INFORMATION FOR SEQ ID NO:7:

25

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1622 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

30

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

35

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 51..1283

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

	CATCAGCCCA CCAGGAGACC TCGCCCGCCG CTCCCCGGG CTCCCCGGCC ATG TCT	56
	Met Ser	
5	1	
	CCC GCC CGG CTC CGG CCC CGA CTG CAC TTC TGC CTG GTC CTG TTG CTG	104
	Pro Ala Arg Leu Arg Pro Arg Leu His Phe Cys Leu Val Leu Leu Leu	
	5 10 15	
10		
	CTG CTG GTG GTG CCC GCG GCA TGG GGC TGC GGG CCG GGT CGG GTG GTG	152
	Leu Leu Val Val Pro Ala Ala Trp Gly Cys Gly Pro Gly Arg Val Val	
	20 25 30	
15		
	GGC AGC CGC CGG CGA CCG CCA CGC AAA CTC GTG CCG CTC GCC TAC AAG	200
	Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala Tyr Lys	
	35 40 45 50	
	CAG TTC AGC CCC AAT GTG CCC GAG AAG ACC CTG GGC GCC AGC GGA CGC	248
20	Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser Gly Arg	
	55 60 65	
	TAT GAA GGC AAG ATC GCT CGC AGC TCC GAG CGC TTC AAG GAG CTC ACC	296
	Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu Leu Thr	
25	70 75 80	
	CCC AAT TAC AAT CCA GAC ATC ATC TTC AAG GAC GAG GAG AAC ACA GGC	344
	Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly	
	85 90 95	
30		
	GCC GAC CGC CTC ATG ACC CAG CGC TGC AAG GAC CGC CTG AAC TCG CTG	392
	Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn Ser Leu	
	100 105 110	
35		
	GCT ATC TCG GTG ATG AAC CAG TGG CCC GGT GTG AAG CTG CGG GTG ACC	440
	Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr	
	115 120 125 130	
	GAG GGC TGG GAC GAG GAC GGC CAC CAC TCA GAG GAG TCC CTG CAT TAT	488

	Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr	
	135 140 145	
	GAG GGC CGC GCG GTG GAC ATC ACC ACA TCA GAC CGC GAC CGC AAT AAG	536
5	Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys	
	150 155 160	
	TAT GGA CTG CTG GCG CGC TTG GCA GTG GAG GCC GGC TTT GAC TGG GTG	584
	Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val	
10	165 170 175	
	TAT TAC GAG TCA AAG GCC CAC GTG CAT TGC TCC GTC AAG TCC GAG CAC	632
	Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser Glu His	
	180 185 190	
15	TCG GCC GCA GCC AAG ACG GGC GGC TGC TTC CCT GCC GGA GCC CAG GTA	680
	Ser Ala Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala Gln Val	
	195 200 205 210	
20	CGC CTG GAG AGT GGG GCG CGT GTG GCC TTG TCA GCC GTG AGG CCG GGA	728
	Arg Leu Glu Ser Gly Ala Arg Val Ala Leu Ser Ala Val Arg Pro Gly	
	215 220 225	
	GAC CGT GTG CTG GCC ATG GGG GAG GAT GGG AGC CCC ACC TTC AGC GAT	776
25	Asp Arg Val Leu Ala Met Gly Glu Asp Gly Ser Pro Thr Phe Ser Asp	
	230 235 240	
	GTG CTC ATT TTC CTG GAC CGC GAG CCC CAC AGG CTG AGA GCC TTC CAG	824
	Val Leu Ile Phe Leu Asp Arg Glu Pro His Arg Leu Arg Ala Phe Gln	
30	245 250 255	
	GTC ATC GAG ACT CAG GAC CCC CCA CGC CGC CTG GCA CTC ACA CCC GCT	872
	Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr Pro Ala	
	260 265 270	
35	CAC CTG CTC TTT ACG GCT GAC AAT CAC ACG GAG CCG GCA GCC CGC TTC	920
	His Leu Leu Phe Thr Ala Asp Asn His Thr Glu Pro Ala Ala Arg Phe	
	275 280 285 290	

	CGG GCC ACA TTT GCC AGC CAC GTG CAG CCT GGC CAG TAC GTG CTG GTG	968
	Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val Leu Val	
	295 300 305	
5	GCT GGG GTG CCA GGC CTG CAG CCT GCC CGC GTG GCA GCT GTC TCT ACA	1016
	Ala Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val Ser Thr	
	310 315 320	
	CAC GTG GCC CTC GGG GCC TAC GCC CCG CTC ACA AAG CAT GGG ACA CTG	1064
10	His Val Ala Leu Gly Ala Tyr Ala Pro Leu Thr Lys His Gly Thr Leu	
	325 330 335	
	GTG GTG GAG GAT GTG GTG GCA TCC TGC TTC GCG GCC GTG GCT GAC CAC	1112
	Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala Asp His	
15	340 345 350	
	CAC CTG GCT CAG TTG GCC TTC TGG CCC CTG AGA CTC TTT CAC AGC TTG	1160
	His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe His Ser Leu	
	355 360 365 370	
20	GCA TGG GGC AGC TGG ACC CCG GGG GAG GGT GTG CAT TGG TAC CCC CAG	1208
	Ala Trp Gly Ser Trp Thr Pro Gly Glu Gly Val His Trp Tyr Pro Gln	
	375 380 385	
25	CTG CTC TAC CGC CTG GGG CGT CTC CTG CTA GAA GAG GGC AGC TTC CAC	1256
	Leu Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Glu Gly Ser Phe His	
	390 395 400	
	CCA CTG GGC ATG TCC GGG GCA GGG AGC TGAAAGGACT CCACCGCTGC	1303
30	Pro Leu Gly Met Ser Gly Ala Gly Ser	
	405 410	
	CCTCCTGGAA CTGCTGTACT GGGTCCAGAA GCCTCTCAGC CAGGAGGGAG CTGGCCCTGG	1363
35	AAGGGACCTG AGCTGGGGGA CACTGGCTCC TGCCATCTCC TCTGCCATGA AGATACACCA	1423
	TTGAGACTTG ACTGGGCAAC ACCAGCGTCC CCCACCCGCG TCGTGGTGTA GTCATAGAGC	1483
	TGCAAGCTGA GCTGGCGAGG GGATGGTTGT TGACCCCTCT CTCCTAGAGA CCTTGAGGCT	1543

GGCACGGCGA CTCCCAACTC AGCCTGCTCT CACTACGAGT TTTCATACTC TGCCTCCCCC 1603

ATTGGGAGGG CCCATTCCC 1622

5

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1191 base pairs

10

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

15

(ix) FEATURE:

(A) NAME/KEY: CDS.

(B) LOCATION: 1..1191

20

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

ATG GCT CTC CTG ACC AAT CTA CTG CCC TTG TGC TGC TTG GCA CTT CTG 48
25 Met Ala Leu Leu Thr Asn Leu Leu Pro Leu Cys Cys Leu Ala Leu Leu
1 5 10 15

GCG CTG CCA GCC CAG AGC TGC GGG CCG GGC CGG GGG CCG GTT GGC CGG 96
30 Ala Leu Pro Ala Gln Ser Cys Gly Pro Gly Arg Gly Pro Val Gly Arg
20 25 30

CGC CGC TAT GCG CGC AAG CAG CTC GTG CCG CTA CTC TAC AAG CAA TTT 144
Arg Arg Tyr Ala Arg Lys Gln Leu Val Pro Leu Leu Tyr Lys Gln Phe
35 40 45

GTG CCC GGC GTG CCA GAG CGG ACC CTG GGC GCC AGT GGG CCA GCG GAG 192
Val Pro Gly Val Pro Glu Arg Thr Leu Gly Ala Ser Gly Pro Ala Glu
50 55 60

	GGG AGG GTG GCA AGG GGC TCC GAG CGC TTC CGG GAC CTC GTG CCC AAC	240
	Gly Arg Val Ala Arg Gly Ser Glu Arg Phe Arg Asp Leu Val Pro Asn	
	65 70 75 80	
5	TAC AAC CCC GAC ATC ATC TTC AAG GAT GAG GAG AAC AGT GGA GCC GAC	288
	Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp	
	85 90 95	
10	CGC CTG ATG ACC GAG CGT TGC AAG GAG AGG GTG AAC GCT TTG GCC ATT	336
	Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile	
	100 105 110	
15	GCC GTG ATG AAC ATG TGG CCC GGA GTG CGC CTA CGA GTG ACT GAG GGC	384
	Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly	
	115 120 125	
20	TGG GAC GAG GAC GGC CAC CAC GCT CAG GAT TCA CTC CAC TAC GAA GGC	432
	Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly	
	130 135 140	
25	CGT GCT TTG GAC ATC ACT ACG TCT GAC CGC GAC CGC AAC AAG TAT GGG	480
	Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly	
	145 150 155 160	
30	TTG CTG GCG CGC CTC GCA GTG GAA GCC GGC TTC GAC TGG GTC TAC TAC	528
	Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr	
	165 170 175	
35	GAG TCC CGC AAC CAC GTC CAC GTG TCG GTC AAA GCT GAT AAC TCA CTG	576
	Glu Ser Arg Asn His Val His Val Ser Val Lys Ala Asp Asn Ser Leu	
	180 185 190	
40	GCG GTC CGG GCG GGC GGC TGC TTT CCG GGA AAT GCA ACT GTG CGC CTG	624
	Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu	
	195 200 205	
45	TGG AGC GGC GAG CGG AAA GGG CTG CGG GAA CTG CAC CGC GGA GAC TGG	672
	Trp Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp	
	210 215 220	

	GTT TTG GCG GCC GAT GCG TCA GGC CGG GTG GTG CCC ACG CCG GTG CTG	720
	Val Leu Ala Ala Asp Ala Ser Gly Arg Val Val Pro Thr Pro Val Leu	
	225 230 235 240	
5	CTC TTC CTG GAC CGG GAC TTG CAG CGC CGG GCT TCA TTT GTG GCT GTG	768
	Leu Phe Leu Asp Arg Asp Leu Gln Arg Arg Ala Ser Phe Val Ala Val	
	245 250 255	
10	GAG ACC GAG TGG CCT CCA CGC AAA CTG TTG CTC ACG CCC TGG CAC CTG	816
	Glu Thr Glu Trp Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp His Leu	
	260 265 270	
	GTG TTT GCC GCT CGA GGG CCG GCG CCC GCG CCA GGC GAC TTT GCA CCG	864
15	Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp Phe Ala Pro	
	275 280 285	
	GTG TTC GCG CGC CGG CTA CGC GCT GGG GAC TCG GTG CTG GCG CCC GGC	912
	Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val Leu Ala Pro Gly	
20	290 295 300	
	GGG GAT GCG CTT CGG CCA GCG CGC GTG GCC CGT GTG GCG CGG GAG GAA	960
	Gly Asp Ala Leu Arg Pro Ala Arg Val Ala Arg Val Ala Arg Glu Glu	
	305 310 315 320	
25	GCC GTG GGC GTG TTC GCG CCG CTC ACC GCG CAC GGG ACG CTG CTG GTG	1008
	Ala Val Gly Val Phe Ala Pro Leu Thr Ala His Gly Thr Leu Leu Val	
	325 330 335	
30	AAC GAT GTC CTG GCC TCT TGC TAC GCG GTT CTG GAG AGT CAC CAG TGG	1056
	Asn Asp Val Leu Ala Ser Cys Tyr Ala Val Leu Glu Ser His Gln Trp	
	340 345 350	
	GCG CAC CGC GCT TTT GCC CCC TTG AGA CTG CTG CAC GCG CTA GGG GCG	1104
35	Ala His Arg Ala Phe Ala Pro Leu Arg Leu Leu His Ala Leu Gly Ala	
	355 360 365	
	CTG CTC CCC GGC GGG GCC GTC CAG CCG ACT GGC ATG CAT TGG TAC TCT	1152
	Leu Leu Pro Gly Gly Ala Val Gln Pro Thr Gly Met His Trp Tyr Ser	

370

375

380

CGG CTC CTC TAC CGC TTA GCG GAG GAG CTA CTG GGC TG

1191

Arg Leu Leu Tyr Arg Leu Ala Glu Glu Leu Leu Gly

5 385

390

395

(2) INFORMATION FOR SEQ ID NO:9:

10

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1251 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

15

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

20

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1248

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

ATG GAC GTA AGG CTG CAT CTG AAG CAA TTT GCT TTA CTG TGT TTT ATC

48

Met Asp Val Arg Leu His Leu Lys Gln Phe Ala Leu Leu Cys Phe Ile

1

5

10

15

30

AGC TTG CTT CTG ACG CCT TGT GGA TTA GCC TGT GGT CCT GGT AGA GGT

96

Ser Leu Leu Leu Thr Pro Cys Gly Leu Ala Cys Gly Pro Gly Arg Gly

20

25

30

35

TAT GGA AAA CGA AGA CAC CCA AAG AAA TTA ACC CCG TTG GCT TAC AAG

144

Tyr Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys

35

40

45

CAA TTC ATC CCC AAC GTT GCT GAG AAA ACG CTT GGA GCC AGC GGC AAA

192

	Gln	Phe	Ile	Pro	Asn	Val	Ala	Glu	Lys	Thr	Leu	Gly	Ala	Ser	Gly	Lys	
	50							55									60
	TAC	GAA	GGC	AAA	ATC	ACA	AGG	AAT	TCA	GAG	AGA	TTT	AAA	GAG	CTG	ATT	240
5	Tyr	Glu	Gly	Lys	Ile	Thr	Arg	Asn	Ser	Glu	Arg	Phe	Lys	Glu	Leu	Ile	
	65					70					75					80	
	CCG	AAT	TAT	AAT	CCC	GAT	ATC	ATC	TTT	AAG	GAC	GAG	GAA	AAC	ACA	AAC	288
10	Pro	Asn	Tyr	Asn	Pro	Asp	Ile	Ile	Phe	Lys	Asp	Glu	Glu	Asn	Thr	Asn	
				85						90					95		
	GCT	GAC	AGG	CTG	ATG	ACC	AAG	CGC	TGT	AAG	GAC	AAG	TTA	AAT	TCG	TTG	336
	Ala	Asp	Arg	Leu	Met	Thr	Lys	Arg	Cys	Lys	Asp	Lys	Leu	Asn	Ser	Leu	
				100					105					110			
15	GCC	ATA	TCC	GTC	ATG	AAC	CAC	TGG	CCC	GGC	GTG	AAA	CTG	CGC	GTC	ACT	384
	Ala	Ile	Ser	Val	Met	Asn	His	Trp	Pro	Gly	Val	Lys	Leu	Arg	Val	Thr	
				115				120						125			
20	GAA	GGC	TGG	GAT	GAG	GAT	GGT	CAC	CAT	TTA	GAA	GAA	TCT	TTG	CAC	TAT	432
	Glu	Gly	Trp	Asp	Glu	Asp	Gly	His	His	Leu	Glu	Glu	Ser	Leu	His	Tyr	
		130					135						140				
	GAG	GGA	CGG	GCA	GTG	GAC	ATC	ACT	ACC	TCA	GAC	AGG	GAT	AAA	AGC	AAG	480
25	Glu	Gly	Arg	Ala	Val	Asp	Ile	Thr	Thr	Ser	Asp	Arg	Asp	Lys	Ser	Lys	
	145					150					155					160	
	TAT	GGG	ATG	CTA	TCC	AGG	CTT	GCA	GTG	GAG	GCA	GGA	TTC	GAC	TGG	GTC	528
30	Tyr	Gly	Met	Leu	Ser	Arg	Leu	Ala	Val	Glu	Ala	Gly	Phe	Asp	Trp	Val	
				165						170					175		
	TAT	TAT	GAA	TCT	AAA	GCC	CAC	ATA	CAC	TGC	TCT	GTC	AAA	GCA	GAA	AAT	576
	Tyr	Tyr	Glu	Ser	Lys	Ala	His	Ile	His	Cys	Ser	Val	Lys	Ala	Glu	Asn	
				180					185					190			
35	TCA	GTG	GCT	GCT	AAA	TCA	GGA	GGA	TGT	TTT	CCT	GGG	TCT	GGG	ACG	GTG	624
	Ser	Val	Ala	Ala	Lys	Ser	Gly	Gly	Cys	Phe	Pro	Gly	Ser	Gly	Thr	Val	
				195					200					205			

	ACA CTT GGT GAT GGG ACG AGG AAA CCC ATC AAA GAT CTT AAA GTG GGC	672
	Thr Leu Gly Asp Gly Thr Arg Lys Pro Ile Lys Asp Leu Lys Val Gly	
	210 215 220	
5	GAC CGG GTT TTG GCT GCA GAC GAG AAG GGA AAT GTC TTA ATA AGC GAC	720
	Asp Arg Val Leu Ala Ala Asp Glu Lys Gly Asn Val Leu Ile Ser Asp	
	225 230 235 240	
	TTT ATT ATG TTT ATA GAC CAC GAT CCG ACA ACG AGA AGG CAA TTC ATC	768
10	Phe Ile Met Phe Ile Asp His Asp Pro Thr Thr Arg Arg Gln Phe Ile	
	245 250 255	
	GTC ATC GAG ACG TCA GAA CCT TTC ACC AAG CTC ACC CTC ACT GCC GCG	816
	Val Ile Glu Thr Ser Glu Pro Phe Thr Lys Leu Thr Leu Thr Ala Ala	
15	260 265 270	
	CAC CTA GTT TTC GTT GGA AAC TCT TCA GCA GCT TCG GGT ATA ACA GCA	864
	His Leu Val Phe Val Gly Asn Ser Ser Ala Ala Ser Gly Ile Thr Ala	
	275 280 285	
20	ACA TTT GCC AGC AAC GTG AAG CCT GGA GAT ACA GTT TTA GTG TGG GAA	912
	Thr Phe Ala Ser Asn Val Lys Pro Gly Asp Thr Val Leu Val Trp Glu	
	290 295 300	
25	GAC ACA TGC GAG AGC CTC AAG AGC GTT ACA GTG AAA AGG ATT TAC ACT	960
	Asp Thr Cys Glu Ser Leu Lys Ser Val Thr Val Lys Arg Ile Tyr Thr	
	305 310 315 320	
	GAG GAG CAC GAG GGC TCT TTT GCG CCA GTC ACC GCG CAC GGA ACC ATA	1008
30	Glu Glu His Glu Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile	
	325 330 335	
	ATA GTG GAT CAG GTG TTG GCA TCG TGC TAC GCG GTC ATT GAG AAC CAC	1056
	Ile Val Asp Gln Val Leu Ala Ser Cys Tyr Ala Val Ile Glu Asn His	
35	340 345 350	
	AAA TGG GCA CAT TGG GCT TTT GCG CCG GTC AGG TTG TGT CAC AAG CTG	1104
	Lys Trp Ala His Trp Ala Phe Ala Pro Val Arg Leu Cys His Lys Leu	
	355 360 365	

ATG ACG TGG CTT TTT CCG GCT CGT GAA TCA AAC GTC AAT TTT CAG GAG 1152
 Met Thr Trp Leu Phe Pro Ala Arg Glu Ser Asn Val Asn Phe Gln Glu
 370 375 380

5

GAT GGT ATC CAC TGG TAC TCA AAT ATG CTG TTT CAC ATC GGC TCT TGG 1200
 Asp Gly Ile His Trp Tyr Ser Asn Met Leu Phe His Ile Gly Ser Trp
 385 390 395 400

10 CTG CTG GAC AGA GAC TCT TTC CAT CCA CTC GGG ATT TTA CAC TTA AGT 1248
 Leu Leu Asp Arg Asp Ser Phe His Pro Leu Gly Ile Leu His Leu Ser
 405 410 415

TGA 1251

15

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 425 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

25

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

30 Met Val Glu Met Leu Leu Leu Thr Arg Ile Leu Leu Val Gly Phe Ile
 1 5 10 15

Cys Ala Leu Leu Val Ser Ser Gly Leu Thr Cys Gly Pro Gly Arg Gly
 20 25 30

35 Ile Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys
 35 40 45

Gln Phe Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg
 50 55 60

Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr
 65 70 75 80

5 Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly
 85 90 95

Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu
 100 105 110

10 Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr
 115 120 125

Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr
 15 130 135 140

Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys
 145 150 155 160

20 Tyr Gly Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val
 165 170 175

Tyr Tyr Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn
 180 185 190

25 Ser Val Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val
 195 200 205

His Leu Glu His Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly
 30 210 215 220

Asp Arg Val Leu Ala Ala Asp Ala Asp Gly Arg Leu Leu Tyr Ser Asp
 225 230 235 240

35 Phe Leu Thr Phe Leu Asp Arg Met Asp Ser Ser Arg Lys Leu Phe Tyr
 245 250 255

Val Ile Glu Thr Arg Gln Pro Arg Ala Arg Leu Leu Leu Thr Ala Ala
 260 265 270

His Leu Leu Phe Val Ala Pro Gln His Asn Gln Ser Glu Ala Thr Gly
 275 280 285

5 Ser Thr Ser Gly Gln Ala Leu Phe Ala Ser Asn Val Lys Pro Gly Gln
 290 295 300

Arg Val Tyr Val Leu Gly Glu Gly Gly Gln Gln Leu Leu Pro Ala Ser
 305 310 315 320

10 Val His Ser Val Ser Leu Arg Glu Glu Ala Ser Gly Ala Tyr Ala Pro
 325 330 335

Leu Thr Ala Gln Gly Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys
 15 340 345 350

Tyr Ala Val Ile Glu Glu His Ser Trp Ala His Trp Ala Phe Ala Pro
 355 360 365

20 Phe Arg Leu Ala Gln Gly Leu Leu Ala Ala Leu Cys Pro Asp Gly Ala
 370 375 380

Ile Pro Thr Ala Ala Thr Thr Thr Thr Gly Ile His Trp Tyr Ser Arg
 385 390 395 400

25 Leu Leu Tyr Arg Ile Gly Ser Trp Val Leu Asp Gly Asp Ala Leu His
 405 410 415

Pro Leu Gly Met Val Ala Pro Ala Ser
 30 420 425

(2) INFORMATION FOR SEQ ID NO:11:

- 35 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 396 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

5 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

```

Met Ala Leu Pro Ala Ser Leu Leu Pro Leu Cys Cys Leu Ala Leu Leu
  1           5           10           15

10 Ala Leu Ser Ala Gln Ser Cys Gly Pro Gly Arg Gly Pro Val Gly Arg
    20           25           30

    Arg Arg Tyr Val Arg Lys Gln Leu Val Pro Leu Leu Tyr Lys Gln Phe
      35           40           45

15 Val Pro Ser Met Pro Glu Arg Thr Leu Gly Ala Ser Gly Pro Ala Glu
    50           55           60

    Gly Arg Val Thr Arg Gly Ser Glu Arg Phe Arg Asp Leu Val Pro Asn
20   65           70           75           80

    Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp
      85           90           95

25 Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile
    100           105           110

    Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly
      115           120           125

30 Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly
    130           135           140

    Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly
35   145           150           155           160

    Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr
      165           170           175

```

Glu Ser Arg Asn His Ile His Val Ser Val Lys Ala Asp Asn Ser Leu
 180 185 190

5 Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu
 195 200 205

Arg Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp
 210 215 220

10 Val Leu Ala Ala Asp Ala Ala Gly Arg Val Val Pro Thr Pro Val Leu
 225 230 235 240

Leu Phe Leu Asp Arg Asp Leu Gln Arg Arg Ala Ser Phe Val Ala Val
 245 250 255

15 Glu Thr Glu Arg Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp His Leu
 260 265 270

20 Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp Phe Ala Pro
 275 280 285

Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val Leu Ala Pro Gly
 290 295 300

25 Gly Asp Ala Leu Gln Pro Ala Arg Val Ala Arg Val Ala Arg Glu Glu
 305 310 315 320

Ala Val Gly Val Phe Ala Pro Leu Thr Ala His Gly Thr Leu Leu Val
 325 330 335

30 Asn Asp Val Leu Ala Ser Cys Tyr Ala Val Leu Glu Ser His Gln Trp
 340 345 350

35 Ala His Arg Ala Phe Ala Pro Leu Arg Leu Leu His Ala Leu Gly Ala
 355 360 365

Leu Leu Pro Gly Gly Ala Val Gln Pro Thr Gly Met His Trp Tyr Ser
 370 375 380

Arg Leu Leu Tyr Arg Leu Ala Glu Glu Leu Met Gly
 385 390 395

5 (2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 amino acids

(B) TYPE: amino acid

10 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

Met Ser Pro Ala Trp Leu Arg Pro Arg Leu Arg Phe Cys Leu Phe Leu
 1 5 10 15

20

Leu Leu Leu Leu Leu Val Pro Ala Ala Arg Gly Cys Gly Pro Gly Arg
 20 25 30

Val Val Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala
 25 35 40 45

Tyr Lys Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser
 50 55 60

30 Gly Arg Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu
 65 70 75 80

Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn
 85 90 95

35

Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn
 100 105 110

Ser Leu Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg

	115	120	125
	Val Thr Glu Gly Arg Asp Glu Asp Gly His His Ser Glu Glu Ser Leu		
	130	135	140
5	His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg		
	145	150	155 160
	Asn Lys Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp		
10	165	170	175
	Trp Val Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser		
	180	185	190
15	Glu His Ser Ala Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala		
	195	200	205
	Gln Val Arg Leu Glu Asn Gly Glu Arg Val Ala Leu Ser Ala Val Lys		
	210	215	220
20	Pro Gly Asp Arg Val Leu Ala Met Gly Glu Asp Gly Thr Pro Thr Phe		
	225	230	235 240
	Ser Asp Val Leu Ile Phe Leu Asp Arg Glu Pro Asn Arg Leu Arg Ala		
25	245	250	255
	Phe Gln Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr		
	260	265	270
30	Pro Ala His Leu Leu Phe Ile Ala Asp Asn His Thr Glu Pro Ala Ala		
	275	280	285
	His Phe Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val		
	290	295	300
35	Leu Val Ser Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val		
	305	310	315 320
	Ser Thr His Val Ala Leu Gly Ser Tyr Ala Pro Leu Thr Arg His Gly		

325 330 335
 Thr Leu Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala
 340 345 350
 5
 Asp His His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe Pro
 355 360 365
 Ser Leu Ala Trp Gly Ser Trp Thr Pro Ser Glu Gly Val His Ser Tyr
 10 370 375 380
 Pro Gln Met Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Glu Ser Thr
 385 390 395 400
 15 Phe His Pro Leu Gly Met Ser Gly Ala Gly Ser
 405 410

20 (2) INFORMATION FOR SEQ ID NO:13:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 437 amino acids
 (B) TYPE: amino acid
 25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

30

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Leu Leu Leu Leu Ala Arg Cys Phe Leu Val Ile Leu Ala Ser Ser
 1 5 10 15
 35 Leu Leu Val Cys Pro Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly
 20 25 30
 Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe

35 40 45
 Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu
 50 55 60
 5
 Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn
 65 70 75 80
 Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp
 10 85 90 95
 Arg Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile
 100 105 110
 15 Ser Val Met Asn Gln Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly
 115 120 125
 Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly
 130 135 140
 20 Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly
 145 150 155 160
 Met Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr
 25 165 170 175
 Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val
 180 185 190
 30 Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu
 195 200 205
 Glu Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Arg Pro Gly Asp Arg
 210 215 220
 35 Val Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu
 225 230 235 240
 Thr Phe Leu Asp Arg Asp Glu Gly Ala Lys Lys Val Phe Tyr Val Ile

	245	250	255
	Glu Thr Leu Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu		
	260	265	270
5	Leu Phe Val Ala Pro His Asn Asp Ser Gly Pro Thr Pro Gly Pro Ser		
	275	280	285
	Ala Leu Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val		
10	290	295	300
	Ala Glu Arg Gly Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser		
	305	310	315 320
15	Val Thr Leu Arg Glu Glu Glu Ala Gly Ala Tyr Ala Pro Leu Thr Ala		
	325	330	335
	His Gly Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val		
	340	345	350
20	Ile Glu Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu		
	355	360	365
	Ala His Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Gly Gly		
25	370	375	380
	Gly Gly Gly Ser Ile Pro Ala Ala Gln Ser Ala Thr Glu Ala Arg Gly		
	385	390	395 400
30	Ala Glu Pro Thr Ala Gly Ile His Trp Tyr Ser Gln Leu Leu Tyr His		
	405	410	415
	Ile Gly Thr Trp Leu Leu Asp Ser Glu Thr Met His Pro Leu Gly Met		
	420	425	430
35	Ala Val Lys Ser Ser		
	435		

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 418 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

Met Arg Leu Leu Thr Arg Val Leu Leu Val Ser Leu Leu Thr Leu Ser
15 1 5 10 15

Leu Val Val Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Tyr Gly Arg
20 25 30

Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile
35 40 45

Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly
50 55 60

Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr
65 70 75 80

Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg
85 90 95

Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ser Leu Ala Ile Ser
100 105 110

Val Met Asn His Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp
115 120 125

Asp Glu Asp Gly His His Phe Glu Glu Ser Leu His Tyr Glu Gly Arg
130 135 140

Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Lys Ser Lys Tyr Gly Thr
 145 150 155 160

5 Leu Ser Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu
 165 170 175

Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala
 180 185 190

10 Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Leu Val Ser Leu Gln
 195 200 205

Asp Gly Gly Gln Lys Ala Val Lys Asp Leu Asn Pro Gly Asp Lys Val
 15 210 215 220

Leu Ala Ala Asp Ser Ala Gly Asn Leu Val Phe Ser Asp Phe Ile Met
 225 230 235 240

20 Phe Thr Asp Arg Asp Ser Thr Thr Arg Arg Val Phe Tyr Val Ile Glu
 245 250 255

Thr Gln Glu Pro Val Glu Lys Ile Thr Leu Thr Ala Ala His Leu Leu
 260 265 270

25 Phe Val Leu Asp Asn Ser Thr Glu Asp Leu His Thr Met Thr Ala Ala
 275 280 285

Tyr Ala Ser Ser Val Arg Ala Gly Gln Lys Val Met Val Val Asp Asp
 30 290 295 300

Ser Gly Gln Leu Lys Ser Val Ile Val Gln Arg Ile Tyr Thr Glu Glu
 305 310 315 320

35 Gln Arg Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile Val Val
 325 330 335

Asp Arg Ile Leu Ala Ser Cys Tyr Ala Val Ile Glu Asp Gln Gly Leu
 340 345 350

Ala His Leu Ala Phe Ala Pro Ala Arg Leu Tyr Tyr Tyr Val Ser Ser
 355 360 365

5 Phe Leu Ser Pro Lys Thr Pro Ala Val Gly Pro Met Arg Leu Tyr Asn
 370 375 380

Arg Arg Gly Ser Thr Gly Thr Pro Gly Ser Cys His Gln Met Gly Thr
 385 390 395 400

10 Trp Leu Leu Asp Ser Asn Met Leu His Pro Leu Gly Met Ser Val Asn
 405 410 415

Ser Ser

15

(2) INFORMATION FOR SEQ ID NO:15:

20 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 475 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

25 (ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

30

Met Leu Leu Leu Ala Arg Cys Leu Leu Leu Val Leu Val Ser Ser Leu
 1 5 10 15

Leu Val Cys Ser Gly Leu Ala Cys Gly Pro Gly Arg Gly Phe Gly Lys
 35 20 25 30

Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys Gln Phe Ile
 35 40 45

Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Arg Tyr Glu Gly
 50 55 60

Lys Ile Ser Arg Asn Ser Glu Arg Phe Lys Glu Leu Thr Pro Asn Tyr
 5 65 70 75 80

Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Gly Ala Asp Arg
 85 90 95

10 Leu Met Thr Gln Arg Cys Lys Asp Lys Leu Asn Ala Leu Ala Ile Ser
 100 105 110

Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg Val Thr Glu Gly Trp
 115 120 125

15 Asp Glu Asp Gly His His Ser Glu Glu Ser Leu His Tyr Glu Gly Arg
 130 135 140

Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg Ser Lys Tyr Gly Met
 20 145 150 155 160

Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu
 165 170 175

25 Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn Ser Val Ala
 180 185 190

Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Ala Thr Val His Leu Glu
 195 200 205

30 Gln Gly Gly Thr Lys Leu Val Lys Asp Leu Ser Pro Gly Asp Arg Val
 210 215 220

Leu Ala Ala Asp Asp Gln Gly Arg Leu Leu Tyr Ser Asp Phe Leu Thr
 35 225 230 235 240

Phe Leu Asp Arg Asp Asp Gly Ala Lys Lys Val Phe Tyr Val Ile Glu
 245 250 255

Thr Arg Glu Pro Arg Glu Arg Leu Leu Leu Thr Ala Ala His Leu Leu
 260 265 270

Phe Val Ala Pro His Asn Asp Ser Ala Thr Gly Glu Pro Glu Ala Ser
 5 275 280 285

Ser Gly Ser Gly Pro Pro Ser Gly Gly Ala Leu Gly Pro Arg Ala Leu
 290 295 300

Phe Ala Ser Arg Val Arg Pro Gly Gln Arg Val Tyr Val Val Ala Glu
 10 305 310 315 320

Arg Asp Gly Asp Arg Arg Leu Leu Pro Ala Ala Val His Ser Val Thr
 325 330 335

15 Leu Ser Glu Glu Ala Ala Gly Ala Tyr Ala Pro Leu Thr Ala Gln Gly
 340 345 350

Thr Ile Leu Ile Asn Arg Val Leu Ala Ser Cys Tyr Ala Val Ile Glu
 20 355 360 365

Glu His Ser Trp Ala His Arg Ala Phe Ala Pro Phe Arg Leu Ala His
 370 375 380

25 Ala Leu Leu Ala Ala Leu Ala Pro Ala Arg Thr Asp Arg Gly Gly Asp
 385 390 395 400

Ser Gly Gly Gly Asp Arg Gly Gly Gly Gly Gly Arg Val Ala Leu Thr
 405 410 415

30 Ala Pro Gly Ala Ala Asp Ala Pro Gly Ala Gly Ala Thr Ala Gly Ile
 420 425 430

His Trp Tyr Ser Gln Leu Leu Tyr Gln Ile Gly Thr Trp Leu Leu Asp
 35 435 440 445

Ser Glu Ala Leu His Pro Leu Gly Met Ala Val Lys Ser Ser Xaa Ser
 450 455 460

Arg Gly Ala Gly Gly Gly Ala Arg Glu Gly Ala
 465 470 475

(2) INFORMATION FOR SEQ ID NO:16:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 411 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

15 Met Ser Pro Ala Arg Leu Arg Pro Arg Leu His Phe Cys Leu Val Leu
 1 5 10 15

Leu Leu Leu Leu Val Val Pro Ala Ala Trp Gly Cys Gly Pro Gly Arg
 20 25 30

20

Val Val Gly Ser Arg Arg Arg Pro Pro Arg Lys Leu Val Pro Leu Ala
 35 40 45

25 Tyr Lys Gln Phe Ser Pro Asn Val Pro Glu Lys Thr Leu Gly Ala Ser
 50 55 60

Gly Arg Tyr Glu Gly Lys Ile Ala Arg Ser Ser Glu Arg Phe Lys Glu
 65 70 75 80

30 Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn
 85 90 95

Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys Asp Arg Leu Asn
 100 105 110

35

Ser Leu Ala Ile Ser Val Met Asn Gln Trp Pro Gly Val Lys Leu Arg
 115 120 125

Val Thr Glu Gly Trp Asp Glu Asp Gly His His Ser Glu Glu Ser Leu

130 135 140
 His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Arg
 145 150 155 160
 5 Asn Lys Tyr Gly Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp
 165 170 175
 Trp Val Tyr Tyr Glu Ser Lys Ala His Val His Cys Ser Val Lys Ser
 10 180 185 190
 Glu His Ser Ala Ala Ala Lys Thr Gly Gly Cys Phe Pro Ala Gly Ala
 195 200 205
 15 Gln Val Arg Leu Glu Ser Gly Ala Arg Val Ala Leu Ser Ala Val Arg
 210 215 220
 Pro Gly Asp Arg Val Leu Ala Met Gly Glu Asp Gly Ser Pro Thr Phe
 20 225 230 235 240
 Ser Asp Val Leu Ile Phe Leu Asp Arg Glu Pro His Arg Leu Arg Ala
 245 250 255
 Phe Gln Val Ile Glu Thr Gln Asp Pro Pro Arg Arg Leu Ala Leu Thr
 25 260 265 270
 Pro Ala His Leu Leu Phe Thr Ala Asp Asn His Thr Glu Pro Ala Ala
 275 280 285
 30 Arg Phe Arg Ala Thr Phe Ala Ser His Val Gln Pro Gly Gln Tyr Val
 290 295 300
 Leu Val Ala Gly Val Pro Gly Leu Gln Pro Ala Arg Val Ala Ala Val
 35 305 310 315 320
 Ser Thr His Val Ala Leu Gly Ala Tyr Ala Pro Leu Thr Lys His Gly
 325 330 335
 Thr Leu Val Val Glu Asp Val Val Ala Ser Cys Phe Ala Ala Val Ala

	340		345		350
	Asp His His Leu Ala Gln Leu Ala Phe Trp Pro Leu Arg Leu Phe His				
	355		360		365
5	Ser Leu Ala Trp Gly Ser Trp Thr Pro Gly Glu Gly Val His Trp Tyr				
	370		375		380
	Pro Gln Leu Leu Tyr Arg Leu Gly Arg Leu Leu Leu Glu Glu Gly Ser				
10	385		390		395 400
	Phe His Pro Leu Gly Met Ser Gly Ala Gly Ser				
	405		410		

15 (2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 396 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

25	Met	Ala	Leu	Leu	Thr	Asn	Leu	Leu	Pro	Leu	Cys	Cys	Leu	Ala	Leu	Leu	
	1				5					10					15		
	Ala	Leu	Pro	Ala	Gln	Ser	Cys	Gly	Pro	Gly	Arg	Gly	Pro	Val	Gly	Arg	
30				20					25					30			
	Arg	Arg	Tyr	Ala	Arg	Lys	Gln	Leu	Val	Pro	Leu	Leu	Tyr	Lys	Gln	Phe	
			35					40					45				
35	Val	Pro	Gly	Val	Pro	Glu	Arg	Thr	Leu	Gly	Ala	Ser	Gly	Pro	Ala	Glu	
		50					55					60					
	Gly	Arg	Val	Ala	Arg	Gly	Ser	Glu	Arg	Phe	Arg	Asp	Leu	Val	Pro	Asn	
	65					70					75					80	

Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Ser Gly Ala Asp
 85 90 95

5 Arg Leu Met Thr Glu Arg Cys Lys Glu Arg Val Asn Ala Leu Ala Ile
 100 105 110

Ala Val Met Asn Met Trp Pro Gly Val Arg Leu Arg Val Thr Glu Gly
 115 120 125

10 Trp Asp Glu Asp Gly His His Ala Gln Asp Ser Leu His Tyr Glu Gly
 130 135 140

Arg Ala Leu Asp Ile Thr Thr Ser Asp Arg Asp Arg Asn Lys Tyr Gly
 15 145 150 155 160

Leu Leu Ala Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr
 165 170 175

20 Glu Ser Arg Asn His Val His Val Ser Val Lys Ala Asp Asn Ser Leu
 180 185 190

Ala Val Arg Ala Gly Gly Cys Phe Pro Gly Asn Ala Thr Val Arg Leu
 195 200 205

25 Trp Ser Gly Glu Arg Lys Gly Leu Arg Glu Leu His Arg Gly Asp Trp
 210 215 220

Val Leu Ala Ala Asp Ala Ser Gly Arg Val Val Pro Thr Pro Val Leu
 30 225 230 235 240

Leu Phe Leu Asp Arg Asp Leu Gln Arg Arg Ala Ser Phe Val Ala Val
 245 250 255

35 Glu Thr Glu Trp Pro Pro Arg Lys Leu Leu Leu Thr Pro Trp His Leu
 260 265 270

Val Phe Ala Ala Arg Gly Pro Ala Pro Ala Pro Gly Asp Phe Ala Pro
 275 280 285

Val Phe Ala Arg Arg Leu Arg Ala Gly Asp Ser Val Leu Ala Pro Gly
 290 295 300

5 Gly Asp Ala Leu Arg Pro Ala Arg Val Ala Arg Val Ala Arg Glu Glu
 305 310 315 320

Ala Val Gly Val Phe Ala Pro Leu Thr Ala His Gly Thr Leu Leu Val
 325 330 335

10 Asn Asp Val Leu Ala Ser Cys Tyr Ala Val Leu Glu Ser His Gln Trp
 340 345 350

Ala His Arg Ala Phe Ala Pro Leu Arg Leu Leu His Ala Leu Gly Ala
 15 355 360 365

Leu Leu Pro Gly Gly Ala Val Gln Pro Thr Gly Met His Trp Tyr Ser
 370 375 380

20 Arg Leu Leu Tyr Arg Leu Ala Glu Glu Leu Leu Gly
 385 390 395

25 (2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 416 amino acids

(B) TYPE: amino acid

30 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

35 Met Asp Val Arg Leu His Leu Lys Gln Phe Ala Leu Leu Cys Phe Ile
 1 5 10 15

Ser Leu Leu Leu Thr Pro Cys Gly Leu Ala Cys Gly Pro Gly Arg Gly

20 25 30
 Tyr Gly Lys Arg Arg His Pro Lys Lys Leu Thr Pro Leu Ala Tyr Lys
 35 40 45
 5
 Gln Phe Ile Pro Asn Val Ala Glu Lys Thr Leu Gly Ala Ser Gly Lys
 50 55 60
 Tyr Glu Gly Lys Ile Thr Arg Asn Ser Glu Arg Phe Lys Glu Leu Ile
 10 65 70 75 80
 Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys Asp Glu Glu Asn Thr Asn
 85 90 95
 15 Ala Asp Arg Leu Met Thr Lys Arg Cys Lys Asp Lys Leu Asn Ser Leu
 100 105 110
 Ala Ile Ser Val Met Asn His Trp Pro Gly Val Lys Leu Arg Val Thr
 115 120 125
 20
 Glu Gly Trp Asp Glu Asp Gly His His Leu Glu Glu Ser Leu His Tyr
 130 135 140
 Glu Gly Arg Ala Val Asp Ile Thr Thr Ser Asp Arg Asp Lys Ser Lys
 25 145 150 155 160
 Tyr Gly Met Leu Ser Arg Leu Ala Val Glu Ala Gly Phe Asp Trp Val
 165 170 175
 30 Tyr Tyr Glu Ser Lys Ala His Ile His Cys Ser Val Lys Ala Glu Asn
 180 185 190
 Ser Val Ala Ala Lys Ser Gly Gly Cys Phe Pro Gly Ser Gly Thr Val
 195 200 205
 35
 Thr Leu Gly Asp Gly Thr Arg Lys Pro Ile Lys Asp Leu Lys Val Gly
 210 215 220
 Asp Arg Val Leu Ala Ala Asp Glu Lys Gly Asn Val Leu Ile Ser Asp

225 230 235 240
 Phe Ile Met Phe Ile Asp His Asp Pro Thr Thr Arg Arg Gln Phe Ile
 245 250 255
 5 Val Ile Glu Thr Ser Glu Pro Phe Thr Lys Leu Thr Leu Thr Ala Ala
 260 265 270
 His Leu Val Phe Val Gly Asn Ser Ser Ala Ala Ser Gly Ile Thr Ala
 10 275 280 285
 Thr Phe Ala Ser Asn Val Lys Pro Gly Asp Thr Val Leu Val Trp Glu
 290 295 300
 15 Asp Thr Cys Glu Ser Leu Lys Ser Val Thr Val Lys Arg Ile Tyr Thr
 305 310 315 320
 Glu Glu His Glu Gly Ser Phe Ala Pro Val Thr Ala His Gly Thr Ile
 325 330 335
 20 Ile Val Asp Gln Val Leu Ala Ser Cys Tyr Ala Val Ile Glu Asn His
 340 345 350
 Lys Trp Ala His Trp Ala Phe Ala Pro Val Arg Leu Cys His Lys Leu
 25 355 360 365
 Met Thr Trp Leu Phe Pro Ala Arg Glu Ser Asn Val Asn Phe Gln Glu
 370 375 380
 30 Asp Gly Ile His Trp Tyr Ser Asn Met Leu Phe His Ile Gly Ser Trp
 385 390 395 400
 Leu Leu Asp Arg Asp Ser Phe His Pro Leu Gly Ile Leu His Leu Ser
 405 410 415
 35

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1416 base pairs

(B) TYPE: nucleic acid

(C) STRANDEDNESS: both

(D) TOPOLOGY: linear

5

(ii) MOLECULE TYPE: cDNA

(ix) FEATURE:

10

(A) NAME/KEY: CDS

(B) LOCATION: 1..1413

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

15

ATG GAT AAC CAC AGC TCA GTG CCT TGG GCC AGT GCC GCC AGT GTC ACC 48
Met Asp Asn His Ser Ser Val Pro Trp Ala Ser Ala Ala Ser Val Thr
1 5 10 15

20 TGT CTC TCC CTG GGA TGC CAA ATG CCA CAG TTC CAG TTC CAG TTC CAG 96
Cys Leu Ser Leu Gly Cys Gln Met Pro Gln Phe Gln Phe Gln Phe Gln
20 25 30

CTC CAA ATC CGC AGC GAG CTC CAT CTC CGC AAG CCC GCA AGA AGA ACG 144
25 Leu Gln Ile Arg Ser Glu Leu His Leu Arg Lys Pro Ala Arg Arg Thr
35 40 45

CAA ACG ATG CGC CAC ATT GCG CAT ACG CAG CGT TGC CTC AGC AGG CTG 192
Gln Thr Met Arg His Ile Ala His Thr Gln Arg Cys Leu Ser Arg Leu
30 50 55 60

ACC TCT CTG GTG GCC CTG CTG CTG ATC GTC TTG CCG ATG GTC TTT AGC 240
Thr Ser Leu Val Ala Leu Leu Leu Ile Val Leu Pro Met Val Phe Ser
65 70 75 80

35

CCG GCT CAC AGC TGC GGT CCT GGC CGA GGA TTG GGT CGT CAT AGG GCG 288
Pro Ala His Ser Cys Gly Pro Gly Arg Gly Leu Gly Arg His Arg Ala
85 90 95

	CGC AAC CTG TAT CCG CTG GTC CTC AAG CAG ACA ATT CCC AAT CTA TCC	336
	Arg Asn Leu Tyr Pro Leu Val Leu Lys Gln Thr Ile Pro Asn Leu Ser	
	100 105 110	
5	GAG TAC ACG AAC AGC GCC TCC GGA CCT CTG GAG GGT GTG ATC CGT CGG	384
	Glu Tyr Thr Asn Ser Ala Ser Gly Pro Leu Glu Gly Val Ile Arg Arg	
	115 120 125	
	GAT TCG CCC AAA TTC AAG GAC CTC GTG CCC AAC TAC AAC AGG GAC ATC	432
10	Asp Ser Pro Lys Phe Lys Asp Leu Val Pro Asn Tyr Asn Arg Asp Ile	
	130 135 140	
	CTT TTC CGT GAC GAG GAA GGC ACC GGA GCG GAT GGC TTG ATG AGC AAG	480
	Leu Phe Arg Asp Glu Glu Gly Thr Gly Ala Asp Gly Leu Met Ser Lys	
15	145 150 155 160	
	CGC TGC AAG GAG AAG CTA AAC GTG CTG GCC TAC TCG GTG ATG AAC GAA	528
	Arg Cys Lys Glu Lys Leu Asn Val Leu Ala Tyr Ser Val Met Asn Glu	
	165 170 175	
20	TGG CCC GGC ATC CGG CTG CTG GTC ACC GAG AGC TGG GAC GAG GAC TAC	576
	Trp Pro Gly Ile Arg Leu Leu Val Thr Glu Ser Trp Asp Glu Asp Tyr	
	180 185 190	
25	CAT CAC GGC CAG GAG TCG CTC CAC TAC GAG GGC CGA GCG GTG ACC ATT	624
	His His Gly Gln Glu Ser Leu His Tyr Glu Gly Arg Ala Val Thr Ile	
	195 200 205	
	GCC ACC TCC GAT CGC GAC CAG TCC AAA TAC GGC ATG CTC GCT CGC CTG	672
30	Ala Thr Ser Asp Arg Asp Gln Ser Lys Tyr Gly Met Leu Ala Arg Leu	
	210 215 220	
	GCC GTC GAG GCT GGA TTC GAT TGG GTC TCC TAC GTC AGC AGG CGC CAC	720
	Ala Val Glu Ala Gly Phe Asp Trp Val Ser Tyr Val Ser Arg Arg His	
35	225 230 235 240	
	ATC TAC TGC TCC GTC AAG TCA GAT TCG TCG ATC AGT TCC CAC GTG CAC	768
	Ile Tyr Cys Ser Val Lys Ser Asp Ser Ser Ile Ser Ser His Val His	
	245 250 255	

	GGC TGC TTC ACG CCG GAG AGC ACA GCG CTG CTG GAG AGT GGA GTC CGG	816
	Gly Cys Phe Thr Pro Glu Ser Thr Ala Leu Leu Glu Ser Gly Val Arg	
	260 265 270	
5	AAG CCG CTC GGC GAG CTC TCT ATC GGA GAT CGT GTT TTG AGC ATG ACC	864
	Lys Pro Leu Gly Glu Leu Ser Ile Gly Asp Arg Val Leu Ser Met Thr	
	275 280 285	
10	GCC AAC GGA CAG GCC GTC TAC AGC GAA GTG ATC CTC TTC ATG GAC CGC	912
	Ala Asn Gly Gln Ala Val Tyr Ser Glu Val Ile Leu Phe Met Asp Arg	
	290 295 300	
	AAC CTC GAG CAG ATG CAA AAC TTT GTG CAG CTG CAC ACG GAC GGT GGA	960
15	Asn Leu Glu Gln Met Gln Asn Phe Val Gln Leu His Thr Asp Gly Gly	
	305 310 315 320	
	GCA GTG CTC ACG GTG ACG CCG GCT CAC CTG GTT AGC GTT TGG CAG CCG	1008
	Ala Val Leu Thr Val Thr Pro Ala His Leu Val Ser Val Trp Gln Pro	
20	325 330 335	
	GAG AGC CAG AAG CTC ACG TTT GTG TTT GCG CAT CGC ATC GAG GAG AAG	1056
	Glu Ser Gln Lys Leu Thr Phe Val Phe Ala His Arg Ile Glu Glu Lys	
	340 345 350	
25	AAC CAG GTG CTC GTA CGG GAT GTG GAG ACG GGC GAG CTG AGG CCC CAG	1104
	Asn Gln Val Leu Val Arg Asp Val Glu Thr Gly Glu Leu Arg Pro Gln	
	355 360 365	
30	CGA GTG GTC AAG TTG GGC AGT GTG CGC AGT AAG GGC GTG GTC GCG CCG	1152
	Arg Val Val Lys Leu Gly Ser Val Arg Ser Lys Gly Val Val Ala Pro	
	370 375 380	
	CTG ACC CGC GAG GGC ACC ATT GTG GTC AAC TCG GTG GCC GCC AGT TGC	1200
35	Leu Thr Arg Glu Gly Thr Ile Val Val Asn Ser Val Ala Ala Ser Cys	
	385 390 395 400	
	TAT GCG GTG ATC AAC AGT CAG TCG CTG GCC CAC TGG GGA CTG GCT CCC	1248
	Tyr Ala Val Ile Asn Ser Gln Ser Leu Ala His Trp Gly Leu Ala Pro	

405 410 415
 ATG CGC CTG CTG TCC ACG CTG GAG GCG TGG CTG CCC GCC AAG GAG CAG 1296
 Met Arg Leu Leu Ser Thr Leu Glu Ala Trp Leu Pro Ala Lys Glu Gln
 5 420 425 430
 TTG CAC AGT TCG CCG AAG GTG GTG AGC TCG GCG CAG CAG CAG AAT GGC 1344
 Leu His Ser Ser Pro Lys Val Val Ser Ser Ala Gln Gln Gln Asn Gly
 435 440 445
 10
 ATC CAT TGG TAT GCC AAT GCG CTC TAC AAG GTC AAG GAC TAC GTG CTG 1392
 Ile His Trp Tyr Ala Asn Ala Leu Tyr Lys Val Lys Asp Tyr Val Leu
 450 455 460
 15 CCG CAG AGC TGG CGC CAC GAT TGA 1416
 Pro Gln Ser Trp Arg His Asp
 465 470

20 (2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 471 amino acids
 (B) TYPE: amino acid
 25 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

30 Met Asp Asn His Ser Ser Val Pro Trp Ala Ser Ala Ala Ser Val Thr
 1 5 10 15
 Cys Leu Ser Leu Gly Cys Gln Met Pro Gln Phe Gln Phe Gln Phe Gln
 35 20 25 30
 Leu Gln Ile Arg Ser Glu Leu His Leu Arg Lys Pro Ala Arg Arg Thr
 35 40 45

Gln Thr Met Arg His Ile Ala His Thr Gln Arg Cys Leu Ser Arg Leu
 50 55 60

Thr Ser Leu Val Ala Leu Leu Leu Ile Val Leu Pro Met Val Phe Ser
 5 65 70 75 80

Pro Ala His Ser Cys Gly Pro Gly Arg Gly Leu Gly Arg His Arg Ala
 85 90 95

10 Arg Asn Leu Tyr Pro Leu Val Leu Lys Gln Thr Ile Pro Asn Leu Ser
 100 105 110

Glu Tyr Thr Asn Ser Ala Ser Gly Pro Leu Glu Gly Val Ile Arg Arg
 115 120 125

15 Asp Ser Pro Lys Phe Lys Asp Leu Val Pro Asn Tyr Asn Arg Asp Ile
 130 135 140

Leu Phe Arg Asp Glu Glu Gly Thr Gly Ala Asp Gly Leu Met Ser Lys
 20 145 150 155 160

Arg Cys Lys Glu Lys Leu Asn Val Leu Ala Tyr Ser Val Met Asn Glu
 165 170 175

25 Trp Pro Gly Ile Arg Leu Leu Val Thr Glu Ser Trp Asp Glu Asp Tyr
 180 185 190

His His Gly Gln Glu Ser Leu His Tyr Glu Gly Arg Ala Val Thr Ile
 195 200 205

30 Ala Thr Ser Asp Arg Asp Gln Ser Lys Tyr Gly Met Leu Ala Arg Leu
 210 215 220

Ala Val Glu Ala Gly Phe Asp Trp Val Ser Tyr Val Ser Arg Arg His
 35 225 230 235 240

Ile Tyr Cys Ser Val Lys Ser Asp Ser Ser Ile Ser Ser His Val His
 245 250 255

Gly Cys Phe Thr Pro Glu Ser Thr Ala Leu Leu Glu Ser Gly Val Arg
 260 265 270

5 Lys Pro Leu Gly Glu Leu Ser Ile Gly Asp Arg Val Leu Ser Met Thr
 275 280 285

Ala Asn Gly Gln Ala Val Tyr Ser Glu Val Ile Leu Phe Met Asp Arg
 290 295 300

10 Asn Leu Glu Gln Met Gln Asn Phe Val Gln Leu His Thr Asp Gly Gly
 305 310 315 320

Ala Val Leu Thr Val Thr Pro Ala His Leu Val Ser Val Trp Gln Pro
 325 330 335

15 Glu Ser Gln Lys Leu Thr Phe Val Phe Ala His Arg Ile Glu Glu Lys
 340 345 350

Asn Gln Val Leu Val Arg Asp Val Glu Thr Gly Glu Leu Arg Pro Gln
 20 355 360 365

Arg Val Val Lys Leu Gly Ser Val Arg Ser Lys Gly Val Val Ala Pro
 370 375 380

25 Leu Thr Arg Glu Gly Thr Ile Val Val Asn Ser Val Ala Ala Ser Cys
 385 390 395 400

Tyr Ala Val Ile Asn Ser Gln Ser Leu Ala His Trp Gly Leu Ala Pro
 405 410 415

30 Met Arg Leu Leu Ser Thr Leu Glu Ala Trp Leu Pro Ala Lys Glu Gln
 420 425 430

Leu His Ser Ser Pro Lys Val Val Ser Ser Ala Gln Gln Gln Asn Gly
 35 435 440 445

Ile His Trp Tyr Ala Asn Ala Leu Tyr Lys Val Lys Asp Tyr Val Leu
 450 455 460

Pro Gln Ser Trp Arg His Asp

465

470

(2) INFORMATION FOR SEQ ID NO:21:

5

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 221 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

10

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

15

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

20

Cys Gly Pro Gly Arg Gly Xaa Gly Xaa Arg Arg His Pro Lys Lys Leu
1 5 10 15

Thr Pro Leu Ala Tyr Lys Gln Phe Ile Pro Asn Val Ala Glu Lys Thr
20 25 30

25

Leu Gly Ala Ser Gly Arg Tyr Glu Gly Lys Ile Xaa Arg Asn Ser Glu
35 40 45

Arg Phe Lys Glu Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile Phe Lys
50 55 60

30

Asp Glu Glu Asn Thr Gly Ala Asp Arg Leu Met Thr Gln Arg Cys Lys
65 70 75 80

35

Asp Lys Leu Asn Xaa Leu Ala Ile Ser Val Met Asn Xaa Trp Pro Gly
85 90 95

Val Xaa Leu Arg Val Thr Glu Gly Trp Asp Glu Asp Gly His His Xaa
100 105 110

Glu Glu Ser Leu His Tyr Glu Gly Arg Ala Val Asp Ile Thr Thr Ser
 115 120 125
 Asp Arg Asp Xaa Ser Lys Tyr Gly Xaa Leu Xaa Arg Leu Ala Val Glu
 5 130 135 140
 Ala Gly Phe Asp Trp Val Tyr Tyr Glu Ser Lys Ala His Ile His Cys
 145 150 155 160
 Ser Val Lys Ala Glu Asn Ser Val Ala Ala Lys Ser Gly Gly Cys Phe
 10 165 170 175
 Pro Gly Ser Ala Xaa Val Xaa Leu Xaa Xaa Gly Gly Xaa Lys Xaa Val
 15 180 185 190
 Lys Asp Leu Xaa Pro Gly Asp Xaa Val Leu Ala Ala Asp Xaa Xaa Gly
 195 200 205
 Xaa Leu Xaa Xaa Ser Asp Phe Xaa Xaa Phe Xaa Asp Arg
 20 210 215 220

(2) INFORMATION FOR SEQ ID NO:22:

25 (i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 167 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

30 (ii) MOLECULE TYPE: peptide
 (v) FRAGMENT TYPE: internal

35 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Cys Gly Pro Gly Arg Gly Xaa Xaa Xaa Arg Arg Xaa Xaa Xaa Pro Lys
 1 5 10 15

Xaa Leu Xaa Pro Leu Xaa Tyr Lys Gln Phe Xaa Pro Xaa Xaa Xaa Glu
 20 25 30

5 Xaa Thr Leu Gly Ala Ser Gly Xaa Xaa Glu Gly Xaa Xaa Xaa Arg Xaa
 35 40 45

Ser Glu Arg Phe Xaa Xaa Leu Thr Pro Asn Tyr Asn Pro Asp Ile Ile
 50 55 60

10 Phe Lys Asp Glu Glu Asn Xaa Gly Ala Asp Arg Leu Met Thr Xaa Arg
 65 70 75 80

Cys Lys Xaa Xaa Xaa Asn Xaa Leu Ala Ile Ser Val Met Asn Xaa Trp
 15 85 90 95

Pro Gly Val Xaa Leu Arg Val Thr Glu Gly Xaa Asp Glu Asp Gly His
 100 105 110

20 His Xaa Xaa Xaa Ser Leu His Tyr Glu Gly Arg Ala Xaa Asp Ile Thr
 115 120 125

Thr Ser Asp Arg Asp Xaa Xaa Lys Tyr Gly Xaa Leu Xaa Arg Leu Ala
 130 135 140

25 Val Glu Ala Gly Phe Asp Trp Val Tyr Tyr Glu Ser Xaa Xaa His Xaa
 145 150 155 160

His Xaa Ser Val Lys Xaa Xaa
 30 165

SEQ ID No. 23

FEATURES

	Location/Qualifiers
source	1..627
35	/organism="Homo sapiens"
	/db_xref="taxon:9606"
	/dev_stage="adult"
	/sex="male"
	/tissue_type="lung"

CDS 1..627
 /standard_name="fibroblast growth factor-10"
 /codon_start=1
 /product="FGF-10"
 5 /protein_id="BAA22331.1"
 /db_xref="PID:d1023194"
 /db_xref="PID:g2440221"
 /db_xref="GI:2440221"

1 atgtggaaat ggatactgac acattgtgcc tcagcctttc cccacctgcc cggctgctgc
 10 61 tgctgctgct tttgttgct gttcttggtg tcttccgtcc ctgtcacctg ccaagccctt
 121 ggtcaggaca tgggtgcacc agaggccacc aactcttctt cctcctcctt ctcctctcct
 181 tccagcgagg gaaggcatgt gcggagctac aatcaccttc aaggagatgt ccgctggaga
 241 aagctattct ctttcaccaa gtactttctc aagattgaga agaacgggaa ggtcagcggg
 301 accaagaagg agaactgccc gtacagcatc ctggagataa catcagtaga aatcggagtt
 15 361 gttgccgtca aagccattaa cagcaactat tacttagcca tgaacaagaa ggggaaactc
 421 tatggctcaa aagaatttaa caatgactgt aagctgaagg agaggataga ggaaaatgga
 481 tacaatacct atgcataatt taactggcag cataatggga ggcaaatgta tgtggcatty
 541 aatggaaaag gagctccaag gagaggacag aaaacacgaa ggaaaaacac ctctgctcac
 601 tttcttccaa tgggtgtaca ctcatag

SEQ ID No. 24

FEATURES

Location/Qualifiers

source

1..208

/organism="Homo sapiens"

/db_xref="taxon:9606"

/dev_stage="adult"

/sex="male"

/tissue_type="lung"

Protein

1..208

/product="FGF-10"

CDS

1..208

/standard_name="fibroblast growth factor-10"

/coded_by="GenBank Accession AB002097.1:1..627"

ORIGIN

35 1 mwkwilthca safphlpgcc cccflllflv ssvpvtcgal gqdmvspeat nsssssfssp
 61 ssagrhrvsy nhlqgdvrwr klfsftkyfl kiekngkvsg tkkencpysi leitsveigv
 121 vavkainsny ylamnkkgl ygskefnndc klkerieeng yntyasfnwq hngrqmyval
 181 ngkgaprrgq ktrrkntsah flpmvvh

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 99/20500

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K38/17 C07K14/47 A61K31/7076 A61K31/472 A61K31/553
C12N5/00 A61P35/00 A61P11/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	HOSUNG MIN ET AL: "Fgf-10 is required for both limb and lung development and exhibits striking functional similarity to Drosophila branchless" GENES & DEVELOPMENT, vol. 12, 1998, pages 3156-3161, XP002135651 abstract	1-21
A	S. BELLUSCI ET AL: "Involvement of Sonic Hedgehog (Shh) in mouse embryonic lung growth and morphogenesis" DEVELOPMENT, vol. 124, 1997, pages 53-63, XP002135652 cited in the application abstract	1-21

-/-

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document relating to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

13 April 2000

Date of mailing of the international search report

03/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Siatou, E

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/20500

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	S. BELLUSCI ET AL: "Fibroblast Growth Factor 10 (FGF10) and branching morphogenesis in the embryonic mouse lung" DEVELOPMENT, vol. 124, 1997, pages 4867-4878, XP002135653 cited in the application abstract	1-21
A	HAMMERSCHMIDT M ET AL: "The world according to hedgehog" TRENDS IN GENETICS,NL,ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, vol. 13, no. 1, 1 January 1997 (1997-01-01), pages 14-21, XP004015059 ISSN: 0168-9525 cited in the application page 15; table 1 page 19, right-hand column, last paragraph -page 20, left-hand column	1-21
A	OLECH V M ET AL: "ROLE OF BASIC FIBROBLAST GROWTH FACTOR IN REVASCULARIZATION OF RABBIT TRACHEAL AUTOGRAFTS" ANNALS OF THORACIC SURGERY,US,NEW YORK, NY, vol. 52, no. 2, 1 August 1991 (1991-08-01), pages 258-264, XP000615306 abstract	1-21

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/ 20500

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-21
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-21
are directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-5 and 18-21 relate to method of modulating lung tissue growth by using an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds used in the claimed method. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds mentioned in claims 6-17 and those disclosed in pages 57, line 13- page 60, line 3.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.